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reamble (UPDATED)
t is essential that the medical profession play a significant
ole in critically evaluating the use of diagnostic procedures
nd therapies as they are introduced and tested in the
etection, management, or prevention of disease states.
igorous and expert analysis of the available data docu-
enting absolute and relative benefits and risks of those
rocedures and therapies can produce helpful guidelines
hat improve the effectiveness of care, optimize patient
utcomes, and favorably affect the overall cost of care by
ocusing resources on the most effective strategies. The
roduction of clinical practice guidelines can provide a
oundation for a variety of other applications such as
erformance measures, appropriateness use criteria, clinical
ecision support tools, and quality improvement tools.
The American College of Cardiology FoundationACCF) and the American Heart Association (AHA) have
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2009 ACCF/AHA Perioperative Guidelines November 24, 2009:e13–118ointly engaged in the production of guidelines in the area of
ardiovascular disease since 1980. The ACCF/AHA Task
orce on Practice Guidelines is charged with developing,
pdating, and revising practice guidelines for cardiovascular
iseases and procedures, and directs this effort. Writing
ommittees are charged with assessing the evidence as an
ndependent group of authors to develop, update, or revise
ecommendations for clinical practice.
Experts in the subject under consideration have been
elected from both organizations to examine subject-specific
ata and write guidelines in partnership with representatives
rom other medical practitioner and specialty groups. Writ-
ng committees are specifically charged to perform a formal
iterature review, weigh the strength of evidence for or
gainst particular treatments or procedures, and include
stimates of expected health outcomes where data exist.
atient-specific modifiers, comorbidities, and issues of pa-
ient preference that might influence the choice of tests or
herapies are considered as well as the frequency of
ollow-up and cost-effectiveness. When available, informa-
ion from studies on cost is considered, but data on efficacy
nd clinical outcomes constitute the primary basis for
ecommendations in these guidelines.
The ACCF/AHA Task Force on Practice Guidelines
akes every effort to avoid actual, potential, or perceived
onflicts of interest that might arise as a result of industry
elationships or personal interests among the writing com-
ittee. Specifically, all members of the writing committee,
s well as peer reviewers of the document, are asked to
isclose all such relationships that might be perceived as
elevant to the writing effort. If a writing committee
ember develops a new relationship with industry during
heir tenure, they are required to notify guideline staff in
riting. These statements are reviewed by the parent task
orce, reviewed by all members in conjunction with each
onference call and/or meeting of the writing committee,
pdated as changes occur and ultimately published as an
ppendix to the document. Please refer to the methodology
anual for ACCF/AHA Guideline Writing Committees
or further description of the relationships with industry and
ther entities policy (1). See Appendix 1 for author rela-
ionships with industry and Appendix 2 for peer reviewer
elationships with industry pertinent to this guideline.
These practice guidelines produced are intended to assist
ealthcare providers in clinical decision making by describ-
ng a range of generally acceptable approaches for diagnosis,
anagement, and prevention of specific diseases or condi-
ions. (See Appendix 3 for a list of abbreviations frequently
sed in this document.) Clinicians should consider the
uality and availability of expertise in the area where care is
rovided. These guidelines attempt to define practices that
eet the needs of most patients in most circumstances. The
ecommendations reflect a consensus of expert opinion after
thorough review of the available current scientific evidence
nd are intended to improve patient care. pPatient adherence to prescribed and agreed upon medical
egimens and lifestyles is an important aspect of treatment.
rescribed courses of treatment in accordance with these
ecommendations are only effective if they are followed.
ecause lack of patient understanding and adherence may
dversely affect outcomes, physicians and other healthcare
roviders should make every effort to engage the patient’s
ctive participation in prescribed medical regimens and
ifestyles.
If these guidelines are used as the basis for regulatory or
ayer decisions, the goal should be quality of care and the
atient’s best interest. The ultimate judgment regarding care of
particular patient must be made by the healthcare provider
nd the patient in light of all of the circumstances presented by
hat patient. Consequently, there are circumstances in which
eviations from these guidelines are appropriate.
The guidelines will be reviewed annually by the ACCF/
HA Task Force on Practice Guidelines and considered
urrent unless they are updated, revised, or withdrawn from
istribution. The executive summary and recommendations
re published in the October 23, 2007, issues of the Journal
f the American College of Cardiology and Circulation. The
ull-text guidelines are e-published in the same issue of
hese journals and posted on the ACC (www.acc.org) and
HA (my.americanheart.org) World Wide Web sites.
opies of the full-text guidelines and the executive sum-
ary are available from both organizations.
This document is a republication of the “ACC/AHA
007 Guidelines on Perioperative Cardiovascular Evalua-
ion and Care for Noncardiac Surgery” (2), revised to
ncorporate updated recommendations and text from the
2009 ACCF/AHA Focused Update on Perioperative Beta
lockade” (3). Recommendations have been updated with
ew information that has emerged from clinical trials or
ther ACCF/AHA guideline or consensus documents. For
asy reference, this online-only version denotes sections that
ave been updated.
Alice K. Jacobs, MD, FACC, FAHA,
Chair, ACCF/AHA Task Force on Practice Guidelines
Sidney C. Smith, Jr., MD, FACC, FAHA,
Immediate Past Chair, ACCF/AHA
Task Force on Practice Guidelines
. Introduction/Definition of the
roblem (UPDATED)
he 2007 full-text guidelines represent an update to those
ublished in 2002 and are intended for physicians and
onphysician caregivers who are involved in the preopera-
ive, operative, and postoperative care of patients undergo-
ng noncardiac surgery. They provide a framework for
onsidering cardiac risk of noncardiac surgery in a variety of
atient and surgical situations. The writing committee that
repared these guidelines strove to incorporate what is
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November 24, 2009:e13–118 2009 ACCF/AHA Perioperative Guidelinesurrently known about perioperative risk and how this
nowledge can be used in the individual patient.
The tables and algorithms provide quick references for
ecision making. The overriding theme of this document is
hat intervention is rarely necessary to simply lower the risk
f surgery unless such intervention is indicated irrespective
f the preoperative context. The purpose of preoperative
valuation is not to give medical clearance but rather to
erform an evaluation of the patient’s current medical
tatus; make recommendations concerning the evaluation,
anagement, and risk of cardiac problems over the entire
erioperative period; and provide a clinical risk profile that
he patient, primary physician and nonphysician caregivers,
nesthesiologist, and surgeon can use in making treatment
ecisions that may influence short- and long-term cardiac
utcomes. No test should be performed unless it is likely to
nfluence patient treatment. The goal of the consultation is
he optimal care of the patient.
.1. Methodology and Evidence Review (UPDATED)
he 2007 guidelines writing committee conducted a com-
rehensive review of the literature relevant to perioperative
ardiac evaluation published since the last publication of
hese guidelines in 2002. Literature searches were con-
ucted in the following databases: PubMed, MEDLINE,
nd the Cochrane Library (including the Cochrane Data-
ase of Systematic Reviews and the Cochrane Controlled
rials Register). Searches were limited to the English
anguage, the years 2002 through 2007, and human subjects.
elated-article searches were conducted in MEDLINE to
nd additional relevant articles. Finally, committee mem-
ers recommended applicable articles outside the scope of
he formal searches.
Major search topics included perioperative risk, cardiac
isk, noncardiac surgery, intraoperative risk, postoperative
isk, risk stratification, cardiac complication, cardiac evalu-
tion, perioperative care, preoperative evaluation, preopera-
ive assessment, and intraoperative complications. Addi-
ional searches cross-referenced these topics with the
ollowing subtopics: troponin, myocardial infarction (MI),
yocardial ischemia, Duke activity status index, functional
apacity, dobutamine, adenosine, venous thrombosis,
hromboembolism, warfarin, percutaneous transluminal
oronary angioplasty (PTCA), stent, adrenergic beta ago-
ists, echocardiography, anticoagulant, beta blocker, coro-
ary artery bypass surgery, valve, diabetes mellitus, wound
nfection, blood sugar control, normothermia, body temper-
ture changes, body temperature regulation, hypertension,
ulmonary hypertension, anemia, aspirin, arrhythmia, im-
lantable defibrillator, artificial pacemaker, pulmonary ar-
ery catheters, Swan-Ganz catheter, and platelet aggrega-
ion inhibitors.
As a result of these searches, more than 400 relevant, new
rticles were identified and reviewed by the committee for
he revision of these guidelines. Using evidence-based
ethodologies developed by the ACCF/AHA Task Force an Practice Guidelines, the committee revised the guide-
ines text and recommendations.
For the 2009 focused update (3), late-breaking clinical
rials presented at the 2008 annual scientific meetings of the
CC, AHA, and European Society of Cardiology, as well
s selected other data through June 2009, were reviewed by
he standing guideline writing committee along with the
arent task force and other experts to identify those trials
nd other key data that may impact guideline recommen-
ations. Recent trial data and other clinical information
ere considered important enough to prompt a focused
pdate of the “ACC/AHA 2007 Guidelines on Periopera-
ive Cardiovascular Evaluation and Care for Noncardiac
urgery” (2). This update addresses predominantly the
rophylactic use of beta blockers perioperatively to mini-
ize cardiac risk, but it does not cover other legitimate uses
f beta blockers (e.g., as an adjunct in anesthetic regimens,
or intraoperative control of heart rate or blood pressure, or
o achieve heart rate control in common perioperative
rrhythmias such as atrial fibrillation).
When considering the new data for this focused update,
he writing group faced the task of weighing evidence from
tudies enrolling large numbers of subjects outside North
merica. While noting that practice patterns and the rigor
pplied to data collection, as well as the genetic make-up of
ubjects, may influence the observed magnitude of a treat-
ent’s effect, the writing group believed the data were
elevant to formulation of recommendations for periopera-
ive management in North America. The reasons for this
ecision include the following: 1) The use of detailed
rotocol-driven management strategies likely reduced treat-
ent variability among sites; and 2) it may be impractical to
xpect that the thousands of patients undergoing noncardiac
urgery who are needed to meet the estimated sample size
or contemporary clinical trials would be enrolled exclusively
t North American sites.
To provide clinicians with a comprehensive set of data,
henever possible, the exact event rates in various treatment
rms of clinical trials are presented to permit calculation of
he absolute risk difference and number needed to treat
NNT) or harm. The relative treatment effects are described
ither as odds ratio (OR), relative risk (RR), or hazard ratio
HR), depending on the format in the original publication.
The schema for classification of recommendations and
evel of evidence are summarized in Table 1, which also
llustrates how the grading system provides an estimate of
he size of treatment effect and an estimate of the certainty
f the treatment effect.
.2. Organization of Committee and Relationships
ith Industry and Other Entities (NEW)
or the 2009 focused update, all members of the 2007
erioperative Guideline Writing Committee were invited to
articipate; those who agreed (referred to as the 2009
ocused Update Writing Group) were required to disclose
ll relationships with industry and other entities relevant to
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mmendation required a confidential vote by the writing
roup members before and after external review of the
ocument. Any writing group member with a relationship
ith industry relevant to the recommendation was recused
rom voting on that recommendation. The committee
ncluded representatives from the American Society of
chocardiography (ASE), Heart Rhythm Society (HRS),
ociety of Cardiovascular Anesthesiologists (SCA), Society
or Cardiac Angiography and Interventions (SCAI), Society
or Vascular Medicine (SVM), and Society for Vascular
urgery (SVS).
.3. Document Review and Approval (UPDATED)
he 2007 guidelines were approved for publication by the
overning bodies of the ACCF and the AHA and have been
fficially endorsed by the ASE, American Society of Nuclear
ardiology (ASNC), HRS, SCA, SCAI, SVM, and SVS.
The 2009 focused update was reviewed by 2 official
eviewers nominated by the ACCF and 2 official reviewers
able 1. Applying Classification of Recommendations and Leve
Data available from clinical trials or registries about the usefulness/efficacy in different subpo
ailure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply th
end themselves to clinical trials. Even though randomized trials are not available, there may b
CCF/AHA Task Force on Practice Guidelines developed a list of suggested phrases to use wh
xpress a complete thought, such that a recommendation, even if separated and presented apar
he full intent of the recommendation. It is hoped that this will increase readers’ comprehensioominated by the AHA, as well as 2 reviewers each from the pSE, ASNC, HRS, SCA, SCAI, SVM, and the SVS, and
individual content reviewers from the ACCF Cardiac
atheterization Committee and the ACCF Interventional
ouncil. All information on reviewer relationships with
ndustry was collected and distributed to the writing group
nd is published in this document (Appendix 5).
The 2009 focused update was approved for publication by
he governing bodies of the ACCF and the AHA and
ndorsed by the ASE, ASNC, HRS, SCA, SCAI, SVM,
nd the SVS.
.4. Epidemiology
he prevalence of cardiovascular disease increases with age,
nd it is estimated that the number of persons older than 65
ears in the United States will increase 25% to 35% over the
ext 30 years (1). Coincidentally, this is the same age group
n which the largest number of surgical procedures is
erformed (2). Thus, it is conceivable that the number of
oncardiac surgical procedures performed in older persons
ill increase from the current 6 million to nearly 12 million
vidence
s, such as sex, age, history of diabetes, history of prior myocardial infarction, history of heart
ecommendation is weak. Many important clinical questions addressed in the guidelines do not
y clear clinical consensus that a particular test or therapy is useful or effective. †In 2003, the
ing recommendations. All guideline recommendations have been written in full sentences that
he rest of the document (including headings above sets of recommendations), would still convey
guidelines and will allow queries at the individual recommendation level.l of E
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ave been associated with significant perioperative cardio-
ascular morbidity and mortality.
.5. Practice Patterns
here are few reliable data available regarding 1) how often
family physician, general internist, physician extender,
pecialist, or surgeon performs a preoperative evaluation on
is or her own patient without a formal cardiovascular
onsultation and 2) how often a formal preoperative con-
ultation is requested from either a generalist or a subspe-
ialist, such as a cardiologist, for different types of surgical
rocedures and different categories of patients. The actual
atterns of practice with regard to the practitioner perform-
ng the evaluation and utilization of testing varies widely,
uggesting the need to determine which practices lead to the
est clinical and economic outcomes (3). There is an
mportant need to determine the relative cost-effectiveness
f different strategies of perioperative evaluation. In many
nstitutions, patients are evaluated in an anesthesia preop-
rative evaluation setting. If sufficient information about the
atient’s cardiovascular status is available, the symptoms are
table, and further evaluation will not influence periopera-
ive management, a formal consultation may not be required
r obtained. This is facilitated by communication between
nesthesia personnel and physicians responsible for the
atient’s cardiovascular care.
.6. Financial Implications
he financial implications of risk stratification cannot be
gnored. The need for better methods of objectively
easuring cardiovascular risk has led to the development
f multiple noninvasive techniques in addition to estab-
ished invasive procedures. Although a variety of strate-
ies to assess and lower cardiac risk have been developed,
heir aggregate cost has received relatively little attention.
iven the striking practice variation and high costs
ssociated with many evaluation strategies, the develop-
ent of practice guidelines based on currently available
nowledge can serve to foster more efficient approaches
o perioperative evaluation.
. General Approach to the Patient
his guideline focuses on the evaluation of the patient
ndergoing noncardiac surgery who is at risk for perioper-
tive cardiac morbidity or mortality. In patients with known
oronary artery disease (CAD) or the new onset of signs or
ymptoms suggestive of CAD, baseline cardiac assessment
hould be performed. In the asymptomatic patient, a more
xtensive assessment of history and physical examination is
arranted in those individuals 50 years of age or older,
ecause the evidence related to the determination of cardiac
isk factors and derivation of a Revised Cardiac Risk Index
ccurred in this population (4). Preoperative cardiac evalu-
tion must therefore be carefully tailored to the circum- Itances that have prompted the evaluation and to the nature
f the surgical illness. Given an acute surgical emergency,
reoperative evaluation might have to be limited to simple
nd critical tests, such as a rapid assessment of cardiovas-
ular vital signs, volume status, hematocrit, electrolytes,
enal function, urine analysis, and ECG. Only the most
ssential tests and interventions are appropriate until the
cute surgical emergency is resolved. A more thorough
valuation can be conducted after surgery. In patients in
hom coronary revascularization is not an option, it is often
ot necessary to perform a noninvasive stress test. Under
ther, less urgent circumstances, the preoperative cardiac
valuation may lead to a variety of responses, including
ancellation of an elective procedure.
.1. Role of the Consultant
f a consultation is requested, then it is important to identify
he key questions and ensure that all of the perioperative
aregivers are considered when providing a response. Several
tudies suggest that such an approach is not always taken. A
ultiple-choice survey regarding the purposes and utility of
ardiology consultations was sent to randomly selected New
ork metropolitan area anesthesiologists, surgeons, and
ardiologists (5). There was substantial disagreement on the
mportance and purposes of a cardiology consultation; for
nstance, intraoperative monitoring, “clearing the patient for
urgery,” and advising as to the safest type of anesthesia were
egarded as important by most cardiologists and surgeons
ut as unimportant by anesthesiologists. In addition, the
harts of 55 consecutive patients aged more than 50 years
ho received preoperative cardiology consultations were
xamined to determine the stated purpose of the consulta-
ion, recommendations made, and concordance by surgeons
nd anesthesiologists with cardiologists’ recommendations.
f the cardiology consultations, 40% contained no recom-
endations other than “proceed with case,” “cleared for
urgery,” or “continue current medications.” A review of
46 medical consultations suggests that the majority of
uch consultations give little advice that truly impacts
ither perioperative management or outcome of surgery
6). In only 5 consultations (3.4%) did the consultant
dentify a new finding; 62 consultations (42.5%) contained
o recommendations.
Once a consultation has been obtained, the consultant
hould review available patient data, obtain a history, and
erform a physical examination that includes a comprehen-
ive cardiovascular examination and elements pertinent to
he patient’s problem and the proposed surgery. The con-
ultant must not rely solely on the question that he or she
as been asked to answer but must provide a comprehensive
valuation of the patient’s risk. The consultation may have
een requested for an ECG anomaly, chest pain, or arrhyth-
ia that may have been thought to be indicative of CAD
ut that the consultant may determine is noncardiac in
rigin or benign, therefore requiring no further evaluation.
n contrast, the consultation may lead to a suspicion of
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atient scheduled for an elective procedure, which justifies a
ore extensive evaluation (7–9). A critical role of the
onsultant is to determine the stability of the patient’s
ardiovascular status and whether the patient is in optimal
edical condition, within the context of the surgical illness.
he consultant may recommend changes in medication,
uggest preoperative tests or procedures, or propose higher
evels of postoperative care. In some instances, an additional
iagnostic cardiac evaluation is necessary on the basis of the
esults of the initial preoperative test. In general, preopera-
ive tests are recommended only if the information obtained
ill result in a change in the surgical procedure performed,
change in medical therapy or monitoring during or after
urgery, or a postponement of surgery until the cardiac
ondition can be corrected or stabilized. Before suggesting
n additional test, the consultant should feel confident that
he information will have the potential to affect treatment.
edundancy should be avoided.
The consultant must also bear in mind that the periop-
rative evaluation may be the ideal opportunity to effect the
ong-term treatment of a patient with significant cardiac
isease or risk of such disease. The referring physician and
atient should be informed of the results of the evaluation
nd implications for the patient’s prognosis. The consultant
an also assist in planning for follow-up, such as suggesting
dditional therapies known to reduce long-term cardiovas-
ular risk or setting up an office appointment. It is the
ardiovascular consultant’s responsibility to ensure clarity of
ommunication, such that findings and impressions will be
ncorporated effectively into the patient’s overall plan of
are. This ideally would include direct communication with
he surgeon, anesthesiologist, and other physicians, as well
s frank discussion directly with the patient and, if appro-
riate, the family. The consultant should not use phrases
uch as “clear for surgery.” As is expected for good medical
are in general, clear documentation in the medical record is
ppropriate.
.2. History
history is crucial to the discovery of cardiac and/or
omorbid diseases that would place the patient in a high
urgical risk category. The history should seek to identify
erious cardiac conditions such as unstable coronary syn-
romes, prior angina, recent or past MI, decompensated
F, significant arrhythmias, and severe valvular disease
Table 2). It should also determine whether the patient has
prior history of a pacemaker or implantable cardioverter
efibrillator (ICD) or a history of orthostatic intolerance.
odifiable risk factors for coronary heart disease (CHD)
hould be recorded, along with evidence of associated
iseases, such as peripheral vascular disease, cerebrovascular
isease, diabetes mellitus, renal impairment, and chronic
ulmonary disease. In patients with established cardiac
isease, any recent change in symptoms must be ascertained. pccurate recording of current medications used, including
erbal and other nutritional supplements, and dosages is
ssential. Use of alcohol, tobacco, and over-the-counter and
llicit drugs should be documented.
The history should also seek to determine the patient’s
unctional capacity (Table 3). An assessment of an individ-
al’s capacity to perform a spectrum of common daily tasks
as been shown to correlate well with maximum oxygen
ptake by treadmill testing (11). A patient classified as high
isk owing to age or known CAD but who is asymptomatic
nd runs for 30 minutes daily may need no further evalua-
ion. In contrast, a sedentary patient without a history of
ardiovascular disease but with clinical factors that suggest
ncreased perioperative risk may benefit from a more exten-
ive preoperative evaluation (8,9,12,13). The preoperative
onsultation may represent the first careful cardiovascular
valuation for the patient in years or, in some instances,
ver. For example, inquiry regarding symptoms suggestive
f angina or anginal equivalents such as dyspnea or HF may
stablish or suggest these diagnoses for the first time.
.3. Physical Examination
cardiovascular examination should include an assessment
f vital signs (including measurement of blood pressure in
oth arms), carotid pulse contour and bruits, jugular venous
able 2. Active Cardiac Conditions for Which the Patient
hould Undergo Evaluation and Treatment Before Noncardiac
urgery (Class I, Level of Evidence: B)
Condition Examples
nstable coronary
syndromes
Unstable or severe angina* (CCS class III or IV)†
Recent MI‡
ecompensated HF (NYHA
functional class IV;
worsening or
new-onset HF)
ignificant arrhythmias High-grade atrioventricular block
Mobitz II atrioventricular block
Third-degree atrioventricular heart block
Symptomatic ventricular arrhythmias
Supraventricular arrhythmias (including atrial
fibrillation) with uncontrolled ventricular rate
(HR greater than 100 bpm at rest)
Symptomatic bradycardia
Newly recognized ventricular tachycardia
evere valvular disease Severe aortic stenosis (mean pressure gradient
greater than 40 mm Hg, aortic valve area
less than 1.0 cm2, or symptomatic)
Symptomatic mitral stenosis (progressive
dyspnea on exertion, exertional presyncope,
or HF)
According to Campeau (10). †May include “stable” angina in patients who are unusually
edentary. ‡The American College of Cardiology National Database Library defines recent MI as
reater than 7 d but less than or equal to 1 month (within 30 d).
CCS indicates Canadian Cardiovascular Society; HF  heart failure; HR, heart rate; MI,
yocardial infarction; and NYHA, New York Heart Association.ressure and pulsations, auscultation of the lungs, precordial
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nation of the extremities for edema and vascular integrity.
he presence of an implanted pacemaker or ICD can also
e confirmed by physical examination. More detailed ob-
ervations will be dictated by specific circumstances. The
ollowing points are worth emphasizing:
The general appearance provides invaluable evidence
egarding the patient’s overall status. Cyanosis, pallor,
yspnea during conversation or with minimal activity,
heyne-Stokes respiration, poor nutritional status, obesity,
keletal deformities, tremor, and anxiety are just a few of the
lues of underlying disease or CAD that can be recognized
y the skilled physician.
In patients with acute HF, rales and chest X-ray evidence
f pulmonary congestion correlate well with elevated pul-
onary venous pressure. However, in patients with chronic
F, these findings may be absent. An elevated jugular
enous pressure or a positive hepatojugular reflux are more
eliable signs of hypervolemia in these patients (15,16).
eripheral edema is not a reliable indicator of chronic HF
nless the jugular venous pressure is elevated or the hepa-
ojugular test is positive.
An examination of the carotid and other arterial pulses
s essential. The presence of associated vascular disease
hould heighten suspicion of occult CAD. Cardiac aus-
ultation will often provide useful clues to underlying
ardiac disease. When present, a third heart sound at the
pical area suggests a failing left ventricle (LV), but its
bsence is not a reliable indicator of good ventricular
unction (16). If a murmur is present, the clinician will
eed to decide whether or not it represents significant
alvular disease. Detection of significant aortic stenosis is
f particular importance because this lesion poses a
igher risk for noncardiac surgery (17). Significant mitral
tenosis or regurgitation increases the risk of HF. Aortic
egurgitation and mitral regurgitation may be minimal,
et they predispose the patient to infective endocarditis
hould bacteremia occur after surgery. Recommendations
or endocarditis prophylaxis have been published else-
able 3. Estimated Energy Requirements for Various Activities
MET
METs
Can you . . .
Take care of yourself?
Eat, dress, or use the toilet?
Walk indoors around the house?
Walk a block or 2 on level ground at 2 to 3 mph (3.2 to 4.8 kph)?
Do light work around the house like dusting or washing dishes?
odified from Hlatky et al. (11), copyright 1989, with permission from Elsevier, and adapted fro
kph indicates kilometers per hour; MET, metabolic equivalent; and mph, miles per hour.here (18) (see Section 3.5. Valvular Heart Disease). o.4. Comorbid Diseases
he consultant must evaluate the cardiovascular system
ithin the framework of the patient’s overall health. Asso-
iated conditions often heighten the risk of anesthesia and
ay complicate cardiac management. The most common of
hese conditions are discussed below.
.4.1. Pulmonary Disease
he presence of either obstructive or restrictive pulmonary
isease places the patient at increased risk of developing
erioperative respiratory complications. Hypoxemia, hyper-
apnia, acidosis, and increased work of breathing can all lead
o further deterioration of an already compromised cardio-
ulmonary system. If significant pulmonary disease is sus-
ected by history or physical examination, determination of
unctional capacity, response to bronchodilators, and/or
valuation for the presence of carbon dioxide retention
hrough arterial blood gas analysis may be justified. If there
s evidence of infection, appropriate antibiotics are critical.
teroids and bronchodilators may be indicated, although the
isk of producing arrhythmia or myocardial ischemia by beta
gonists must be considered. Recommendations for preop-
rative chest radiographs can be found elsewhere (19).
.4.2. Diabetes Mellitus
variety of metabolic diseases may accompany cardiac
isease. Diabetes mellitus is the most common. Its presence
hould heighten suspicion of CAD, particularly because
AD and myocardial ischemia are more likely in patients
ith diabetes mellitus (20–22). Lee et al. identified insulin
herapy for diabetes mellitus as a significant risk factor for
ardiac morbidity (4). Older patients with diabetes mellitus
re more likely to develop HF postoperatively than those
ithout diabetes mellitus even after adjustment for treat-
ent with angiotensin-converting enzyme (ACE) inhibi-
ors (23). Management of blood glucose levels in the
erioperative period may be difficult. Fragile patients with
iabetes mellitus need careful treatment with adjusted doses
METs Can you . . .
Climb a flight of stairs or walk up a hill?
Walk on level ground at 4 mph (6.4 kph)?
Run a short distance?
Do heavy work around the house like scrubbing floors or
lifting or moving heavy furniture?
Participate in moderate recreational activities like golf,
bowling, dancing, doubles tennis, or throwing a baseball or
football?
reater than
10 METs
Can you . . .
Participate in strenuous sports like swimming, singles tennis,
football, basketball, or skiing?
cher et al. (14).4
Gr infusions of short-acting insulin based on frequent blood
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aintain relatively high glucose levels perioperatively to
void the attendant risks of hypoglycemic episodes; how-
ver, aggressive perioperative glucose control in coronary
ypass surgery patients by a continuous, intravenous insulin
nfusion was found to be superior to intermittent subcuta-
eous insulin administration in significantly reducing post-
perative wound infection (24). A similar benefit is less well
stablished but may be found in noncardiac surgery (25). A
iscussion of the perioperative management of blood glu-
ose concentration can be found in Section 8.7.
.4.3. Renal Impairment
zotemia is commonly associated with cardiac disease and
s associated with an increased risk of cardiovascular events.
aintenance of adequate intravascular volume for renal
erfusion during diuresis of a patient with HF is often
hallenging. Excessive diuresis in combination with initia-
ion of ACE inhibitors or angiotensin receptor blockers may
esult in an increase in blood urea nitrogen and serum
reatinine concentrations. In patients with known vascular
isease, a small increase in blood urea nitrogen and creati-
ine may suggest the presence of renal artery stenosis.
owever, small increases in blood urea nitrogen and serum
reatinine concentrations are not an indication to discon-
inue these drugs, because they have been shown to improve
urvival in patients with HF due to systolic dysfunction.
reexisting renal disease (preoperative serum creatinine
evels 2 mg per dL or greater or reduced glomerular
ltration rate) has been identified as a risk factor for
ostoperative renal dysfunction and increased long-term
orbidity and mortality compared with patients without
enal disease (26,27). In coronary artery bypass patients who
re more than 70 years old, preoperative creatinine levels
reater than 2.6 mg per dL place the patient at much greater
isk for chronic dialysis postoperatively than creatinine levels
elow 2.6 mg per dL (28). Intuitively, one might extrapolate
hese findings to those older patients with comparable
reatinine levels who undergo major noncardiac surgical
rocedures. One large study has shown that a preoperative
reatinine level greater than 2 mg per dL is a significant,
ndependent risk factor for cardiac complications after major
oncardiac surgery (4).
Creatinine clearance, another indicator of renal function,
as been used to predict postoperative complications
29,30). Creatinine clearance incorporates serum creatinine,
ge, and weight to provide a more accurate assessment of
enal function than serum creatinine alone. Kertai et al.
valuated 852 subjects undergoing major vascular surgery
nd demonstrated an increase in mortality as both serum
reatinine increased and creatinine clearance decreased, with
reatinine clearance providing a more accurate assessment
29). To date, there has been no validation of this relation-
hip by other investigators or in a prospective study. The
HA, in a scientific statement, advocated use of the aodification in Diet in Renal Disease equation to calculate
lomerular filtration rate to determine kidney function (27).
.4.4. Hematologic Disorders
nemia imposes a stress on the cardiovascular system that
ay exacerbate myocardial ischemia and aggravate HF (31).
reoperative transfusion, when used appropriately in pa-
ients with advanced CAD and/or HF, may reduce periop-
rative cardiac morbidity. However, with current concern
bout transfusion reaction, clerical error, or transmission of
ommunicable disease through the use of blood products, a
onservative approach with respect to transfusion is war-
anted. Hematocrits less than 28% are associated with an
ncreased incidence of perioperative ischemia and postoper-
tive complications in patients undergoing prostate and
ascular surgery (31–33). In the VA National Surgical
uality Improvement Program database, mild degrees of
reoperative anemia or polycythemia were associated with
n increased risk of 30-day postoperative mortality and
ardiac events in older, mostly male veterans undergoing
ajor noncardiac surgery (34). The adjusted risk of 30-day
ostoperative mortality and cardiac morbidity begins to rise
hen hematocrit levels decrease to less than 39% or exceed
1%.
Polycythemia, thrombocytosis, and other conditions that
ncrease viscosity and hypercoagulability may increase the
isk of thromboembolism or hemorrhage. Appropriate steps
o reduce these risks should be considered and tailored to
he individual patient’s particular circumstances. Current
uidelines are available that address perioperative transfu-
ion practices (35).
.5. Ancillary Studies
he consultant should review all pertinent available labora-
ory data. In the present era of cost containment, the
aboratory data available may be minimal. Therefore, the
onsultant may require additional tests such as blood chem-
stries and a chest x-ray on the basis of history and physical
xamination. Blood levels of cardiac drugs should be ob-
ained only when there are specific indications, such as
hanges in renal function, a recent change in dose, or
ymptoms that suggest toxicity.
The ECG is frequently obtained as part of a preoperative
valuation in all patients over a specific age or undergoing a
pecific set of procedures. Section 5.2.1. identifies the
ndications for a preoperative ECG based on the available
vidence. An abnormal ECG report is often the reason that
onsultation is requested, but if not previously done, an
CG should be obtained as part of the consultation.
etabolic and electrolyte disturbances, medications, intra-
ranial disease, and pulmonary disease, among other things,
an alter the ECG. Conduction disturbances, such as right
undle-branch block or first-degree atrioventricular block,
ay lead to concern but usually do not justify further
orkup. The same is often true of asymptomatic ventricularrrhythmias, even in the presence of structural heart disease
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clinically silent condition of major importance.
.6. Multivariable Indices to Predict Preoperative
ardiac Morbidity
he basic clinical evaluation obtained by history, physical
xamination, and review of the ECG usually provides the
onsultant with sufficient data to estimate cardiac risk. In an
ttempt to codify those clinical and laboratory factors that
nfluence outcome, numerous investigators have developed
isk indices over the past 25 years based on multivariable
nalyses (17,38–47). Although some authors have sug-
ested a scoring system that assigns more weight to some
actors than others and sums these to arrive at a composite
isk (17,45,47), most recent articles have suggested simpler
riteria (4,38–44). Lee et al. derived and validated a “simple
ndex” for the prediction of cardiac risk for stable patients
ndergoing nonurgent major noncardiac surgery (4). Six
ndependent risk correlates were identified: ischemic heart
isease (defined as history of MI, history of positive tread-
ill test, use of nitroglycerin, current complaints of chest
ain thought to be secondary to coronary ischemia, or ECG
ith abnormal Q waves); congestive HF (defined as history
f HF, pulmonary edema, paroxysmal nocturnal dyspnea,
eripheral edema, bilateral rales, S3, or X-ray with pulmo-
ary vascular redistribution); cerebral vascular disease (his-
ory of transient ischemic attack or stroke); high-risk surgery
abdominal aortic aneurysm or other vascular, thoracic,
bdominal, or orthopedic surgery); preoperative insulin
reatment for diabetes mellitus; and preoperative creatinine
reater than 2 mg per dL. Increasing numbers of risk factors
orrelated with increased risk, yet the risk was substantially
ower than described in many of the original indices (4).
hese improvements in outcome most likely reflect selec-
ion bias with respect to who presents for elective surgery,
dvances in surgical technique and anesthesia, and advances
n the management of CAD both perioperatively and in
eneral. The Revised Cardiac Risk Index has become one of
he most widely used risk indices (4).
.7. Clinical Assessment
n the original guidelines, the committee chose to segregate
linical risk factors into major, intermediate, and minor risk
actors. There continues to be a group of active cardiac
onditions that when present indicate major clinical risk.
he presence of 1 or more of these conditions mandates
ntensive management and may result in delay or cancella-
ion of surgery unless the surgery is emergent (Table 2).
hese include:
• unstable coronary syndromes;
X unstable or severe angina,
X recent MI,
• decompensated HF;
• significant arrhythmias; and
• severe valvular disease.
*
tGiven the increasing use of the Revised Cardiac Risk
ndex, the committee chose to replace the intermediate-risk
ategory with the clinical risk factors from the index, with
he exclusion of the type of surgery, which is incorporated
lsewhere in the approach to the patient. Clinical risk
actors include:
• history of ischemic heart disease;
• history of compensated or prior HF;
• history of cerebrovascular disease;
• diabetes mellitus; and
• renal insufficiency (4).
A history of MI or abnormal Q waves by ECG is listed
s a clinical risk factor, whereas an acute MI (defined as at
east 1 documented MI 7 days or less before the examina-
ion) or recent MI (more than 7 days but less than or equal
o 1 month before the examination) with evidence of
mportant ischemic risk by clinical symptoms or noninvasive
tudy is an active cardiac condition. This definition reflects
he consensus of the ACC Cardiovascular Database Com-
ittee. In this way, the separation of MI into the traditional
- and 6-month intervals has been avoided (17,48). Current
anagement of MI provides for risk stratification during
onvalescence (49). If a recent stress test does not indicate
esidual myocardium at risk, the likelihood of reinfarction
fter noncardiac surgery is low. Although there are no
dequate clinical trials on which to base firm recommenda-
ions, it appears reasonable to wait 4 to 6 weeks after MI to
erform elective surgery.
Minor predictors are recognized markers for cardiovas-
ular disease that have not been proven to increase periop-
rative risk independently, for example, advanced age
greater than 70 years), abnormal ECG (LV hypertrophy,
eft bundle-branch block, ST-T abnormalities), rhythm
ther than sinus, and uncontrolled systemic hypertension.
he presence of multiple minor predictors might lead to a
igher suspicion of CAD but is not incorporated into the
ecommendations for treatment.
.7.1. Stepwise Approach to Perioperative Cardiac
ssessment
ecommendations for Perioperative Cardiac Assessment
LASS I
. Patients who have a need for emergency noncardiac surgery should
proceed to the operating room and continue perioperative surveil-
lance and postoperative risk stratification and risk factor manage-
ment. (Level of Evidence: C)
. Patients with active cardiac conditions* should be evaluated and
treated per ACC/AHA guidelines and, if appropriate, consider pro-
ceeding to the operating room. (Level of Evidence: B)
. Patients undergoing low-risk surgery are recommended to proceed
to planned surgery.† (Level of Evidence: B)See Table 2 for active cardiac conditions. †See Class III recommendations in Sec-
ion 5.2.3. Noninvasive Stress Testing.
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ity and no clinical risk factors‡ should proceed with planned sur-
gery.† (Level of Evidence: B)
LASS IIa
. It is probably recommended that patients with functional capacity
greater than or equal to 4 METs without symptoms§ proceed to
planned surgery. (Level of Evidence: B)
. It is probably recommended that patients with poor (less than 4
METs) or unknown functional capacity and 3 or more clinical risk
factors‡ who are scheduled for vascular surgery consider testing if
it will change management.¶ (Level of Evidence: B)
. It is probably recommended that patients with poor (less than 4
METs) or unknown functional capacity and 3 or more clinical risk
factors‡ who are scheduled for intermediate-risk surgery proceed
with planned surgery with heart rate control.¶ (Level of Evidence: B)
Clinical risk factors include ischemic heart disease, compensated or prior heart
ailure, diabetes mellitus, renal insufficiency, and cerebrovascular disease.
See Table 3 for estimated MET level equivalent.
Noninvasive testing may be considered before surgery in specific patients with risk
actors if it will change management.
igure 1. Cardiac Evaluation and Care Algorithm for Noncardiac S
ase, or Cardiac Risk for Patients 50 Years of Age or Greater
See Table 2 for active cardiac conditions. †See Class III recommendations in Sect
Noninvasive testing may be considered before surgery in specific patients with risk
ase, compensated or prior heart failure, diabetes mellitus, renal insufficiency, and
ations in which this has been shown to reduce cardiac morbidity/mortality. ACC/AH
OE, level of evidence; and MET, metabolic equivalent.(
Consider perioperative beta blockade (see Table 11) for populations in which this
as been shown to reduce cardiac morbidity/mortality.. It is probably recommended that patients with poor (less than 4
METs) or unknown functional capacity and 1 or 2 clinical risk
factors‡ who are scheduled for vascular or intermediate-risk surgery
proceed with planned surgery with heart rate control.¶ (Level of
Evidence: B)
LASS IIb
. Noninvasive testing might be considered if it will change manage-
ment for patients with poor (less than 4 METs) or unknown func-
tional capacity and 3 or more clinical risk factors‡ who are sched-
uled for intermediate-risk surgery. (Level of Evidence: B)
. Noninvasive testing might be considered if it will change manage-
ment for patients with poor (less than 4 METs) or unknown func-
tional capacity and 1 or 2 clinical risk factors‡ who are scheduled
for vascular or intermediate-risk surgery. (Level of Evidence: B)
igure 1 presents, in algorithmic form, a framework for
etermining which patients are candidates for cardiac test-
ng. The clinician must consider several interacting variables
nd give them appropriate weight. Since publication of the
erioperative cardiovascular evaluation guidelines in 2002
y Based on Active Clinical Conditions, Known Cardiovascular Dis-
.3. Noninvasive Stress Testing. ‡See Table 3 for estimated MET level equivalent.
s if it will change management. Clinical risk factors include ischemic heart dis-
ovascular disease. ¶Consider perioperative beta blockade (see Table 11) for popu-
ates American College of Cardiology/American Heart Association; HR, heart rate;urger
ion 5.2
factor
cerebr50), several new randomized trials and cohort studies have
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November 24, 2009:e13–118 2009 ACCF/AHA Perioperative Guidelinesed to modification of the original algorithm. Given the
vailability of this evidence, the writing committee chose to
nclude the level of the recommendations and strength of
vidence for each of the pathways.
Step 1: The consultant should determine the urgency of
oncardiac surgery. In many instances, patient- or surgery-
pecific factors dictate an obvious strategy (e.g., emergency
urgery) that may not allow for further cardiac assessment or
reatment. In such cases, the consultant may function best
y providing recommendations for perioperative medical
anagement and surveillance. Selected postoperative risk
tratification is often appropriate in patients with elevated
isk for long-term coronary events who have never had such
n assessment before. This is usually initiated after the
atient has recovered from blood loss, deconditioning, and
ther postoperative complications that might confound
nterpretation of noninvasive test results.
Step 2: Does the patient have 1 of the active cardiac
onditions in Table 2? If not, proceed to step 3. In patients
eing considered for elective noncardiac surgery, the pres-
nce of unstable coronary disease, decompensated HF, or
evere arrhythmia or valvular heart disease usually leads to
ancellation or delay of surgery until the cardiac problem has
een clarified and treated appropriately. Examples of unsta-
le coronary syndromes include previous MI with evidence
f important ischemic risk by clinical symptoms or nonin-
asive study, unstable or severe angina, and new or poorly
ontrolled ischemia-mediated HF. Many patients in these
ircumstances are referred for coronary angiography to
ssess further therapeutic options. Depending on the results
f the test or interventions and the risk of delaying surgery,
t may be appropriate to proceed to the planned surgery with
aximal medical therapy.
Step 3: Is the patient undergoing low-risk surgery? Many
rocedures are associated with a combined morbidity and
ortality rate less than 1% (see Section 4.), even in
igh-risk patients. Additionally, mortality on the day of
urgery, for most ambulatory surgical procedures, is actually
ower than mortality on day 30, which suggests that the
ncremental risk of ambulatory surgery is negligible or may
e protective (51). Therefore, interventions based on car-
iovascular testing in stable patients would rarely result in a
hange in management, and it would be appropriate to
roceed with the planned surgical procedure.
Step 4: Does the patient have a functional capacity
reater than or equal to 4 METs without symptoms?
unctional status has been shown to be reliable for periop-
rative and long-term prediction of cardiac events (52–56).
n highly functional asymptomatic patients, management
ill rarely be changed based on the results of any further
ardiovascular testing. It is therefore appropriate to proceed
ith the planned surgery. In patients with known cardio-
ascular disease or at least 1 clinical risk factor, perioperative
eart rate control with beta blockade appears appropriate as
utlined in Section 7.2. aIf the patient has not had a recent exercise test, functional
tatus can usually be estimated from the ability to perform
ctivities of daily living (55). Functional capacity can be
xpressed as metabolic equivalents (METs); the resting or
asal oxygen consumption (VO2) of a 70-kg, 40-year-old
an in a resting state is 3.5 mL per kg per min, or 1 MET.
or this purpose, functional capacity has been classified as
xcellent (greater than 10 METs), good (7 to 10 METs),
oderate (4 to 6 METs), poor (less than 4 METs), or
nknown. Multiples of the baseline MET values provide a
niform terminology across different exercise protocols to
xpress aerobic demands for specific activities. Maximum
nd submaximum levels of work differ per unit of time
ccording to the exercise protocol used. Thus, 6 minutes of
Naughton protocol is not equivalent to 6 minutes on a
tandard Bruce protocol in terms of work performed and
nergy expended. The predicted MET level for a certain
ctivity is influenced by the degree of conditioning and
enetic predisposition. Perioperative cardiac and long-term
isks are increased in patients unable to meet a 4-MET
emand during most normal daily activities (55). In 1 series
f 600 consecutive patients undergoing major noncardiac
rocedures, perioperative myocardial ischemia and cardio-
ascular events were more common in patients who reported
oor exercise tolerance (inability to walk 4 blocks or climb 2
ights of stairs), even after adjustment for baseline charac-
eristics known to be associated with increased risk (55).
he likelihood of a serious complication occurring was
nversely related to the number of blocks that could be
alked (p0.006) or flights of stairs that could be climbed
p0.01). Examples of leisure activities associated with less
han 4 METs are slow ballroom dancing, golfing with a
art, playing a musical instrument, and walking at a speed of
pproximately 2 to 3 mph. Activities that require more than
METs include moderate cycling, climbing hills, ice skating,
oller blading, skiing, singles tennis, and jogging. The Duke
ctivity Status Index contains questions that can be used to
stimate the patient’s functional capacity (11,52). Use of the
uke Activity Status Index or other activity scales (53) and
nowledge of the METs levels required for physical activities,
s listed above and described in Table 3, provide the clinician
ith a relatively easy set of questions to estimate whether a
atient’s functional capacity will be less than or greater than 4
ETs. At activity levels less than 4 METs, specific questions
o establish risk gradients are less reliable. Furthermore, a
linical questionnaire only estimates functional capacity and
oes not provide as objective a measurement as exercise
readmill testing or arm ergometry. Other activity scales have
een advocated, including the Specific Activity Scale (57).
Step 5: If the patient has poor functional capacity, is
ymptomatic, or has unknown functional capacity, then the
resence of clinical risk factors will determine the need for
urther evaluation. If the patient has no clinical risk factors,
hen it is appropriate to proceed with the planned surgery,
nd no further change in management is indicated.
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2009 ACCF/AHA Perioperative Guidelines November 24, 2009:e13–118If the patient has 1 or 2 clinical risk factors, then it is
easonable to either proceed with the planned surgery, with
eart rate control with beta blockade, or consider testing if
t will change management. Two studies in vascular surgery
atients with 1 to 2 clinical risk factors were unable to
emonstrate any difference in outcome in the group who
roceeded with the planned surgery with good medical
anagement or tight heart rate control, but there are
ircumstances in which the clinician may change aspects of
are based on the results of the test (58,59).
In patients with 3 or more clinical risk factors, the
urgery-specific cardiac risk is important. The surgery-
pecific cardiac risk (Table 4) of noncardiac surgery is
elated to 2 important factors. First, the type of surgery itself
ay identify a patient with a greater likelihood of underly-
ng heart disease and higher perioperative morbidity and
ortality. Perhaps the most extensively studied example is
ascular surgery, in which underlying CAD is present in a
ubstantial portion of patients. If the patient is undergoing
ascular surgery, testing should only be considered if it
ill change management. Other types of surgery may be
ssociated with similar risk to vascular surgery but have
ot been studied extensively. For nonvascular surgery, the
egree of hemodynamic cardiac stress dictates the
urgery-specific risk. Depending on the noncardiac sur-
ical procedure, it may be associated with profound
lterations in heart rate, blood pressure, vascular volume,
ain, bleeding, clotting tendencies, oxygenation, neuro-
umoral activation, and other perturbations. The inten-
ity of these coronary and myocardial stressors helps
etermine the likelihood of perioperative cardiac events.
he perioperative morbidity related to the procedures
anges from 1% to 5%. In these patients who are
onsidered ready to undergo intermediate-risk surgery,
here are insufficient data to determine the best strategy
proceeding with the planned surgery with tight heart
ate control with beta blockade or further cardiovascular
able 4. Cardiac Risk* Stratification for Noncardiac Surgical
rocedures
Risk Stratification Procedure Examples
ascular (reported cardiac risk
often more than 5%)
Aortic and other major vascular surgery
Peripheral vascular surgery
ntermediate (reported cardiac
risk generally 1% to 5%)
Intraperitoneal and intrathoracic surgery
Carotid endarterectomy
Head and neck surgery
Orthopedic surgery
Prostate surgery
ow† (reported cardiac risk
generally less than 1%)
Endoscopic procedures
Superficial procedure
Cataract surgery
Breast surgery
Ambulatory surgery
Combined incidence of cardiac death and nonfatal myocardial infarction. †These procedures do
ot generally require further preoperative cardiac testing.esting if it will change management). s. Disease-Specific Approaches
.1. Coronary Artery Disease
.1.1. Patients With Known CAD
n some patients, such as those with an acute MI, prior
oronary artery bypass grafting (CABG), coronary angio-
lasty, or a coronary angiogram that shows luminal obstruc-
ions or irregularities, the presence of CAD may be obvious.
n the other hand, many patients without cardiac symp-
oms may have severe double- or triple-vessel disease that is
ot clinically obvious because the patients may present
typically or are functionally limited by severe arthritis or
eripheral vascular disease. A subset of patients who are
andidates for revascularization independent of planned
oncardiac surgery may benefit from noninvasive evaluation.
n patients with known CAD, as well as those with
reviously occult coronary disease, the questions become 1)
hat is the amount of myocardium in jeopardy? 2) What is
he ischemic threshold, i.e., the amount of stress required to
roduce ischemia? 3) What is the patient’s ventricular
unction? and 4) Is the patient on his or her optimal medical
egimen? Clarification of these questions is an important
oal of the preoperative history and physical examination,
nd selected noninvasive testing is used to determine the
atient’s prognostic gradient of ischemic response during
tress testing (Table 5). Given recent evidence regarding the
imited value of coronary revascularization before noncar-
iac surgery (see Section 7.1.), the indication for preopera-
ive testing is limited to the group in whom coronary
evascularization may be beneficial independent of noncar-
iac surgery.
.1.2. Influence of Age and Gender
dvanced age is a special risk, not only because of the
ncreased likelihood of coronary disease but also because of
he effects of aging on the myocardium. The mortality of
cute MI increases dramatically in the aged (68). Intraop-
rative or perioperative MI has a higher mortality in the
ged (17,44,45).
Gender is important because premenopausal women have
lower incidence of CAD, and in general, symptomatic
AD occurs 10 or more years later in women than in men
70). Women who have premature menopause, such as after
ophorectomy, are an exception to this rule. Women with
iabetes mellitus have an increased risk that is equivalent to
en of the same age. The mortality rate after acute MI is
reater for women than for men, but older age and diabetes
ellitus account for much of this difference (69). Whether
r not other factors such as coronary artery size or different
athophysiology also contribute to the increased risk in
omen is not yet fully understood.
.2. Hypertension
umerous studies (17,38,41,44,71,72) have shown that
tage 1 or stage 2 hypertension (systolic blood pressure
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November 24, 2009:e13–118 2009 ACCF/AHA Perioperative Guidelineselow 180 mm Hg and diastolic blood pressure below 110 mm
g) is not an independent risk factor for perioperative cardio-
ascular complications. However, hypertension is common,
nd treatment has been shown to be associated with decreased
ates of death due to stroke and CHD in the nonsurgical
etting. Unfortunately, all too few patients with hypertension
re treated, and fewer yet have their hypertension controlled.
ccordingly, the perioperative evaluation is a unique opportu-
ity to identify patients with hypertension and initiate appro-
riate therapy. As a universally measured variable with a
ecognized association with CAD, hypertension serves as a
seful marker for potential CAD (73). In addition, several
nvestigators have demonstrated exaggerated intraoperative
lood pressure fluctuation with associated ECG evidence of
yocardial ischemia in patients with preoperative blood pres-
able 5. Prognostic Gradient of Ischemic Responses During
n ECG-Monitored Exercise Test in Patients With Suspected
r Proven CAD
Risk Level Ischemic Response Gradient
igh Ischemia induced by low-level exercise† (less than 4
METs or heart rate less than 100 bpm or less than
70% of age-predicted heart rate) manifested by 1 or
more of the following:
● Horizontal or downsloping ST depression greater than
0.1 mV
● ST-segment elevation greater than 0.1 mV in
noninfarct lead
● Five or more abnormal leads
● Persistent ischemic response greater than 3 min after
exertion
● Typical angina
● Exercise-induced decrease in systolic blood pressure by
10 mm Hg
ntermediate Ischemia induced by moderate-level exercise* (4 to 6
METs or heart rate 100 to 130 bpm [70% to 85% of
age-predicted heart rate]) manifested by 1 or more of
the following:
● Horizontal or downsloping ST depression greater than
0.1 mV
● Persistent ischemic response greater than 1 to 3 min
after exertion
● Three to 4 abnormal leads
ow No ischemia or ischemia induced at high-level exercise*
(greater than 7 METs or heart rate greater than 130
bpm [greater than 85% of age-predicted heart rate])
manifested by:
● Horizontal or downsloping ST depression greater than
0.1 mV
● One or 2 abnormal leads
nadequate test Inability to reach adequate target workload or heart rate
response for age without an ischemic response. For
patients undergoing noncardiac surgery, the inability
to exercise to at least the intermediate-risk level
without ischemia should be considered an inadequate
test.
Based on Weiner et al., 1984 (60); Morris et al., 1991 (61); Chaitman, 1986 (62); Gianrossi
t al., 1989 (63); Detrano et al., 1989 (64); Mark et al., 1987 (65); Mark et al., 1991 (66); and
ibbons et al. (67). †Workload and heart rate estimates for risk severity require adjustment for
atient age. Maximum target heart rates for 40- and 80-year-old subjects taking no cardioactive
edication are 180 and 140 bpm, respectively (63–70).
bpm indicates beats per min; CAD, coronary artery disease; ECG, electrocardiogram; and MET,
etabolic equivalent.ure elevation (74–77). This effect can be modified by treat- pent (75–80). Because intraoperative ischemia correlates with
ostoperative cardiac morbidity (71,81), it follows that control
f blood pressure preoperatively may help reduce the tendency
o perioperative ischemia. Although an elevated blood pressure
n an initial recording in a patient with previously undiagnosed
r untreated hypertension has been shown to correlate with
lood pressure lability under anesthesia (81,82), the definition
f the severity of hypertension rests with subsequent recordings
n a nonstressful environment (73). In patients undergoing
herapy for hypertension, a thorough review of current medi-
ations and dosages, along with awareness of known intoler-
nce to previously prescribed drugs, is essential. The physical
xamination should include a search for target-organ damage
nd evidence of associated cardiovascular pathology. A fundu-
copic examination may provide useful data regarding the
everity and chronicity of hypertension.
The physical examination and simple laboratory tests can
ule out some of the rare but important causes of hyperten-
ion. Further evaluation to exclude secondary hypertension
s rarely warranted before necessary surgery. If pheochro-
ocytoma is a serious possibility, surgery should be delayed
o permit its exclusion. A loud abdominal bruit may suggest
enal artery stenosis. A radial to femoral artery pulse delay
uggests coarctation of the aorta, whereas hypokalemia in
he absence of diuretic therapy raises the possibility of
yperaldosteronism.
If the initial evaluation establishes hypertension as mild
r moderate, and there are no associated metabolic or
ardiovascular abnormalities, there is no evidence that it is
eneficial to delay surgery (83). Several investigators have
stablished the value of effective preoperative blood pressure
ontrol among patients with established hypertension
76,77,80,84), and antihypertensive medications should be
ontinued during the perioperative period. Particular care
hould be taken to avoid withdrawal of beta blockers and
lonidine because of potential heart rate or blood pressure
ebound (see Sections 7.2.1.3. and 7.2.3.). In patients
nable to take oral medications, parenteral beta blockers and
ransdermal clonidine may be used. Medication selection
nd risks should be assessed on the basis of national
uidelines (73).
For stage 3 hypertension (systolic blood pressure greater
han or equal to 180 mm Hg and diastolic blood pressure
reater than or equal to 110 mm Hg), the potential benefits
f delaying surgery to optimize the effects of antihyperten-
ive medications should be weighed against the risk of
elaying the surgical procedure. With rapidly acting intra-
enous agents, blood pressure can usually be controlled
ithin a matter of several hours. One randomized trial was
nable to demonstrate a benefit to delaying surgery. Wek-
ler et al. studied 989 chronically treated hypertensive
atients who presented for noncardiac surgery with diastolic
lood pressure between 110 and 130 mm Hg who had no
revious MI, unstable or severe angina pectoris, renal
ailure, pregnancy-induced hypertension, LV hypertrophy,
revious coronary revascularization, aortic stenosis, preop-
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2009 ACCF/AHA Perioperative Guidelines November 24, 2009:e13–118rative dysrhythmias, conduction defects, or stroke (85).
he control group had their surgery postponed, and they
emained in the hospital for blood pressure control, whereas
he study patients received 10 mg of nifedipine delivered
ntranasally. They observed no statistically significant dif-
erences in postoperative complications, which suggests that
his subset of patients without significant cardiovascular
omorbidities can proceed with surgery despite elevated
lood pressure on the day of surgery. Alternatively, beta
lockers appear to be particularly attractive agents for the
reatment of preoperative high blood pressure. Several
eports have shown that the introduction of preoperative
eta-adrenergic blockers leads to effective modulation of
evere blood pressure fluctuations and a reduction in the
umber and duration of perioperative coronary ischemic
pisodes (75–80). The preoperative administration of beta-
drenergic blocking drugs has been shown to decrease the
ncidence of postoperative atrial fibrillation (86), and in
atients who have or are at risk for CAD who must undergo
oncardiac surgery, treatment with beta blockers during
ospitalization can reduce mortality and the incidence of
ardiovascular complications (87,88). A full discussion of
he benefits and risks of beta blockers can be found in
ection 7.2.1.
Interestingly, patients with preoperative hypertension
ppear more likely to develop intraoperative hypotension
han nonhypertensive persons; this is particularly true for
atients taking ACE inhibitors or angiotensin II receptor
ntagonists (89). In some patients, this may be related to a
ecrease in vascular volume. In 1 report, intraoperative
ypotension was associated with a greater incidence of
erioperative cardiac and renal complications than intraop-
rative hypertension, although other studies have not shown
his (77,90–95). Several authors have suggested withhold-
ng ACE inhibitors and angiotensin receptor antagonists
he morning of surgery (96–98). Consideration should be
iven to restarting ACE inhibitors in the postoperative
eriod only after the patient is euvolemic, to decrease the
isk of perioperative renal dysfunction.
.3. Heart Failure
eart failure has been identified in several studies as being
ssociated with a poorer outcome when noncardiac surgery
s performed. In a study by Goldman et al. (17), both the
resence of a third heart sound and signs of HF were
ssociated with a substantially increased risk during noncar-
iac surgery. Detsky et al. (45) identified alveolar pulmonary
dema as a significant risk factor, and in the report by
ooperman et al. (47), HF also bestowed a significant risk.
ee et al. also identified HF (defined as the presence of any
f the following: history of congestive HF, pulmonary
dema, or paroxysmal nocturnal dyspnea; physical examina-
ion showing bilateral rales or S3 gallop; or chest X-ray
howing pulmonary vascular redistribution) as an indepen-
ent predictor of risk (4). Every effort must be made to
etect unsuspected HF by a careful history and physical pxamination. If possible, it is important to identify the cause
f HF, because this may have implications concerning risk
f death versus perioperative HF. For instance, prior HF
ue to hypertensive heart disease may portend a different
isk than prior HF that results from CAD.
.4. Cardiomyopathy
here is little information on the preoperative evaluation of
atients with cardiomyopathy before noncardiac surgery. At
his time, preoperative recommendations must be based on
thorough understanding of the pathophysiology of the
yopathic process. Every reasonable effort should be made
efore surgery to determine the cause of the primary
yocardial disease. Knowledge of the cause may alter
ntraoperative and postoperative management of intrave-
ous fluids. In patients with a history or signs of HF,
reoperative assessment of LV function may be recom-
ended to quantify the severity of systolic and diastolic
ysfunction. This information is valuable for both intraop-
rative and postoperative management. This assessment
requently includes echocardiography.
Hypertrophic obstructive cardiomyopathy poses special
roblems. Reduction of blood volume, decreased systemic
ascular resistance, and increased venous capacitance may cause
reduction in LV volume and thereby potentially increase a
endency to outflow obstruction, with potentially untoward
esults. Furthermore, reduced filling pressures may result in a
ignificant fall in stroke volume because of the decreased
ompliance of the hypertrophied ventricle. Beta-adrenergic
gonists should be avoided because they may increase the
egree of dynamic obstruction and decrease diastolic filling. In
relatively small series of 35 patients with hypertrophic
bstructive cardiomyopathy, there were no deaths or serious
entricular arrhythmias during or immediately after general
urgical procedures; 1 patient had major vascular surgery (99).
n the 22 patients who underwent catheterization, the mean
est and peak provocable gradients were 30 and 81 mm Hg,
espectively. The only patient who had a perioperative MI had
-vessel coronary disease. Significant arrhythmias or hypoten-
ion that required vasoconstrictors occurred in 14% and 13% of
atients, respectively (99). In another study, 77 patients with
ypertrophic obstructive cardiomyopathy who underwent non-
ardiac surgery were evaluated. There were no deaths, but these
atients had a significant incidence of adverse cardiac events,
requently manifested as HF. Independent risk factors for
dverse outcome in all patients included major surgery and
ncreasing duration of surgery. Echocardiographic features,
ncluding resting outflow tract gradient, were not associated
ith adverse cardiac events (100).
.5. Valvular Heart Disease
ardiac murmurs are common in patients facing noncardiac
urgery. The consultant must be able to distinguish organic
rom functional murmurs, significant from insignificant
urmurs, and the origin of the murmur to determine whichatients require prophylaxis for endocarditis and which
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November 24, 2009:e13–118 2009 ACCF/AHA Perioperative Guidelinesatients require further quantitation of the severity of the
alvular lesion. We recommend physicians review all of the
vailable data and use individual clinical judgment when
etermining whether to recommend prophylaxis. Specific
ecommendations for endocarditis prophylaxis have been
ublished elsewhere (18).
Severe aortic stenosis poses the greatest risk for noncar-
iac surgery (17,101,102). If the aortic stenosis is symptom-
tic, elective noncardiac surgery should generally be post-
oned or canceled. Such patients require aortic valve
eplacement before elective but necessary noncardiac sur-
ery. If the aortic stenosis is severe but asymptomatic, the
urgery should be postponed or canceled if the valve has not
een evaluated within the year. On the other hand, in
atients with severe aortic stenosis who refuse cardiac
urgery or are otherwise not candidates for aortic valve
eplacement, noncardiac surgery can be performed with a
ortality risk of approximately 10% (103,104). In a data-
ase analysis in which severity of aortic stenosis was not
efined, the presence of aortic stenosis was associated with
n increased risk of acute MI (OR 1.55) but not death after
djustment for other comorbidities (105). If a patient is not
candidate for valve replacement, percutaneous balloon
ortic valvuloplasty may be reasonable as a bridge to surgery
n hemodynamically unstable adult patients with aortic
tenosis who are at high risk for aortic valve replacement
urgery and may be reasonable in adult patients with aortic
tenosis in whom aortic valve replacement cannot be per-
ormed because of serious comorbid conditions (102,106).
Mitral stenosis, although increasingly rare, is important
o recognize. When stenosis is mild or moderate, the
onsultant must ensure control of heart rate during the
erioperative period, because the reduction in diastolic
lling period that accompanies tachycardia can lead to
evere pulmonary congestion. Significant mitral stenosis
ncreases the risk of HF. However, preoperative surgical
orrection of mitral valve disease is not indicated before
oncardiac surgery unless the valvular condition should be
orrected to prolong survival and prevent complications that
re unrelated to the proposed noncardiac surgery. When the
tenosis is severe, the patient may benefit from balloon
itral valvuloplasty or open surgical repair before high-risk
urgery (107).
Aortic regurgitation suspected on examination warrants
ualification for long-term follow-up and indicated therapy.
f such qualification is not done, the regurgitation needs to
e identified, and provide appropriate medical treatment.
ttention to volume control and afterload reduction is
ecommended. In contrast to mitral stenosis, severe aortic
egurgitation is not benefited by unusually slow heart rates,
hich can increase the volume of regurgitation by increasing
he duration of diastole. Tachycardia thus reduces the time
f regurgitation in severe aortic regurgitation.
Mitral regurgitation has many causes, the 2 most com-
on being mitral valve prolapse that results from myxoma-ous degeneration and functional mitral regurgitation that tomplicates postinfarction LV remodeling. Specific recom-
endations regarding perioperative antibiotic prophylaxis
or patients with mitral valve prolapse can be found else-
here (18).
Patients with severe mitral regurgitation (often manifested
linically by an apical holosystolic murmur, a third heart sound,
nd a diastolic flow rumble) may benefit from afterload
eduction and administration of diuretics to produce maximal
emodynamic stabilization before high-risk surgery. It is also
mportant for the consultant to note even mild reduction of the
V ejection fraction (LVEF) in patients with mitral regurgi-
ation, because LVEF may overestimate true LV performance.
n such patients, even a mildly reduced LVEF may be a sign of
educed ventricular reserve. In patients with persistent or
ermanent atrial fibrillation at high risk for thromboembolism,
reoperative and postoperative therapy with intravenous hep-
rin or subcutaneous low-molecular-weight heparin may be
onsidered to cover periods of subtherapeutic anticoagulation
108–111). Patients who have severe symptomatic mitral
egurgitation or aortic insufficiency should be considered for
urther evaluation. These topics are discussed in more detail in
he AHA/ACC Valvular Heart Disease Guidelines (102).
Patients with a mechanical prosthetic valve are of concern
ecause of the need for endocarditis prophylaxis (18) when
hey undergo surgery that may result in bacteremia and the
eed for careful anticoagulation management. The Seventh
merican College of Chest Physicians Consensus Confer-
nce on Antithrombotic and Thrombolytic Therapy recom-
ends the following (112): For patients who require min-
mally invasive procedures (dental work, superficial
iopsies), the recommendation is to briefly reduce the
nternational normalized ratio (INR) to the low or subthera-
eutic range and resume the normal dose of oral anticoag-
lation immediately after the procedure. Perioperative un-
ractionated heparin therapy is recommended for patients in
hom the risk of bleeding with oral anticoagulation is high
nd the risk of thromboembolism without anticoagulation is
lso high (mechanical valve in the mitral position, Bjork-
hiley valve, recent [i.e., less than 1 year] thrombosis or
mbolus, or 3 or more of the following risk factors: atrial
brillation, previous embolus at any time, hypercoagulable
ondition, mechanical prosthesis, and LVEF less than 30%
113). For patients between these 2 extremes, physicians
ust assess the risk and benefit of reduced anticoagulation
ersus perioperative heparin therapy.
.6. Arrhythmias and Conduction Defects
ardiac arrhythmias and conduction disturbances are not
ncommon findings in the perioperative period (17,39,114),
articularly in the elderly. Both supraventricular and ven-
ricular arrhythmias have been identified as independent risk
actors for coronary events in the perioperative period
17,114). More recent detailed studies using continuous
CG monitoring found that asymptomatic ventricular ar-
hythmias, including couplets and nonsustained ventricular
achycardia, were not associated with an increase in cardiac
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2009 ACCF/AHA Perioperative Guidelines November 24, 2009:e13–118omplications after noncardiac surgery (37). Nevertheless,
he presence of an arrhythmia in the preoperative setting
hould provoke a search for underlying cardiopulmonary
isease, ongoing myocardial ischemia or infarction, drug
oxicity, or metabolic derangements.
Some cardiac arrhythmias, although relatively benign,
ay unmask underlying cardiac problems; for example,
trial fibrillation and other types of supraventricular arrhyth-
ias can produce ischemia by increasing myocardial oxygen
emand in patients with coronary disease. Atrial fibrillation
s the most common type of sustained supraventricular
achycardia, particularly in elderly patients who are likely to
e undergoing surgical procedures. Rarely, arrhythmias,
ecause of the hemodynamic or metabolic derangements
hey cause, may deteriorate into more life-threatening
hythm disturbances; for example, atrial fibrillation with a
apid ventricular response in a patient with an accessory
ypass pathway may degenerate into ventricular fibrillation.
entricular arrhythmias, whether single premature ventric-
lar contractions, complex ventricular ectopy, or nonsus-
ained ventricular tachycardia, usually do not require therapy
nless they result in hemodynamic compromise. Although
requent ventricular premature beats and nonsustained ven-
ricular tachycardia are considered risk factors for the
evelopment of intraoperative and postoperative arrhyth-
ias and sustained ventricular arrhythmias during long-
erm follow-up, they are not associated with an increased
isk of nonfatal MI or cardiac death in the perioperative
eriod (36,37). However, patients who develop sustained
nd/or nonsustained ventricular tachycardia during the peri-
perative period should be referred to a cardiologist for
urther evaluation, including an evaluation of their ventric-
lar function and screening for CAD. Physicians should
ave a low threshold to institute prophylactic beta-blocker
herapy in patients at increased risk of developing a periop-
rative or postoperative supraventricular or ventricular
achyarrhythmia. Several studies suggest that beta-blocker
herapy can reduce mortality and the incidence of cardio-
ascular complications (including the development of ar-
hythmias) during surgery and for up to 2 years afterward
86–88,115).
High-grade cardiac conduction abnormalities, such as
omplete atrioventricular block, if unanticipated, can in-
rease operative risk and may necessitate temporary or
ermanent transvenous pacing. On the other hand, patients
ith intraventricular conduction delays, even in the presence
f a left or right bundle-branch block, and no history of
dvanced heart block or symptoms rarely progress to com-
lete heart block perioperatively (116). The availability of
ransthoracic pacing units makes the decision for temporary
ransvenous pacing less critical.
.7. Implanted Pacemakers and ICDs
ach year, more than 250 000 patients undergo placement
f a permanent pacemaker, and more than 150 000 patients
ndergo placement of an ICD. The presence of a pacemaker tr ICD has important implications regarding preoperative,
ntraoperative, and postoperative patient management. The
ituations in which device malfunction may occur, as well as
he techniques that may be used to prevent them, are
iscussed in Section 7.5.
.8. Pulmonary Vascular Disease and
ongenital Heart Disease
here are no reported studies that specifically assess the
erioperative risk associated with pulmonary vascular dis-
ase in patients having noncardiac surgery. A number of
eports have evaluated cardiovascular function many years
fter surgery for congenital heart disease. Five years after
urgery for ventricular septal defect or patent ductus arteri-
sus, pulmonary vasoreactivity often remains abnormal,
esulting in high pulmonary pressures with hypoxia. Such
atients may not tolerate intraoperative or postoperative
ypoxia as well as normal individuals.
Patients with congenital heart disease have also demon-
trated a reduced cardiac reserve during exercise (117). Post-
perative studies of patients with coarctation of the aorta or
etralogy of Fallot have demonstrated findings consistent
ith underlying ventricular dysfunction (118,119). These
bservations should be kept in mind when such patients are
valuated before noncardiac surgery. Patients receiving pri-
ary cardiac repair at a younger age in the present era may
e less prone to postoperative ventricular dysfunction be-
ause of improved surgical techniques.
Although most experts agree that pulmonary hyperten-
ion poses an increased risk for noncardiac surgery, no major
tudy of this has been performed. The only analogous
ituation is labor and delivery for women with Eisenmenger
yndrome due to a congenital intracardiac shunt. Peripar-
um mortality was reported to be between 30% and 70% in
971, but no recent data exist to clarify whether or not this
as fallen with improvements in care (120). In patients with
evere pulmonary hypertension and a cardiac shunt, sys-
emic hypotension results in increased right-to-left shunting
nd predisposes the patient to development of acidosis,
hich can lead to further decreases in systemic vascular
esistance. This cycle must be recognized and treated
ppropriately.
. Surgery-Specific Issues
ardiac complications after noncardiac surgery are a reflec-
ion of factors specific to the patient, the operation, and the
ircumstances under which the operation is undertaken. To
he extent that preoperative cardiac evaluation reliably
redicts postoperative cardiac outcomes, it may lead to
nterventions that lower perioperative risk, decrease long-
erm mortality, or alter the surgical decision-making pro-
ess. Such alterations might include either choosing a
ower-risk, less-invasive procedure or opting for nonopera-
ive management (e.g., recommending an endovascular
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November 24, 2009:e13–118 2009 ACCF/AHA Perioperative Guidelinesather than open operative approach for a particular aneu-
ysm or occlusive lesion, electing to follow up rather than
perate on a moderate-sized [4 to 5 cm] infrarenal aortic
neurysm, or choosing nonoperative treatment for the
isabled claudicant who has no limb-threatening ischemia).
lthough different operations are associated with different
ardiac risks, these differences are most often a reflection of
he context in which the patient undergoes surgery (stability
r opportunity for adequate preoperative preparation),
urgery-specific factors (e.g., fluid shifts, stress levels, dura-
ion of procedure, or blood loss), or patient-specific factors
the incidence of CAD associated with the condition for
hich the patient is undergoing surgery).
To the extent that preoperative cardiac evaluation can
dentify potentially reducible cardiac risks, interventions
irected at reducing those risks might improve both short-
nd long-term cardiac outcomes. The potential for im-
rovement in long-term outcomes is particularly relevant to
perative decision making in patients undergoing surgery
irected at long-term goals. When, for example, surgery in
symptomatic individuals is undertaken with the objective
f prolonging life (e.g., elective repair of aortic aneurysm) or
reventing a future stroke (e.g., carotid endarterectomy), the
ecision to intervene must be made with the expectation
hat the patient will live long enough to benefit from the
rophylactic intervention.
.1. Urgency
angano (121) determined that cardiac complications are 2
o 5 times more likely to occur with emergency surgical
rocedures than with elective operations. This finding is not
urprising, because the necessity for immediate surgical
ntervention may make it impossible to evaluate and treat
uch patients optimally. For instance, collected data have
onfirmed that the composite mortality rate for elective
epair of patients with asymptomatic abdominal aortic
neurysms is significantly lower (3.5%) than that for rup-
ured aneurysms (42%) (122). The mortality rate for graft
eplacements of symptomatic but intact abdominal aortic
neurysms remains relatively high (19%) despite the fact
hat, like elective cases, they are not associated with ante-
edent blood loss or hypotension (123). Unfortunately, most
rue surgical emergencies (e.g., symptomatic abdominal
ortic aneurysms, perforated viscus, or major trauma) do not
ermit more than a cursory cardiac evaluation.
In addition, some situations do not lend themselves to
omprehensive cardiac evaluation, although surgical care
ay qualify as semielective. In some patients, the impend-
ng danger of the disease is greater than the anticipated
erioperative risk. Examples include patients who require
rterial bypass procedures for limb salvage or mesenteric
evascularization to prevent intestinal gangrene. Patients
ith malignant neoplasms also pose a diagnostic and ther-
peutic dilemma with respect to preoperative cardiac eval-
ation, especially when it is difficult to determine whether
he malignancy is curable before surgical exploration. Each cf these situations illustrates the importance of close com-
unication among consultant, surgeon, and anesthesiolo-
ist to plan an approach for cardiac assessment that is
ppropriate for the individual patient and the underlying
isease.
.2. Surgical Risk
or elective surgery, cardiac risk can be stratified according
o a number of factors, including the magnitude of the
urgical procedure. Backer et al. (124) encountered no
ardiac complications after 288 ophthalmologic procedures
n 195 patients with a prior history of MI compared with a
einfarction rate of 6.1% for a number of nonophthalmo-
ogic surgeries at the same center. Indeed, large-scale studies
ave supported the low morbidity and mortality rates in
uperficial procedures performed on an ambulatory basis.
or example, Warner et al. (125) determined the perioper-
tive (30 day) incidence of symptomatic MI and cardiac
eath in 38 500 patients who underwent 45 090 consecutive
rocedures with anesthetics. Fourteen perioperative MIs
ccurred (0.03%), of which 2 resulted in death on postop-
rative day 7 after the infarction. Two MIs occurred either
ntraoperatively or within the first 8 hours, 1 of which was
atal. Using age- and gender-adjusted annual incidence rates
or MIs and sudden death, the authors predicted that 17.8
Is should have occurred among this population during the
tudy period, which suggests that these events may have
ccurred independent of the procedure. In contrast, Lee et
l. (4) reported that major perioperative cardiac events
ccurred in 1.4% of relatively unselected patients 50 years of
ge or older undergoing elective noncardiac surgery that
equired hospital admission. In a pooled analysis of prospec-
ive studies in which patients who had or were at risk for
ardiac disease underwent at least 1 measurement of a
ardiac enzyme or cardiac biomarker after surgery, 3.9%
xperienced a major perioperative cardiac event (126).
Several large surveys have demonstrated that periopera-
ive cardiac morbidity is particularly concentrated among
atients who undergo major thoracic, abdominal, or vascular
urgery, especially when they are 70 years of age or older
121,124,127–129). Ashton et al. (38) prospectively studied
he incidence of perioperative MI associated with thoracic,
bdominal, urologic, orthopedic, and vascular surgery in a
ohort of 1487 men older than 40 years. The highest MI
ate (4.1%; OR 10.39, 95% CI 2.3 to 47.5) occurred in the
ubset of patients with an established diagnosis of CAD.
evertheless, independent significant risk factors for infarc-
ion also included age greater than 75 years (OR 4.77, 95%
I 1.17 to 19.41) and the need for elective vascular surgery
ven in the absence of suspected CAD (adjusted OR 3.72,
5% CI 1.12 to 12.37). An exception to this assumption is
ntrathoracic surgery, notably for pulmonary neoplasm. This
roup has a high incidence of tobacco consumption, a
otable risk factor for both lung cancer and atherosclerosis.
n addition, limitations with respect to exercise tolerance
an be due to either CAD, lung disease, or both, which
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2009 ACCF/AHA Perioperative Guidelines November 24, 2009:e13–118akes the assessment of CAD more difficult. It is advisable
o have a high index of suspicion of CAD in patients
ndergoing intrathoracic surgery.
Few procedure-specific data are available regarding peri-
perative cardiac morbidity in most surgical specialties,
erhaps because advanced age and serious, incidental CAD
re assumed to be distributed randomly within groups of
atients who undergo noncardiac operations in such fields as
eneral surgery, orthopedics, urology, gynecology, and neu-
osurgery. As shown by Ashton et al. (38) and many others,
owever, patients who require vascular surgery appear to
ave an increased risk for cardiac complications because 1)
any of the risk factors that contribute to peripheral
ascular disease (e.g., diabetes mellitus, tobacco use, and
yperlipidemia) are also risk factors for CAD; 2) the usual
ymptomatic presentation for CAD in these patients may be
bscured by exercise limitations imposed by advanced age,
ntermittent claudication, or both; and 3) major open
ascular surgery may be associated with substantial fluctua-
ions in intravascular/extravascular fluid volumes, cardiac
lling pressures, systemic blood pressure, heart rate, and
hrombogenicity (121).
Several studies have attempted to stratify the incidence of
erioperative and long-term mortality and cardiac morbidity
ccording to the original type of vascular surgery performed.
sing the Medicare National Inpatient Sample from 1994
hrough 1999, Birkmeyer et al. noted that in high-volume
ospitals, the perioperative mortality rates for carotid end-
rterectomy, lower-extremity bypass, and aneurysm surgery
ere 1.5%, 4.1%, and 3.9%, respectively (130). In a pro-
pective series of 53 aortic procedures and 87 infrainguinal
ypass grafts for which operative mortality rates were nearly
dentical (9% and 7%, respectively), Krupski et al. (131)
ound that the risk for fatal/nonfatal MI within a 2-year
ollow-up period was 3.5 times higher (21% versus 6%)
mong patients who received infrainguinal bypass grafts.
his difference probably is related to the fact that diabetes
ellitus (44% versus 11%) and history of previous MI (43%
ersus 28%), angina (36% versus 15%), or HF (29% versus
%) also were significantly more prevalent in the infrain-
uinal bypass group. L’Italien et al. (132) have presented
omparable data regarding the perioperative incidence of
atal or nonfatal MI and the 4-year event-free survival rate
fter 321 aortic procedures, 177 infrainguinal bypass grafts,
nd 49 carotid endarterectomies. Slight differences in the
verall incidence of MI among the 3 surgical groups, which
ay have been related to the prevalence of diabetes mellitus,
ere less significant than the influence of discrete cardiac
isk factors (previous MI, angina, HF, fixed or reversible
yocardial perfusion imaging defects, and ST-T depression
uring stress testing) (132).
Although these and other studies (8) suggest that the
linical evidence of CAD in a patient who has peripheral
ascular disease appears to be a better predictor of subse-
uent cardiac events than the particular type of peripheral
ascular operation to be performed, the introduction of hndovascular alternatives, either alone or in combination
ith an adjunctive open surgical procedure, has led to a
eduction in all-cause perioperative mortality and morbidity.
or example, the DREAM (Dutch Randomized Endovas-
ular Aneurysm Management) trial was a multicenter ran-
omized trial of endovascular abdominal aortic aneurysm
epair versus open repair in which 351 patients were
andomized with aneurysms at least 5 cm in diameter.
atients were enrolled if considered fit for open repair and
f they had suitable anatomy. Initial results were reported in
004 (133) and revealed a 30-day operative mortality rate in
avor of endovascular repair (1.7% for endovascular repair
ersus 4.7% for open repair, RR 3.9, 95% CI 0.9 to 32.9,
0.10). However, 2-year follow-up (134) demonstrated
umulative survival rates were not significantly different
etween the 2 approaches (89.6% for open repair versus
7.7% for endovascular repair). Similar results were noted
or the EVAR (EndoVascular Abdominal aortic aneurysm
epair)-1 trial conducted in the United Kingdom
135,136). Indeed, in a random sample of inpatient Medi-
are claims from 2000 to 2003, endovascular abdominal
ortic aneurysm repair increased during this period to 41%
f all elective repairs in the United States, with a decline in
ortality from 5.0% to 3.7% (p0.001) (123). Likewise,
ecent clinical trials support the notion that endovascular
anagement of thoracic aneurysms dramatically reduces
ll-cause perioperative mortality and morbidity; however,
he underlying cardiovascular disease may lead to similar
ong-term outcomes (137).
Several studies have suggested that variations in surgical
ortality and morbidity are inversely related to hospital
olume. Nonetheless, the relative effect of hospital volume is
rocedure-specific, even among relatively complex opera-
ions. Using information from the national Medicare claims
atabase and the Nationwide Inpatient Sample, Birkmeyer
t al. (130) examined the mortality associated with 6
ifferent types of cardiovascular procedures and 8 types of
ajor cancer resections between 1994 and 1999. Absolute
ifferences in adjusted mortality rates between very-low-
olume hospitals and very-high-volume hospitals ranged
rom more than 12% for pancreatic resection (16.3% versus
.8%) to only 0.2% for carotid endarterectomy (1.7% versus
.5%). The absolute differences in adjusted mortality rates
etween very-low-volume hospitals and very-high-volume
ospitals were greater than 5% for esophagectomy and
neumonectomy; 2% to 5% for gastrectomy, cystectomy,
epair of a nonruptured abdominal aneurysm, and replace-
ent of an aortic or mitral valve; and less than 2% for
oronary artery bypass grafting, lower-extremity bypass,
olectomy, lobectomy, and nephrectomy (130). In a
ollow-up report, the observed associations between hospital
olume and operative mortality for many of these proce-
ures were largely mediated by surgeon volume (138).
oreover, these investigators have also noted that theigher operative mortality observed for black patients across
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November 24, 2009:e13–118 2009 ACCF/AHA Perioperative Guidelineswide range of surgical procedures is due in large part to the
igher mortality rates at the hospitals they attend (139).
Some investigators suggest that community-wide quality
mprovement initiatives may lead to improvement in care
rocesses and outcomes. For example, a significant decrease
n the combined event rate (30-day stroke or mortality) for
arotid endarterectomy procedures was observed in a ran-
om sample of Medicare patients in 10 states during initial
June 1, 1995, to May 31, 1996) and subsequent (June 1,
998, to May 31, 1999) reviews. Significant state-to-state
ariation was present, however, with a combined event rate
or carotid endarterectomy alone that ranged from 2.7%
Georgia) to 5.9% (Indiana) for all indications combined,
rom 4.4% (Georgia) to 10.9% (Michigan) in patients with
ecent transient ischemia or stroke, from 1.4% (Georgia) to
.0% (Oklahoma) in patients with no symptoms, and from
.7% (Georgia) to 7.9% (Indiana) in patients with nonspe-
ific symptoms (140). Although this may be related to other
actors, quality improvement is likely to be the strongest
nfluence.
Given that the prevalence of CAD contributes sub-
tantially to the perioperative risk of major surgical
rocedures, at least some of the differences in surgical
utcome from 1 hospital to another may potentially be
elated to variations in the degree to which CAD is
ecognized and treated appropriately. The level of this
wareness also has implications regarding survival. In the
rospectively randomized Veterans Administration Trial
f Carotid Endarterectomy versus Nonoperative Man-
gement for Asymptomatic Carotid Stenosis, for exam-
le, more than 20% of both randomized cohorts died of
ardiac-related complications within a follow-up period
f 4 years (141). Historically, Hertzer (9) observed in a
elective review of several thousand open vascular surgical
rocedures (carotid endarterectomy, aortic aneurysm re-
ection, and lower-extremity revascularization) reported
n the English literature from 1970 to 1987 that cardiac
omplications were responsible for approximately half of
ll perioperative deaths and that fatal events were nearly
-times more likely to occur in the presence of standard
reoperative indications of CAD. Furthermore, the late
5-year) mortality rate for patients who were suspected to
ave CAD was twice that for patients who were not
approximately 40% versus 20%). It is intriguing that in
his report, both the perioperative and 5-year mortality
ates for patients who previously had coronary bypass
urgery were similar to the results reported for patients
ho had no clinical indications of CAD at the time of
eripheral vascular surgery. Similarly, in the Coronary
rtery Surgery Study (CASS), which included 24 959
articipants with known CAD, prior CABG was associ-
ted with reduced cardiac risk after noncardiac operations
nvolving the thorax, abdomen, vasculature, and head and
eck (postoperative deaths 1.7% versus 3.3%, MI 0.8%
ersus 2.7%) (142). Nonetheless, results from the ran-
omized, prospective Coronary Artery Revascularization trophylaxis (CARP) trial demonstrated that coronary
rtery revascularization before elective major vascular
urgery did not improve long-term survival or alter early
ostoperative outcomes, including death, MI, and length
f the hospital stay, among patients with stable CAD
143). However, patients with a stenosis of the left main
oronary artery of greater than 50%, an LVEF of less
han 20%, and severe aortic stenosis were excluded from
he trial. In contrast to the CASS report, the lack of
enefit for coronary artery revascularization in the CARP
rial was attributed to a significant recent increase in use
f beta blockers, antiplatelet agents, ACE inhibitors, and
tatins (142,143). Indeed, Mangano et al. and Polder-
ans et al. documented the cardioprotective effect of
erioperative beta blockade in substantially and signifi-
antly reducing cardiac morbidity and mortality in high-
isk patients undergoing major vascular surgery (87,88).
owever, despite aggressive perioperative medical man-
gement, the risk of early cardiac morbidity and late
ortality remains significant after major vascular surgery.
or example, in the CARP trial, the incidence of early
I was 8.4%, with a median mortality of 23% at 27
onths (143).
Patients undergoing major vascular surgery constitute a
articular challenge, because these are high-risk operations
n a patient population with a high prevalence of significant
AD. There are, however, other surgical procedures for
hich the interaction of patient-specific and surgery-
pecific factors has been examined. Nonthoracic solid organ
ransplantation generally represents a high-risk procedure in
patient with multiple comorbidities. Significant CAD is
ommon in patients with diabetes mellitus who have end-
tage renal disease. In a study of 176 consecutive patients
ndergoing either kidney or kidney-pancreas transplants,
here was a high correlation between adverse postoperative
ardiac events and preoperative documentation of reversible
efects on intravenous dipyridamole myocardial perfusion
maging in combination with significant CAD on coronary
ngiograms: 3 of 27 patients (11.1%) versus 1 of 111
atients (0.9%) with a normal dipyridamole myocardial
erfusion imaging (144). Similarly, in a review of 2694 adult
enal transplants performed at the University of Minnesota
etween January 1, 1985, and December 31, 1998, there was
n overall incidence of cardiac complications of 6.1%, which
as significantly related to age greater than 50 years and
reexisting cardiac disease (145).
Although the prevalence of CAD is relatively low in
atients with end-stage liver disease who are undergoing
iver transplantation, 2 studies (146,147) have documented
he reliability of dobutamine stress echocardiography (DSE)
n predicting post-transplant cardiac events. Stress echocar-
iography has also been shown to be useful in predicting
ardiac outcomes in patients with advanced obstructive
ulmonary disease who are undergoing lung volume reduc-
ion surgery (148,149).
s
a
t
d
t
f
a
o
t
b
a
i
i
fi
s
p
s
L
o
t
p
o
t
w
n
t
o
a
t
p
s
m
r
m
s
d
b
p
B
c
i
s
a
s
p
t
d
p
fl
l
p
s
c
f
5
5
R
E
C
1
2
C
1
C
1
R
s
c
d
e
m
a
d
f
e
w
(
H
t
h
w
t
c
d
(
m
p
T
s
p
n
w
p
a
l
9
c
e34 Fleisher et al. JACC Vol. 54, No. 22, 2009
2009 ACCF/AHA Perioperative Guidelines November 24, 2009:e13–118As Fleisher and Barash (150) have emphasized, the
pecific surgical setting must be considered within any
lgorithm regarding preoperative cardiac evaluation. The
erm “noncardiac operation” is exceedingly broad in its
efinition; it embraces aging patients with complex
echnical problems, as well as younger patients scheduled
or straightforward surgical procedures. As described
bove, cardiovascular morbidity and mortality vary not
nly among procedures but also among institutions for
he same procedure. Therefore, in assessing the risks and
enefits of a perioperative intervention strategy, risks
ssociated with noncardiac surgery must be individual-
zed. It is important to remember, however, that the
ndications for coronary intervention should not be rede-
ned simply because a patient who has CAD of marginal
ignificance also happens to require a major noncardiac
rocedure. Conversely, the long-term implications of
evere left main or triple-vessel disease and diminished
V function are no less ominous after a minor noncardiac
peration than they are in any other patient situation. In
he final analysis, 1 of the ultimate objectives of the
reoperative cardiac assessment is to exclude the presence
f such serious CAD that some form of direct interven-
ion would be warranted even if no noncardiac operation
ere necessary. In this regard, the presentation for
oncardiac surgery may simply represent the first time
hat a patient with overt or suspected CHD has had an
pportunity for cardiovascular assessment.
In summary, the surgical procedures have been classified
s low-risk, intermediate-risk, and vascular surgery. Al-
hough coronary disease is the overwhelming risk factor for
erioperative morbidity, procedures with different levels of
tress are associated with different levels of morbidity and
ortality. Superficial and ophthalmologic procedures rep-
esent the lowest risk and are rarely associated with excess
orbidity and mortality. Major vascular procedures repre-
ent the highest-risk procedures and are now considered
istinctly in the decision to perform further evaluation
ecause of the large body of evidence regarding the value of
erioperative interventions in this population (Figure 1).
oth endovascular abdominal aortic aneurysm repair and
arotid endarterectomy should be considered within the
ntermediate-risk category distinct from the open vascular
urgery procedures on the basis of preoperative morbidity
nd mortality rates, but clinicians should incorporate the
imilarly poor long-term survival that accompanies these
rocedures into their decision-making processes. Within
he intermediate-risk category, morbidity and mortality vary
epending on the surgical location and extent of the
rocedure. Some procedures may be short, with minimal
uid shifts, whereas others may be associated with pro-
onged duration, large fluid shifts, and greater potential for
ostoperative myocardial ischemia and respiratory depres-
ion. Therefore, the physician must exercise judgment to
orrectly assess perioperative surgical risks and the need for
urther evaluation. o. Supplemental Preoperative Evaluation
.1. Assessment of LV Function
ecommendations for Preoperative Noninvasive
valuation of LV Function
LASS IIa
. It is reasonable for patients with dyspnea of unknown origin to
undergo preoperative evaluation of LV function. (Level of Evi-
dence: C)
. It is reasonable for patients with current or prior HF with worsening
dyspnea or other change in clinical status to undergo preoperative
evaluation of LV function if not performed within 12 months. (Level
of Evidence: C)
LASS IIb
. Reassessment of LV function in clinically stable patients with pre-
viously documented cardiomyopathy is not well established. (Level
of Evidence: C)
LASS III
. Routine perioperative evaluation of LV function in patients is not
recommended. (Level of Evidence: B)
esting LV function has been evaluated before noncardiac
urgery by radionuclide angiography, echocardiography, and
ontrast ventriculography (46,151–160). Of 9 studies that
emonstrated a positive relation between decreased preop-
rative ejection fraction and postoperative mortality or
orbidity, 7 were prospective (151,152,154,155,158,161,162),
nd 2 were retrospective (153,156).
Halm et al. (161) studied a cohort of 339 men either with
ocumented ischemic heart disease or multiple risk factors
or CHD; 49% had clinically evident vascular disease. An
chocardiographic determination of LVEF less than 40%
as associated with all adverse perioperative outcomes
cardiac death, nonfatal MI, unstable angina, congestive
F, and ventricular tachycardia). In multivariable analysis
hat included the clinical risk factors of definite CAD or
istory of congestive HF, neither LVEF nor regional
all-motion score added significant independent value in
he prediction of individual events such as postoperative
ardiac death, nonfatal MI, or HF (161).
In a study of 570 patients having transthoracic echocar-
iography before major noncardiac surgery, Rohde et al.
162) found that any degree of LV systolic dysfunction was
arginally associated with postoperative MI or cardiogenic
ulmonary edema (OR 2.1, 95% CI 1.0 to 4.5; p0.05).
he finding of any degree of LV dysfunction had a poor
ensitivity (43%) and positive predictive value (13%) in
redicting these events, with a specificity of 76% and
egative predictive value of 94%. This finding is concordant
ith a subsequent meta-analysis (163) of 8 studies of
reoperative resting LV function as assessed by radionuclide
ngiography. In that study, Kertai et al. found that LVEF
ess than 35% had a sensitivity of 50% and a specificity of
1% in the prediction of perioperative nonfatal MI or
ardiac death (163). The greatest risk of complications was
bserved in patients with an LVEF at rest of less than 35%.
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November 24, 2009:e13–118 2009 ACCF/AHA Perioperative Guidelinesn the perioperative phase, poor LV systolic or diastolic
unction is mainly predictive of postoperative HF and, in
ritically ill patients, death. It is noteworthy, however, that
esting LV function was not found to be a consistent
redictor of perioperative ischemic events.
.2. Assessment of Risk for CAD and Assessment
f Functional Capacity
.2.1. The 12-Lead ECG
ecommendations for Preoperative Resting
2-Lead ECG
LASS I
. Preoperative resting 12-lead ECG is recommended for patients with
at least 1 clinical risk factor‡ who are undergoing vascular surgical
procedures. (Level of Evidence: B)
. Preoperative resting 12-lead ECG is recommended for patients with
known CHD, peripheral arterial disease, or cerebrovascular disease
who are undergoing intermediate-risk surgical procedures. (Level of
Evidence: C)
LASS IIa
. Preoperative resting 12-lead ECG is reasonable in persons with no
clinical risk factors who are undergoing vascular surgical proce-
dures. (Level of Evidence: B)
LASS IIb
. Preoperative resting 12-lead ECG may be reasonable in patients
with at least 1 clinical risk factor who are undergoing intermediate-
risk operative procedures. (Level of Evidence: B)
LASS III
. Preoperative and postoperative resting 12-lead ECGs are not indi-
cated in asymptomatic persons undergoing low-risk surgical proce-
dures. (Level of Evidence: B)
n patients with established or documented coronary dis-
ase, the resting 12-lead ECG contains important prognos-
ic information that relates to long-term morbidity and
ortality (164–167). The magnitude and extent of Q waves
rovide a crude estimate of LVEF and are a predictor of
ong-term mortality (168,169). Horizontal or downsloping
T-segment depression greater than 0.5 mm, LV hypertro-
hy with a “strain” pattern, and left bundle-branch block in
atients with established coronary disease are all associated
ith decreased life expectancy (164–172). In particular, the
resence of LV hypertrophy or ST-segment depression on a
reoperative 12-lead ECG predicts adverse perioperative
ardiac events (173).
The resting 12-lead ECG has been examined both
reoperatively and postoperatively to evaluate its prognostic
alue. To create an index for risk of cardiovascular compli-
ations, Lee et al. studied 4135 patients aged 50 years or
lder undergoing major noncardiac surgery (4). Major
oncardiac surgery was defined by an expected hospital
ength of stay of at least 2 days. In this cohort, the presence
f a pathological Q wave on the preoperative ECG wasr
Clinical risk factors include history of ischemic heart disease, history of compensated or
rior HF, history of cerebrovascular disease, diabetes mellitus, and renal insufficiency.ssociated with an increased risk of major cardiac compli-
ations, defined as an MI, pulmonary edema, ventricular
brillation, primary cardiac arrest, or complete heart block.
athological Q waves were found in 17% of the patient
opulation.
In contrast to these findings, Liu et al. studied the
redictive value of a preoperative 12-lead ECG in 513
atients aged 70 years or older undergoing elective or urgent
oncardiac surgery (174). In this cohort, 75% of the patients
ad a baseline ECG abnormality, and 3.7% of the patients
ied. The causes of death, in decreasing order, were sepsis,
ultisystem organ failure, bowel perforation, stroke, respi-
atory failure, and cardiac complications. Electrocardio-
raphic abnormalities were not predictive of any outcome,
lthough no abnormality was examined individually.
The resting 12-lead ECG did not identify increased
erioperative risk in patients undergoing low-risk surgery
175). In a study of 18 189 patients at 9 centers undergoing
lective cataract surgery, half of the patients underwent basic
esting that included a 12-lead ECG, complete blood count,
nd electrolyte measurement. There was no difference in
utcome between the group that had routine testing versus
he group that did not. The no-testing group was eligible to
ndergo a test in response to a specific complaint or physical
nding.
Although the optimal time interval between obtaining a
2-lead ECG and elective surgery is unknown, general
onsensus suggests that an ECG within 30 days of surgery
s adequate for those with stable disease in whom a
reoperative ECG is indicated.
.2.2. Exercise Stress Testing for Myocardial Ischemia
nd Functional Capacity
he aim of supplemental preoperative testing is to provide
n objective measure of functional capacity, to identify the
resence of important preoperative myocardial ischemia or
ardiac arrhythmias, and to estimate perioperative cardiac
isk and long-term prognosis. Poor functional capacity in
atients with chronic CAD or those convalescing after an
cute cardiac event is associated with an increased risk of
ubsequent cardiac morbidity and mortality (61). Decreased
unctional capacity may be caused by several factors, includ-
ng inadequate cardiac reserve, advanced age, transient
yocardial dysfunction from myocardial ischemia, decon-
itioning, and poor pulmonary reserve.
In evaluating the role of exercise testing to assess patients
ndergoing noncardiac procedures, it is useful to summarize
hat is known about ECG exercise testing in general. The
ensitivity gradient for detecting obstructive coronary dis-
ase is dependent on severity of stenosis and extent of
isease, as well as the criteria used for a positive test. As
any as 50% of patients with single-vessel coronary disease
nd adequate levels of exercise can have a normal exercise
CG (62). The mean sensitivity and specificity of exercise
esting for obstructive coronary disease are 68% and 77%,
espectively (63). The sensitivity and specificity are 81% and
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eft main coronary disease, respectively (64).
Weiner et al. (60) studied 4083 medically treated patients
n CASS and identified a high-risk patient subset (12% of
he population) with an annual mortality rate greater than or
qual to 5% per year when the exercise workload was less
han Bruce stage I and the exercise ECG showed ST-
egment depression greater than or equal to 1 mm. A
ow-risk subset (34% of the population) who were able to
omplete or do more than Bruce stage III with a normal
xercise ECG had an annual mortality rate of less than 1%
er year over 4 years of follow-up (60). Similar results have
een reported by others (65,66).
Table 6 lists publications in which exercise test results and
erioperative events were reported. In most series, very-
igh-risk patients (recent MI, unstable angina, HF, and
erious ventricular arrhythmias) were excluded. McPhail et
l. (176) reported on preoperative exercise treadmill testing
nd supplemental arm ergometry in 100 patients undergo-
ng surgery for peripheral vascular disease or abdominal
ortic aneurysm. Of the 100 patients, 30 were able to reach
5% of age-predicted heart rate maximum, and only 2 had
able 6. Preoperative Exercise Testing Before Major Noncardia
Study
(Reference) n
% of Patients
With
Abnormal
Test
Criteria for
Abnormal Test % Events
Peripheral Vascular Surgery or
cCabe et al.,
1981 (177)
314 36 STD, CP, or A 38 (15/39
utler et al.,
1981 (178)
130 39 STD 7 (9/130
rous et al.,
1984 (179)
808 17 STD NR
ardine et al.,
1985 (180)
86 48 STD 11 (2/19)
on Knorring &
Lepantalo
1986 (181)
105 25 STD, A, or CP 3 (3/105
eppo et al.,
1987 (182)*
60 28 STD 12 (7/60)
anson et al.,
1988 (183)
74 57 STD 3 (1/37)
cPhail et al.,
1988 (176)*
100 70 Less than 85%
MPHR
19 (19/10
rbinati et al.,
1994 (184)
121 23 STD 0
Peripheral Vascular Surge
arliner et al.,
1985 (185)
200 16 STD 8 (16/20
umbers in parentheses that do not refer to references are number of patients divided by the tot
eripheral vascular surgery was less than the total number tested. *Studies with prospective c
A indicates cardiac arrhythmia; CP, chest pain; D, death; F, failure; H, hypotension; I, myocardia
, number of patients; NR, not reported; NS, not significant; and STD, exercise-induced electrocardiac complications (6%). In contrast, 70% of the popu- (ation were unable to reach 85% of age-predicted heart rate
r had an abnormal exercise ECG. In this group, the cardiac
omplication rate (MI, death, HF, or ventricular arrhyth-
ia) was 24% (17 patients).
A peak exercise heart rate greater than 75% of age-
redicted maximum can be expected in approximately half
f all patients who undergo treadmill exercise, with supple-
ental arm ergometry when necessary for patients limited
y claudication (178). The frequency of an abnormal exer-
ise ECG response is dependent on prior clinical history
178,181). Among patients without a cardiac history and
ith a normal resting ECG, approximately 20% to 50% will
ave an abnormal exercise ECG. The frequency is greater
35% to 50%) in patients with a prior history of MI or an
bnormal rest ECG. The risk of perioperative cardiac events
nd long-term risk are increased significantly in patients
ith an abnormal exercise ECG at low workloads
176,178,179).
In contrast to the above-mentioned studies of patients
ith vascular disease, in a general population of patients in
hich only 20% to 35% had peripheral vascular disease and
ho were undergoing noncardiac surgery, Carliner et al.
rgery
Prediction of Cardiac Events
Event Comments
% Positive
Test
% Negative
Test
minal Aortic Aneurysm Repair
81 (13/16) 91 (21/23) D, M, I, H, A
16 (8/50) 99 (79/80) D, M Less than 75% MPHR
increased risk
21 (19/89) NR D, M
11 (1/9) 90 (9/10) D, M
8 (2/26) 99 (78/79) D, M
25 (3/12) 92 (44/48) D, M Exercise test results
used to refer
patients for
revascularization
5 (1/19) 100 (18/18) D, M Arm ergometry
24 (17/70) 93 (28/30) D, M, A, F Less than 85% MPHR;
p0.04; STD; NS
0/28 100 (93/93) D, M Carotid
endarterectomy
patients. STD
predicted late death
ajor Noncardiac Surgery
16 (5/32) 93 (157/168) D, M 5 METs (NS)
ber of patients. In references 177, 179, 180, and 183, the total number of patients undergoing
n of postoperative electrocardiogram and cardiac enzymes.
mia; M, myocardial infarction; MET, metabolic equivalent; MPHR, maximum predicted heart rate;
aphic ischemia.c Su
Abdo
)
)
)
0)
ry or M
0)
al num
ollectio185) reported exercise-induced ST-segment depression
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November 24, 2009:e13–118 2009 ACCF/AHA Perioperative Guidelinesreater than or equal to 1 mm in 16% of 200 patients older
han 40 years (mean age 59 years) being considered for
lective surgery. Only 2 patients (1%) had a markedly
bnormal (ST-segment depression of 2 mm or more)
xercise test. Of the 32 patients with an abnormal exercise
est, 5 (16%) died or had a nonfatal MI. Of 168 patients
ith a negative test, 157 (93%) did not die or have an MI.
n that series, however, the results of preoperative exercise
esting were not statistically significant independent predic-
ors of cardiac risk.
Table 5 provides a prognostic gradient of ischemic
esponses during an ECG-monitored exercise test as devel-
ped for a general population of patients with suspected or
roven CAD (186). The onset of a myocardial ischemic
esponse at low exercise workloads is associated with a
ignificantly increased risk of perioperative and long-term
ardiac events. In contrast, the onset of a myocardial
schemic response at high exercise workloads is associated
ith significantly less risk. The prognostic gradient is also
nfluenced by the age of the patient, the extent of the
oronary disease, the degree of LV dysfunction, hemody-
amic response to exercise, and presence or absence of
hronotropic incompetence. American College of Cardiol-
gy/American Heart Association guidelines concerning the
ndications for and interpretation of exercise stress testing
re available (67).
.2.3. Noninvasive Stress Testing
ecommendations for Noninvasive Stress Testing
efore Noncardiac Surgery
LASS I
. Patients with active cardiac conditions (see Table 2) in whom
noncardiac surgery is planned should be evaluated and treated per
ACC/AHA guidelines# before noncardiac surgery. (Level of Evi-
dence: B)
LASS IIa
. Noninvasive stress testing of patients with 3 or more clinical risk
factors and poor functional capacity (less than 4 METs) who require
vascular surgery** is reasonable if it will change management.
(Level of Evidence: B)
LASS IIb
. Noninvasive stress testing may be considered for patients with at
least 1 to 2 clinical risk factors and poor functional capacity (less
than 4 METs) who require intermediate risk or vascular surgery if it
will change management. (Level of Evidence: B)
ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibril-
ation (108), ACC/AHA/ACP Guidelines for the Management of Patients with
hronic Stable Angina (188), ACC/AHA 2005 Guideline Update for the Diagnosis
nd Management of Chronic Heart Failure in the Adult (189), ACC/AHA
uidelines for the Management of Patients With ST-Elevation Myocardial Infarc-
ion (49), ACC/AHA/ESC Guidelines for the Management of Patients With
upraventricular Arrhythmias (190), ACC/AHA 2002 Guideline Update for the
anagement of Patients With Unstable Angina and Non–ST-Segment Elevation
yocardial Infarction (187), ACC/AHA 2006 Guidelines for the Management of
atients With Valvular Heart Disease (102), and ACC/AHA/ESC Guidelines for
he Management of Patients With Ventricular Arrhythmias and the Prevention of
udden Cardiac Death (191).b
*Vascular surgery is defined by emergency aortic and other major vascular surgery and
eripheral vascular surgery. See Table 4.LASS III
. Noninvasive testing is not useful for patients with no clinical risk
factors undergoing intermediate-risk noncardiac surgery. (Level of
Evidence: C)
. Noninvasive testing is not useful for patients undergoing low-risk
noncardiac surgery. (Level of Evidence: C)
he 2 main techniques used in preoperative evaluation of
atients undergoing noncardiac surgery who cannot exercise
re to increase myocardial oxygen demand (by pacing or
ntravenous dobutamine) and to induce hyperemic re-
ponses by pharmacological vasodilators such as intravenous
ipyridamole or adenosine. The most common examples
resently in use are DSE and intravenous dipyridamole/
denosine myocardial perfusion imaging with both
hallium-201 and technetium-99m.
.2.3.1. RADIONUCLIDE MYOCARDIAL PERFUSION IMAGING METHODS
ublications that report the results of stress myocardial
erfusion testing before both vascular and nonvascular
urgery are summarized in Table 7. The bulk of the studies
ncluded were prospectively recruited patient studies, a
ajority of which involved patients undergoing vascular
urgery. Cardiac events in the perioperative period were
efined for the purpose of this table as MI or death due to
ardiac causes, and information about events and scan
esults had to be available. These studies have shown that
eversible perfusion defects, which reflect jeopardized viable
yocardium, carry the greatest risk of perioperative cardiac
eath or MI. The percentage of patients with evidence of
schemic risk reflected in reversible myocardial perfusion
efects ranged from 23% to 69%. The positive predictive
alue of reversible defects for perioperative death or MI
anged from 2% to 20% in reports that included more than
00 patients. In more recent publications, the positive
redictive value of myocardial perfusion imaging has been
ecreased significantly. This is probably related to the fact
hat in recent years, the results of preoperative stress nuclear
maging studies have been actively used to select patients for
herapeutic interventions such as coronary revascularization,
s well as to adjust perioperative medical treatment and
onitoring and to select different surgical procedures. The
esult is a lower cardiac event rate in patients with abnormal
tudies. However, because of a very high sensitivity of
bnormal stress nuclear imaging studies for detecting pa-
ients at risk for perioperative cardiac events, the negative
redictive value of a normal scan has remained uniformly
igh at approximately 99% for MI or cardiac death. Most
tudies have found that fixed perfusion defects do not have
ignificant predictive value for perioperative cardiac events.
ven though patients with fixed defects in some studies had
ncreased risk compared with patients with normal images,
he risk was significantly lower than in patients with
eversible defects.
Shaw et al. (223) conducted a meta-analysis of dipyrid-
mole myocardial perfusion imaging for risk stratification
efore elective vascular surgery (10 studies, 1994 patients)
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Reference n
% of Patients
With
Ischemia
Events %
(MI/Death)
Perioperative Events*
Comments
Ischemia: %
Positive
Predictive Value
Normal: %
Negative
Predictive Value
ascular Surgery
oucher et al.,
1985 (192)
48 33 (16) 6 (3) 19 (3/16) 100 (32/32) First study to define risk of thallium
redistribution
utler and Leppo,
1987 (193)
116 47 (54) 10 (11) 20 (11/54) 100 (60/60) Only aortic surgery
letcher and Kershaw,
1988 (194)
67 22 (67) 4 (3) 20 (3/15) 100 (56/56)
achs et al., 1988 (195) 46 31 (14) 4 (2) 14(2/14) 100 (24/24)
agle et al., 1989 (44) 200 41 (82) 8 (15) 16 (13/82) 98 (61/62) Defined clinical risk
cEnroe et al.,
1990 (196)
95 36 (34) 7 (7) 9 (3/34) 96 (44/46) Fixed defects predict events
ounis et al., 1990 (197) 111 36 (40) 7 (8) 15 (6/40) 100 (51/51) Included long-term follow-up
angano et al.,
1991 (198)
60 37 (22) 5 (3) 5 (1/22) 95 (19/20) Managing physicians blinded to scan result
trawn and Guernsey,
1991 (199)
68 N/A 6 (4) N/A 100 (21/21)
atters et al.,
1991 (200)
26 58 (15) 12 (3) 20 (3/15) 100 (11/11) Included echocardiographic (TEE) studies
endel et al.,
1992 (201)
327 51 (167) 9 (28) 14 (23/167) 99 (97/98) Included long-term follow-up
ette et al., 1992 (202) 355 45 (161) 8 (30) 17 (28/161) 99 (160/162) Used quantitative scan index
adsen et al.,
1992 (203)
65 69 (45) 8 (5) 11 (5/45) 100 (20/20)
rown and Rowen,
1993 (204)
231 33 (77) 5 (12) 13 (10/77) 99 (120/121) Prognostic utility enhanced by combined
scan and clinical factors
resowik et al.,
1993 (205)
170 39 (67) 3 (5) 4 (3/67) 98 (64/65)
aron et al., 1994 (206) 457 35 (160) 5 (22) 4 (7/160) 96 (195/203)
NFMI only
Did not analyze for cardiac deaths; no
independent value of scan
ry et al., 1994 (207) 237 46 (110) 7 (17) 11 (12/110) 100 (97/97) Cost-effectiveness data included
outelou et al.,
1995 (208)
106 44 (47) 3 (3) 6 (3/47) 100 (49/49) Used adenosine/SPECT thallium imaging
arshall et al.,
1995 (209)
117 47 (55) 10 (12) 16 (9/55) 97 (33/34) Used adenosine thallium and sestamibi;
size of ischemic defect enhanced
prognostic utility
an Damme et al.,
1997 (210)
142 34 (48) 2 (3) N/A N/A Used dobutamine SPECT sestamibi and
echocardiographic imaging;
echocardiographic and nuclear scan
prognostic utility was equivalent
uang et al., 1998 (211) 106 36 (39) 5 (5) 13 (5/39) 100 (24/24) Dipyridamole thallium SPECT
ohen et al., 2003 (212) 153 31 (48) 4 (6) 4 (2/48) 100 (21/21) Dipyridamole SPECT sestamibi imaging;
perioperative and long-term follow-up.
Perfusion defect in the LAD territory was
best predictor of long-term death/MI.
arafuji et al.,
2005 (213)
302 30 (92) 1.3 (4) 2 (2/92) 100 (210/210) SPECT thallium with adenosine stress in
239 patients; dipyridamole in 63.
Summed stress score greater than or
equal to 14 (20-segment model) best
multivariate predictor of events.
onvascular Surgery†
amp et al., 1990 (214) 40 23 (9) 15 (6) 67 (6/9) 100 (23/23) Diabetes mellitus, renal transplant
qbal et al., 1991 (215) 31 41 (11) 11 (3) 27 (3/11) 100 (20/20) Exercise 86%, diabetes mellitus, pancreas
transplant
oley et al., 1992 (216) 100 36 (36) 4 (4) 8 (3/36) 98 (63/64) Define clinical risk factors in patients with
known or suspected CAD
haw et al., 1992 (217) 60 47 (28) 10 (6) 21 (6/28) 100 (19/19) Used adenosineContinued on next page
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cintigraphic technique. In addition, they noted that the
ositive predictive value of perfusion imaging was correlated
ith the pretest cardiac risk of the patients. Overall, a
eversible myocardial perfusion defect predicted periopera-
ive events, and a fixed thallium defect predicted long-term
ardiac events. Semiquantitative analysis of myocardial per-
usion imaging improved the clinical risk stratification by
efining a relationship of increasing risk of cardiac events as
efect size increased.
Importantly, the risk of perioperative cardiac events as a
unction of stress nuclear myocardial perfusion imaging is
ontinuous rather than categorical. Several studies have
hown that the risk of cardiac events increases as the extent
f reversible defects increases (201,202,204). Abnormal
maging studies with a small degree of reversible defect carry
small risk of cardiac events, whereas the cardiac risk
ncreases significantly as the size of the reversible defect
ncreases to a moderate degree (20% to 25% of LV mass). A
eta-analysis of studies examining the relationship of peri-
perative cardiac risk and semiquantitative assessment of
eversible defects on dipyridamole myocardial perfusion
maging in patients undergoing noncardiac vascular surgery
as reported by Etchells et al. (224). In 9 studies comprising
179 patients, they found that reversible defects in fewer
han 20% of myocardial segments were associated with a
mall, nonsignificant increased risk of perioperative death or
I. Reversible defects that involved more than 20% of
yocardial segments were associated with a significantly
igher risk of perioperative cardiac death or MI that
ncreased progressively as the extent of reversible defects
ncreased.
Beattie et al. (225) conducted a meta-analysis (68 studies)
omparing stress myocardial perfusion imaging versus stress
chocardiography in 10 049 patients at risk for MI before
lective noncardiac surgery. The authors concluded that
oth myocardial perfusion imaging and stress echocardiog-
able 7. Continued
Reference n
% of Patients
With
Ischemia
Events %
(MI/Death)
I
Pre
akase et al.,
1993 (218)
53 28 (15) 11 (6)
ounis et al., 1994 (219) 161 31 (50) 9 (15)
tratmann et al.,
1996 (220)
229 29 (67) 4 (10)
oghbi et al.,
2003 (221)
87 8 (7) 2 (2)
atel et al., 2003 (222) 174 31 (54) 7 (12)
ll studies except those by Coley et al. (216) and Shaw et al. (217) acquired patient information
linded to scan results. Patients with fixed defects were omitted from calculations of positive a
atients/total number of patients whose test results indicated either ischemia or a normal sca
CAD indicates coronary artery disease; LAD, left anterior descending coronary artery; MI, my
yocardial infarction; SPECT, single-photon emission computed tomography; and TEE, transesoaphy detected a moderate-to-large defect in 14% of pa- mients (likelihood ratio 8.35, 95% CI 5.6 to 12.45) and that
moderate-to-large perfusion defect predicted postopera-
ive MI and death.
Mondillo et al. (226) sought to compare the predictive
alue of different noninvasive tests in patients scheduled for
oncardiac surgery. A total of 118 patients were risk
tratified according to clinical markers and LVEF to low-,
oderate-, or high-risk categories and randomly assigned to
of 3 noninvasive tests: dipyridamole stress echocardiogra-
hy, dobutamine stress echocardiography, or dipyridamole
erfusion scintigraphy. Although the low-risk group was
vent-free, 10.4% of the moderate-risk group and 24% of
he high-risk group experienced events. Of the clinical risk
ategories, only the high-risk category was related to cardiac
omplications (p0.05). Multivariable analysis showed the
est predictors of events were the severity and extent of
schemia (dipyridamole, p0.01; dobutamine, p0.005).
nly reversible perfusion defects at scintigraphy were sig-
ificantly related to perioperative events. The strongest
redictor of cardiac events was the presence of more than 3
eversible defects (p0.05).
A meta-analysis was performed on 58 studies of 6
reoperative noninvasive tests, including studies on myocar-
ial perfusion scintigraphy (n23), DSE (n8), and dipy-
idamole stress echocardiography (n4) (163). The sum-
ary receiver operating characteristic curve with the end
oint of prediction of perioperative cardiac death and
onfatal MI was highest with DSE, with a weighted
ensitivity of 85% (95% CI 74% to 97%) and specificity of
0% (95% CI 62% to 79%). Although DSE performed
etter than the other tests, statistical significance was only
eached compared with myocardial perfusion scintigraphy
relative diagnostic OR 5.5, 95% CI 2.0 to 14.9). However,
he large majority of the cited nuclear studies involved older
lanar imaging technology that is generally no longer in use.
The use of techniques to quantify the extent of abnor-
erioperative Events*
Comments
ia: %
tive
e Value
Normal: %
Negative
Predictive Value
/15) 100 (32/32) Patients with documented or suspected
CAD; included rest echocardiogram
/50) 98 (87/89) Intermediate- to high-risk CAD
/67) 99 (1/92) Used dipyridamole sestamibi and noted
fixed defect had more prognostic utility
than transient defect
/7) 97 (1/79) Liver transplant cohort
/54) 97 (116/120) Renal transplant cohort
ctively. Only in reports by Mangano et al. (198) and Baron et al. (206) were attending physicians
ative predictive value. *Positive and negative predictive values are predictive value (number of
dies utilizing pharmacological and/or exercise thallium testing.
l infarction; n, number of patients who underwent surgery; N/A, not available; NFMI, nonfatal
l echocardiography.P
schem
Posi
dictiv
27 (4
18 (9
6 (4
14 (1
15 (8
prospe
nd neg
n). †Stuality and the current routine use of quantitative gated
s
i
p
A
a
r
u
A
t
o
a
a
v
r
s
6
p
s
a
r
t
c
s
c
e
c
f
f
u
p
w
c
r
t
n
2
i
t
c
b
i
c
e
h
r
l
a
b
a
h
p
p
d
f
p
s
a
5
D
m
u
e
c
d
r
o
s
n
e
o
a
i
d
a
1
l
p
p
O
t
r
w
l
a
s
T
c
w
a
p
e
i
a
w
r
r
d
1
o
n
m
d
e
c
r
e40 Fleisher et al. JACC Vol. 54, No. 22, 2009
2009 ACCF/AHA Perioperative Guidelines November 24, 2009:e13–118ingle-photon emission computed tomography perfusion
maging to evaluate LVEF will probably improve the
ositive predictive nature of myocardial perfusion imaging.
lthough there are relatively few published reports using
denosine myocardial perfusion imaging in the preoperative
isk assessment of patients before noncardiac surgery, its
sefulness appears to be equivalent to that of dipyridamole.
merican College of Cardiology/American Heart Associa-
ion guidelines concerning indications for and interpretation
f stress testing with myocardial perfusion imaging are
vailable (227).
The need for caution in routine screening with dipyrid-
mole myocardial perfusion imaging of all patients before
ascular surgery has been raised by Baron et al. (206). In this
eview of patients undergoing elective abdominal aortic
urgery, the presence of definite CAD and age greater than
5 years were better predictors of cardiac complications than
erfusion imaging. Subsequently, several studies have pro-
pectively examined the impact of preoperative cardiac risk
ssessment using a methodology that generally followed the
ecommendations outlined in prior ACC/AHA preopera-
ive guidelines. In a report by Vanzetto et al. (228),
onsecutive patients were evaluated before abdominal aortic
urgery. If no major or fewer than 2 intermediate clinical
ardiac risk factors were present, patients went directly to
lective surgery. The authors noted a 5.6% incidence of
ardiac events (death/MI) in those patients with 1 risk
actor and a rate of 2.4% in those with no cardiac risk
actors. All high-risk patients (2 or more cardiac risk factors)
nderwent dipyridamole myocardial perfusion single-
hoton emission computed tomography imaging, and those
ith a normal scan (38%) had a cardiac event rate of 2% in
ontrast to a rate of 23% in 43 patients demonstrating
eversible thallium defects. Bartels et al. (54) also reported
hat patients referred for elective vascular surgery who had
o clinical intermediate or major clinical risk factors had a
% incidence of cardiac events. Those patients with either
ntermediate risk factors and a functional capacity of less
han 5 METs or high clinical risk underwent stress myo-
ardial perfusion imaging or had intensified medical therapy
efore elective surgery. Using this ACC/AHA guideline–
nfluenced approach, the overall cardiac mortality for the
ohort was only 1%, and there were no significant differ-
nces in outcome among patients with low, intermediate, or
igh clinical risk. Another report (229) also used the clinical
isk factor parameters to divide vascular surgery patients into
ow, intermediate, and high cardiac risk groups. Those
uthors did not include functional capacity measurements
ut noted a 0% death or MI rate in the perioperative period
mong the low-risk patients.
In summary, stress nuclear myocardial perfusion imaging
as a high sensitivity for detecting patients at risk for
erioperative cardiac events. Perioperative cardiac risk ap-
ears to be directly proportional to the amount of myocar-
ium at risk as reflected in the extent of reversible defects
ound on imaging. Because of the overall low positive iredictive value of stress nuclear imaging, it is best used
electively in patients with a high clinical risk of perioper-
tive cardiac events.
.2.3.2. DOBUTAMINE STRESS ECHOCARDIOGRAPHY
obutamine stress echocardiography has become the
ethod of choice for pharmacological stress testing with
ltrasound imaging. With incremental infusion of suprath-
rapeutic doses of dobutamine, which increases myocardial
ontractility and heart rate, significant coronary stenotic
isease can be identified with the induction of LV ischemic
egional wall-motion abnormalities within the distribution
f the affected vessels. The dobutamine infusion is often
upplemented with intravenous atropine to optimize chro-
otropic response to stress. In patients with suboptimal LV
ndocardial definition, intravenous contrast imaging for LV
pacification is now routinely used for image enhancement
nd improved diagnostic interpretation (230).
Several reports have documented the accuracy of DSE to
dentify patients with significant angiographic coronary
isease (231–236). The use of DSE in preoperative risk
ssessment was evaluated in 16 studies, all published since
991 and identified by a computerized search of the English
anguage literature (Table 8) (146,149,160,237–249). The
opulations predominantly but not exclusively included
atients undergoing peripheral vascular surgical procedures.
nly 2 studies blinded the physicians and surgeons who
reated the patients to the dobutamine stress echocardiog-
aphy results (160,239). In the remaining studies, the results
ere used to influence preoperative management, particu-
arly the decision whether or not to proceed with coronary
ngiography or coronary revascularization before elective
urgery. Each study used similar but not identical protocols.
he definition of a positive and negative test result differed
onsiderably on the basis of subjective analysis of regional
all motion (i.e., worsening of preexisting wall-motion
bnormalities were considered by some investigators as a
ositive finding and by others as a negative finding). The
nd points used to define clinical outcome varied and
ncluded both “soft” (i.e., arrhythmia, HF, and ischemia)
nd “hard” (i.e., MI or cardiac death) perioperative events.
The data indicate that DSE can be performed safely and
ith acceptable patient tolerance. The range of positive test
esults was 5% to 50%. The predictive value of a positive test
anged from 0% to 33% for hard events (nonfatal MI or
eath). The negative predictive value ranged from 93% to
00%. In the series by Poldermans et al. (160), the presence
f a new wall-motion abnormality was a powerful determi-
ant of an increased risk for perioperative events after
ultivariable adjustment for different clinical and echocar-
iographic variables. Several studies have suggested that the
xtent of the wall-motion abnormality and/or wall-motion
hange at low ischemic thresholds, particularly at a heart
ate of less than 60% of age-predicted maximum (241,245),
s especially important. These findings have been shown to
b
t
o
w
D
s
m
o
v
f
a
h
w
t
T
L
L
E
L
P
D
P
S
P
B
B
D
B
M
T
L
*
infarcti
a
e41JACC Vol. 54, No. 22, 2009 Fleisher et al.
November 24, 2009:e13–118 2009 ACCF/AHA Perioperative Guidelinese predictors of long-term (241,242,250,251) and short-
erm (252) outcomes.
Integration of the presence of clinical risk factors such as
ngoing stable angina, prior MI, HF, and diabetes mellitus
ith analysis of the ischemic threshold enhances the value of
SE in predicting perioperative nonfatal MI or death. In a
tudy by Das et al. (245), an ischemic response at 60% or
able 8. Summary of Studies Examining the Value of Dobutami
Reference n
Patients
With
Ischemia, %
Events
(MI/Death)
(n)
Crit
Abnor
ane et al.,
1991 (237)
38 50 8% (3) New WMA
alka et al.,
1992 (238)
60 50 15% (9) New or wo
WMA
ichelberger et al.,
1993 (239)
75 36 3% (2) New or wo
WMA
angan et al.,
1993 (240)
74 24 4% (3) New WMA
change
oldermans et al.,
1993 (160)
131 27 4% (5) New or wo
WMA
a´vila-Roma´n et al.,
1993 (242)
88 23 2% (2) New or wo
WMA
oldermans et al.,
1995 (241)
302 24 6% (17) New or wo
WMA
hafritz et al.,
1997 (243)
42 0 2% (1) New or wo
WMA
lotkin et al.,
1998 (146)
80 8 3% (2) New or wo
WMA, E
and/or
of ches
dyspnea
allal et al.,
1999 (244)
233 17 3% (7) New or wo
WMA
ossone et al.,
1999 (149)
46 9 2% (1) New or wo
WMA
as et al.,
2000 (245)
530 40 6% (32) New or wo
WMA or
develop
hyperdy
function
oersma et al.,
2001 (246)
1097 20 4% (44) New or wo
WMA
organ et al.,
2002 (247)
78 5 0%(0) Undefined
orres et al.,
2002 (248)
105 47 10% (10) New or wo
WMA
abib et al.,
2004 (249)
429 7 2% (10) New or wo
WMA
Numbers in parentheses refer to number of patients/total in group. †Intervening revasculariza
DSE indicates dobutamine stress echocardiogram; ECG, electrocardiogram; MI, myocardial
bnormality.ore of maximal predicted heart rate was associated with nnly a 4% event rate if no clinical risk factors were present
ersus a 22% event rate in patients with more than 2 risk
actors. The same investigators found a high event rate with
n ischemic threshold of less than 60% of maximal predicted
eart rate (29% in patients with no risk factors compared
ith 40% in those patients with more than 2 risk factors). In
hat study, the only multivariable predictors of perioperative
tress Echocardiography for Preoperative Risk Assessment
r
est
MI or Death*
Comments
Positive
Predictive Value
Negative
Predictive Value
16% (3/19) 100% (19/19) Vascular and general
surgery
g 23% (7/30) 93% (28/30) Multivariate analysis
g 7% (2/27) 100% (48/48) Managing physicians
blinded to DSE
results
G 17% (3/18) 100% (56/56)
g 14% (5/35) 100% (96/96) Multivariate analysis;
managing physicians
blinded to DSE
results
g 10% (2/20) 100% (68/68) Included long-term
follow-up
g 24% (17/72) 100% (228/228) Multivariate analysis
g N/A 97% (41/42)
g
anges,
oms
or
33% (2/6) 100% (74/74) Orthotopic liver
transplantation
g 0% (0/39)† 96% (187/194) Included long-term
follow-up
g 25% (1/4) 100% (42/42) Lung volume reduction
surgery; included
long-term follow-up
g
e to
15% (32/214) 100% (316/316) Multivariate analysis;
nonvascular surgery
g 14% (30/222) 98% (861/875) Major vascular surgery;
multivariate
analysis; long-term
follow-up
0% (0/4) 100% (100%) High-risk noncardiac
surgery in one third
of patients
g 18% (9/49) 98% (55/56) Multivariate analysis;
vascular surgery in
82% of patients;
long-term follow-up
g 9% (3/32) 98% (390/397) Vascular surgery in
30% of patients
9 ischemic patients (23%).
on; n, number of patients who underwent surgery; N/A, not available; and WMA, wall-motionne S
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7.6; p0.0001) and congestive HF (OR 4.66, 95% CI 1.55
o 14.02; p0.006) (245).
Labib et al. (249) investigated the negative predictive
alue of preoperative patients who did or did not reach 85%
f maximum predicted heart rate on a DSE test, as well as
he impact of resting wall-motion abnormalities without
schemia for the prediction of perioperative MI. Of the 429
atients, 16% had a peak heart rate less than 85% of the
aximum predicted (77% of the group undergoing therapy
ith beta blockers). Cardiac events were statistically less
requent in the negative-DSE group than in the positive-
SE group (7 of 397 or 1.8% versus 3 of 32 or 9.4%;
0.03). In the negative-DSE group, no difference was
een in clinical events between the maximal and submaximal
roups; however, when resting wall motion was compared in
atients who had a negative DSE (n397), patients with a
xed wall-motion abnormality at rest had more clinical
vents than the group with normal wall motion (7 of 100 or
% versus 0 of 297 or 0%; p0.0001). Variables associated
ith postoperative cardiac events (MI or death) included
AD (OR 5.56, 95% CI 1.06 to 29.05; p0.035), resting
all-motion abnormality (OR not available; p0.001), and
esting ejection fraction less than 35% (OR 13.78, 95% CI
.41 to 78.99; p0.019).
Even in high-risk noncardiac surgery, patients with
schemia induced by DSE have a clearly lower (3% to 7%)
isk of perioperative nonfatal MI or death if they are
lassified as moderate to low risk by clinical risk scoring
ersus a 3- to 5-fold greater risk in those with a high clinical
isk score (4,245,246). This risk may be reduced signifi-
antly with beta-blocker therapy (88,246). In patients at low
o intermediate clinical risk who are undergoing established
nd therapeutic beta blockade, DSE is unlikely to impact
he early perioperative outcome (246) but contributes to the
tratification of long-term cardiac risk (251).
Dobutamine stress magnetic resonance imaging has been
sed to identify myocardial ischemia in those not well suited
or dobutamine stress transthoracic echocardiography (253–
55). In more than 500 patients across 6 studies, both the
ensitivity and specificity of dobutamine stress magnetic
esonance for appreciating 50% coronary arterial luminal
arrowings have been demonstrated to range between 83%
nd 91% (253–258). Results from dobutamine stress mag-
etic resonance are useful for identifying those at risk for the
uture occurrence or cardiac death or MI (259). Dobut-
mine stress magnetic resonance imaging has been used to
ssess perioperative risk in those individuals undergoing
oncardiac surgery (260). In a study of 102 patients with
ntermediate clinical predictors of a cardiac event during
oncardiac surgery (260), the presence of inducible ischemia
n a dobutamine stress magnetic resonance stress test was
ssociated with a 20% incidence of adverse cardiac events
MI, cardiac death, or perioperative congestive HF) com-
ared with a 2% incidence in those without inducible
schemia (p0.004). pThis difference was significant (p0.04) after adjustment
or age greater than 70 years, diabetes mellitus, the presence
f stable angina before testing, a history of HF, LVEF, or a
wave on the resting ECG. As shown with other nonin-
asive imaging techniques, dobutamine stress magnetic
esonance results do not provide incremental prognostic
nformation in individuals with preoperative clinical data
ndicating a low risk for sustaining a cardiac event during
oncardiac surgery (260).
An early meta-analysis (223) has suggested that DSE is
uperior to dipyridamole-thallium stress testing in the
rediction of perioperative cardiac events during vascular
urgery. Subsequent large, prospective, individual studies
irectly comparing stress echocardiography and nuclear
maging in the context of risk stratification for noncardiac
urgery, however, have been lacking (261,262).
A recent, much larger meta-analysis by Beattie et al.
225) re-examined the predictive value of pharmacological
tress testing with echocardiography versus nuclear perfu-
ion scintigraphy. This study did not differentiate between
he type of pharmacological stressor used, nor was there a
ubgroup analysis with regard to the type of noncardiac
urgery. The meta-analysis included 25 studies of stress
chocardiography (3373 patients) and 50 studies of stress
uclear perfusion imaging (6827 patients). Five studies of
ipyridamole stress echocardiography were included with
hose that used dobutamine stress. Perioperative MI and
eath were the only end-point events considered. In this
nalysis, the likelihood ratio, defined as sensitivity/
specificity, of a perioperative cardiac event with a positive
tress echocardiogram was more than twice that of a positive
tress nuclear perfusion study (likelihood ratio 4.09, 95% CI
.21 to 6.56 versus 1.83, 95% CI 1.59 to 2.10; p0.001).
he finding of a moderate to large ischemic abnormality by
ither pharmacological stress imaging modality was highly
redictive of perioperative MI or death (likelihood ratio
.35, 95% CI 5.6 to 12.45), but such an abnormality was
etected in only approximately 15% of all patients tested by
ither method (225).
.2.3.3. STRESS TESTING IN THE PRESENCE OF LEFT BUNDLE-BRANCH BLOCK
he tachycardia induced during exercise and conceivably
lso during dobutamine infusion may result in reversible
eptal defects even in the absence of left anterior descending
rtery disease in some patients. This response is unusual
ith either dipyridamole or adenosine stress testing. Con-
equently, the specificity of exercise myocardial perfusion
maging in the presence of left bundle-branch block is low
reported to be 33%), and overall diagnostic accuracy varies
rom 36% to 60% (263,264). In contrast, the use of
asodilators in such patients has a sensitivity of 98%, a
pecificity of 84%, and a diagnostic accuracy of 88% to 92%
265–267). Comparison of DSE to exercise thallium-201
PECT imaging for the diagnosis of LAD coronary disease
n the setting of left bundle-branch block has also found
harmacologic stress to be superior to exercise, with diag-
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gain these findings were primarily due to the low speci-
city of exercise perfusion imaging (42%) compared to DSE
92%), despite high sensitivities of 100% and 91%, respec-
ively (268). In a study by Mairesse et al. (269), dobutamine
tress testing with imaging by echocardiography and perfu-
ion scintigraphy were directly compared in 24 patients with
eft bundle-branch block. For the detection of LAD isch-
mia, the diagnostic sensitivity of DSE was similar to
erfusion imaging (83% versus 75%), with identical speci-
cities (92%) and equivalent diagnostic accuracies (87%
ersus 83%), respectively. In the presence of left bundle-
ranch block, the diagnostic accuracy of perfusion scintig-
aphy in detection of CAD in other coronary distributions
anged from 42% to 75% compared to 79% with DSE (269).
Pharmacologic stress testing with either perfusion
cintigraphy or DSE is hence preferred over exercise
tress testing for the preoperative evaluation of CAD in
atients with left bundle-branch block. Furthermore,
xercise should not be combined with dipyridamole in
uch patients, and synthetic catecholamines will also yield
alse-positive results (270).
.2.4. Ambulatory ECG Monitoring
he predictive value of preoperative ST changes on 24- to
8-hour ambulatory ECG monitoring for cardiac death or
I in patients undergoing vascular and nonvascular sur-
ery has been reported by several investigators. The fre-
uency of abnormal ST-segment changes observed in 869
atients reported in 7 series was 25% (range 9% to 39%)
42,271–275). The positive and negative predictive values
or perioperative MI and cardiac death are shown in Table
able 9. Predictive Value of Preoperative ST-Segment Changes
nfarction and Cardiac Death After Major Vascular Surgery
Author n
Patients With
Abnormal Test, %
Criteria for
Abnormal Test
aby et al.,
1989 (274)
176 18 A
asternack et al.,
1989 (275)
200 39 A
angano et al.,
1990 (42)
144 18 A, B
leisher and
Barash, 1992
(150)
67 24 A, B
cPhail et al.,
1993 (273)
100 34 A
irwin et al.,
1993 (272)
96 9 A
leisher et al.,
1995 (276)
86 23 A, B
Positive predictive value for postoperative cardiac events.
A indicates greater than or equal to 1 mm of ST-segment depression; B, greater than or equal
f patients.. In 2 studies, preoperative ST changes had a predictive salue similar to dipyridamole myocardial perfusion imaging
273,276).
Although the test has been shown to be predictive of
ardiac morbidity, there are several limitations. Differences
n the study protocols (24- versus 48-hour, ambulatory
ersus in-hospital monitoring) may account for the variabil-
ty in the predictive value of the test. Preoperative ambula-
ory ECG monitoring for ST-segment changes cannot be
erformed in a significant percentage of patients because of
aseline ECG changes. The test, as currently used, only
rovides a binary outcome and therefore cannot further
tratify the high-risk group in order to identify the subset
or whom coronary angiography should be considered (276).
.3. Recommendations: If a Test Is Indicated,
hich Test?
n most ambulatory patients, the test of choice is exercise
CG testing, which can both provide an estimate of
unctional capacity and detect myocardial ischemia through
hanges in the ECG and hemodynamic response. Although
readmill exercise stress testing in patients with abdominal
ortic aneurysms would cause concern with regard to in-
uced rupture, there is evidence that it can be performed
afely in this population. In a series of more than 250
atients with an abdominal aortic aneurysm greater than 4
m (including 97 that were 6 cm or greater) who underwent
readmill exercise, only a single patient developed subacute
neurysm rupture 12 hours after testing, which was repaired
uccessfully (277).
In patients with important abnormalities on their resting
CG (e.g., left bundle-branch block, LV hypertrophy with
strain” pattern, or digitalis effect), stress cardiac imaging
ected by Ambulatory Monitoring for Perioperative Myocardial
Perioperative Events, % (n/N)
Comments
Positive
redictive Value*
Negative
Predictive Value
10% (3/32) 1% (1/144) 24 to 48 h during ambulation
9% (7/78) 2% (2/122)
4% (1/26) 4% (5/118) Immediately before surgery
13% (2/16) 4% (2/51) Immediately before surgery
15% (5/34) 6% (4/66)
11% (1/9) 16% (14/87) Definition of MI based on
enzymes only
10% (2/20) 3% (2/66) Quantitative monitoring not
predictive
of ST-segment elevation; MI, myocardial infarction; n, number of patients; and N, total numberDet
Phould be considered. As discussed with left bundle-branch
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2009 ACCF/AHA Perioperative Guidelines November 24, 2009:e13–118lock, exercise myocardial perfusion imaging has an unac-
eptably low specificity because of septal perfusion defects
hat are not related to CAD. For these patients, pharma-
ologic stress myocardial perfusion scintigraphy or dobut-
mine stress echocardiography is recommended over exer-
ise stress imaging.
In patients unable to perform adequate exercise, a non-
xercise stress test should be considered. In this case,
harmacological stress testing with adenosine, dipyridam-
le, or dobutamine myocardial perfusion imaging testing
nd dobutamine echocardiography are commonly used tests.
ntravenous dipyridamole and adenosine should be avoided
n patients with significant bronchospasm, critical carotid
cclusive disease, or a condition that prevents their being
ithdrawn from theophylline preparations or other adeno-
ine antagonists. Dobutamine should not be used as a
tressor in patients with serious arrhythmias, severe hyper-
ension, or hypotension. For patients in whom echocardio-
raphic image quality is likely to be poor, a myocardial
erfusion study is more appropriate. Soft tissue attenuation
an also be a problem with myocardial perfusion imaging,
lthough recent development of attenuation correction for
cquisition and analysis has been very helpful in reducing
his issue. If there is an additional question about valvular
ysfunction, the echocardiographic stress test is favored. In
any instances, either stress perfusion or stress echocardi-
graphy is appropriate. The expertise of the practitioner’s
vailable stress laboratory resources in identifying severe
oronary disease is as important as the particular type of
tress test ordered.
The current evidence does not support the use of an
mbulatory ECG as the only diagnostic test to refer patients
or coronary angiography, but it may be useful in rare
ircumstances to direct medical therapy. In general, indica-
ions for preoperative coronary angiography are similar to
hose identified for the nonoperative setting.
. Implications of Guidelines and Other Risk
ssessment Strategies for Costs and
utcomes
he decision to recommend further testing or treatment for
he individual patient being considered for noncardiac
urgery ultimately becomes a balancing act between the
stimated probabilities of effectiveness versus risk. The
roposed benefit, of course, is the possibility of identifying
nd/or treating advanced but relatively unsuspected CAD
hat might result in significant cardiac morbidity or mortal-
ty either perioperatively or in the long term. In the process
f further screening and treatment, the risks from the tests
nd treatments themselves may offset or even exceed the
otential benefit of evaluation. Furthermore, the cost of
creening and treatment strategies must be considered.
lthough physicians should be concerned with improvinghe clinical outcome of their patients, cost is an appropriate gonsideration when different evaluation and treatment strat-
gies are available that cannot be distinguished from one
nother in terms of clinical outcome.
Froehlich et al. (278) compared test utilization and
utcome for aortic surgery patients before and after imple-
entation of the ACC/AHA preoperative assessment
uidelines at their center using a comprehensive educational
rogram. They demonstrated dramatic reductions in stress
esting after implementation of the guidelines, mostly with
uclear imaging (88% to 47%), cardiac catheterization (24%
o 11%), coronary revascularization (24% to 2%), and overall
reoperative costs ($1087 to $171). At the same time,
erioperative outcome was actually improved as the
eath/MI rate fell from 11% to 4%. Of note, implementa-
ion of the guidelines had the greatest impact in the
reoperative evaluation of clinically low-risk patients. This
tudy supports the ACC/AHA guideline approach of clin-
cal assessment of risk followed by selective testing with
tress nuclear myocardial perfusion imaging in higher-risk
ubgroups of patients, and confirms that cardiac patients at
ow clinical risk can typically undergo elective surgery with
low event rate without further testing. The approach of
elective testing, based on an understanding of test perfor-
ance, a clinical patient assessment, and the potential
mpact of test results on clinical decision making, is sup-
orted as leading to appropriateness of testing, as outlined
n the ACC Foundation/American Society of Nuclear
ardiology proposed method for evaluating the appropri-
teness of cardiovascular imaging (279).
Formal decision and cost-effectiveness analyses of the
alue of preoperative cardiac evaluation have been published
nd have yielded highly varied results (207,280,281). These
odels were created before the publication of the CARP
rial and the DECREASE (Dutch Echocardiographic Car-
iac Risk Evaluation Applying Stress Echocardiography)-II
rial (59) and assumed that coronary revascularization had
enefits in clinical populations that differed from center to
enter; therefore, it is difficult to determine the exact risks of
ggressive screening and treatments versus the benefits in
erms of risk reduction. Additionally, the models all dem-
nstrate that the optimal strategy depends on the mortality
ates for both cardiac procedures and noncardiac surgeries in
he clinically relevant range. One model, which did not
upport a strategy incorporating coronary angiography and
evascularization, used lower mortality rates than those used
r reported in the other studies (280–282). Therefore, the
se of any decision and cost-effectiveness model in a specific
ituation depends on the comparability of local mortality
ates to those of the model.
One report suggested that the cost of a selected coronary
creening approach, as described in the present guidelines,
as as low as $214 per patient (283). Resource utilization
nd costs of preoperative evaluation also decreased in
atients undergoing elective abdominal aortic surgery in the
eriod of implementation for the initial version of these
uidelines compared with historical controls, whereas out-
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ost per year of life saved for this selected screening strategy
f less than $45 000 when applied to patients undergoing
ascular surgery (284,285). However, none of these studies
ncluded a strategy of selected screening followed by aggres-
ive beta-blocker treatment in high-risk individuals, as
escribed by Poldermans et al. (88).
Available data suggest that implementation of various
trategies of beta blockade in patients undergoing major
ascular surgery is cost-effective and even cost-saving
rom the perspective of a short-term provider. Fleisher et
l. (286) used decision analytic techniques to compare 5
ifferent strategies for implementing beta blockade in
atients undergoing abdominal aortic aneurysm surgery.
hese ranged from 1) no routine beta blockade to 2) oral
isoprolol 7 days preoperatively followed by perioperative
ntravenous metoprolol and oral bisoprolol, 3) immediate
reoperative atenolol with postoperative intravenous then
ral atenolol, 4) intraoperative esmolol with conversion
o intravenous and then oral atenolol in the immediate
ostoperative period, and 5) intraoperative and postop-
rative (at 18 hours) esmolol followed by atenolol. Using
edicare costs as a proxy, they found that the institution
f an oral beta blocker a minimum of 7 days before
urgery was associated with a cost savings of approxi-
ately $500 from the hospital’s perspective; that is, beta
lockade was associated with both better outcomes and
ower cost. All other strategies tested were cost saving,
ut to a lesser degree. Of note, this decision analysis did
ot include the performance of any screening tests or the
osts of such testing. Schmidt et al. (287) estimated the
mpact of a clinical practice guideline for perioperative
eta blockers at a medical center in western Massachu-
etts in high-risk patients with 2 or more cardiac risk
actors or known CAD. Using effectiveness data for
eta-blocker treatment from Mangano et al. (87), they
stimated that full use of beta blockers in eligible patients
ould result in 62 to 89 fewer deaths annually at a cost of
pproximately $33 000 to $40 000. Prophylactic beta
lockade also represents an excellent strategy in patients
or whom coronary revascularization for long-term ben-
fit is not a serious consideration.
. Perioperative Therapy
.1. Preoperative Coronary Revascularization With
ABG or Percutaneous Coronary Intervention
All of the Class I indications below are consistent with the
ACC/AHA 2004 Guideline Update for Coronary Artery
ypass Graft Surgery.”)
LASS I
. Coronary revascularization before noncardiac surgery is useful in
patients with stable angina who have significant left main coronaryartery stenosis. (Level of Evidence: A)
g
o. Coronary revascularization before noncardiac surgery is useful in
patients with stable angina who have 3-vessel disease. (Survival
benefit is greater when LVEF is less than 0.50.) (Level of Evi-
dence: A)
. Coronary revascularization before noncardiac surgery is useful in
patients with stable angina who have 2-vessel disease with signifi-
cant proximal LAD stenosis and either EF less than 0.50 or demon-
strable ischemia on noninvasive testing. (Level of Evidence: A)
. Coronary revascularization before noncardiac surgery is recom-
mended for patients with high-risk unstable angina or non–ST-
segment elevation MI.†† (Level of Evidence: A)
. Coronary revascularization before noncardiac surgery is recom-
mended in patients with acute ST-elevation MI. (Level of Evidence: A)
LASS IIa
. In patients in whom coronary revascularization with PCI is appropri-
ate for mitigation of cardiac symptoms and who need elective
noncardiac surgery in the subsequent 12 months, a strategy of
balloon angioplasty or bare-metal stent placement followed by 4 to
6 weeks of dual-antiplatelet therapy is probably indicated. (Level of
Evidence: B)
. In patients who have received drug-eluting coronary stents and who
must undergo urgent surgical procedures that mandate the discon-
tinuation of thienopyridine therapy, it is reasonable to continue
aspirin if at all possible and restart the thienopyridine as soon as
possible. (Level of Evidence: C)
LASS IIb
. The usefulness of preoperative coronary revascularization is not well
established in high-risk ischemic patients (e.g., abnormal dobut-
amine stress echocardiograph with at least 5 segments of wall-
motion abnormalities). (Level of Evidence: C)
. The usefulness of preoperative coronary revascularization is not well
established for low-risk ischemic patients with an abnormal dobut-
amine stress echocardiograph (segments 1 to 4). (Level of Evi-
dence: B)
LASS III
. It is not recommended that routine prophylactic coronary revascu-
larization be performed in patients with stable CAD before noncar-
diac surgery. (Level of Evidence: B)
. Elective noncardiac surgery is not recommended within 4 to 6
weeks of bare-metal coronary stent implantation or within 12
months of drug-eluting coronary stent implantation in patients in
whom thienopyridine therapy, or aspirin and thienopyridine therapy,
will need to be discontinued perioperatively. (Level of Evidence: B)
. Elective noncardiac surgery is not recommended within 4 weeks of
coronary revascularization with balloon angioplasty. (Level of Evi-
dence: B)
.1.1. Rationale for Surgical Coronary
evascularization
o understand the value of preoperative evaluation, it is
mportant to understand the pathophysiology of periopera-
ive cardiac morbidity. This topic has been reviewed else-
†High-risk unstable angina/non–ST-segment elevation MI patients were identified
s those with age greater than 75 years, accelerating tempo of ischemic symptoms in
he preceding 48 hours, ongoing rest pain greater than 20 minutes in duration,
ulmonary edema, angina with S3 gallop or rales, new or worsening mitral regurgi-
ation murmur, hypotension, bradycardia, tachycardia, dynamic ST-segment change
reater than or equal to 1 mm, new or presumed new bundle-branch block on ECG,
r elevated cardiac biomarkers, such as troponin.
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2009 ACCF/AHA Perioperative Guidelines November 24, 2009:e13–118here (288). Ellis et al. (289) analyzed the coronary angio-
rams of 63 patients undergoing major nonthoracic vascular
urgery in a case-control study that indirectly supported
enefit from preoperative coronary bypass surgery and found
hat a coronary occlusion proximal to viable myocardium
as associated with a higher rate of perioperative MI and
eath, which raises the question of whether revascularizing
oronary occlusions might not reduce the frequency of these
dverse events. However, in that study, the number of mild,
nonobstructive” lesions was also associated with MI and
eath. This is consistent with studies that show that the
ost severe stenoses may not always be responsible for MI
nd that coronary thrombosis frequently occurs at the site of
ilder stenoses. Thus, preoperative revascularization of
evere stenoses may not reduce perioperative ischemic com-
lications (290).
.1.2. Preoperative CABG
ntil recently, all of the evidence regarding the value of
urgical coronary revascularization was derived from cohort
tudies in patients who presented for noncardiac surgery
fter successful cardiac surgery. There are now several
andomized trials that have assessed the overall benefit of
rophylactic coronary bypass surgery to lower perioperative
ardiac risk of noncardiac surgery, the results of which can
e applied to specific subsets of patients and will be
iscussed later.
There have been several cohort studies published. In
984, results of preoperative coronary angiography were
eported in a large series of 1001 patients under consider-
tion for elective vascular surgical procedures at the Cleve-
and Clinic (291). Severe CAD was identified by routine
oronary angiography in 251 patients who met contempo-
ary indications for CABG. In the 216 patients who
nderwent CABG, the mortality rate after CABG was
.3%, with a subsequent mortality rate of 1.5% after vascular
urgery. In the entire cohort of 1001 patients, operative
eaths with vascular surgery occurred in 1 (1.4%) of 74
atients with normal coronary arteries, in 5 (1.8%) of 278
atients with mild to moderate CAD, in 9 (3.6%) of 250
atients with advanced but compensated CAD, and in 6
14%) of 44 patients with severe, uncorrected, or inoperable
AD (292).
Eagle et al. analyzed 3368 patients in the CASS database
ho underwent noncardiac surgery during more than 10
ears of follow-up after entry in the CASS study (142).
atients undergoing urologic, orthopedic, breast, and skin
perations had a very low mortality rate, less than 1%,
egardless of whether they had undergone prior CABG for
AD. However, patients undergoing thoracic, abdominal,
ascular, and head and neck surgery had a much higher risk
f death and MI in the 30 days after the surgical procedure.
n the subset of patients undergoing these higher-risk
urgical procedures, patients who had undergone prior
ABG had a lower risk of death (1.7% versus 3.3%;
0.03) and nonfatal MI (0.8% versus 2.7%; p0.002) bhan patients without prior CABG. Prior CABG before
oncardiac surgery demonstrated the most benefit among
atients with multivessel CAD and those with more severe
ngina. These data indicate that patients undergoing low-
isk procedures are unlikely to derive benefit from CABG
efore low-risk surgery but suggest that patients with
ultivessel disease and severe angina undergoing high-risk
urgery might well benefit from revascularization before
oncardiac surgery.
Prior to the publication of randomized trials to address
his issue, several authors used decision analysis and
valuation of claims databases to determine the value of
oronary revascularization before noncardiac surgery. In
n attempt to balance the potential risks versus benefits of
ABG before vascular surgery, the additional short-term
isks and long-term benefits should be understood. Long-
erm benefits of such strategies were not incorporated
nto 2 decision models (280,281) that demonstrated that
he value of coronary revascularization before noncardiac
urgery depended on local mortality rates for both CABG
nd noncardiac surgery. If the long-term benefits had
een included, the value of preoperative coronary revas-
ularization would have been increased. For instance, the
uropean Coronary Surgery Study Group (283) has
eported interesting findings in a small subset of 58
atients with peripheral vascular disease within a much
arger series of 768 men who were randomly assigned to
eceive either coronary bypass surgery or medical man-
gement for angina pectoris. Although the presence of
ncidental peripheral vascular disease was associated with
eductions in the 8-year survival rates for either surgical
r medical management of CAD, its influence was
specially unfavorable in patients who received medical
herapy alone; that is, the long-term survival rate was
5% after coronary bypass surgery compared with 57% for
onsurgical treatment (p0.02). Rihal et al. (461) have
eported similar findings in more than 2000 patients
nrolled in the CASS study. Compared with coronary
ypass surgery in patients with both CHD and peripheral
ascular disease, surgically treated patients with 3-vessel
isease had significantly better long-term survival than
hose treated medically after adjustment for all covariates,
ncluding clinical measures of disease stability, stress test
esults, and LV function. In a study at the Cleveland
linic Foundation, the cumulative 5-year survival rate for
he 216 patients who received coronary bypass was 72%
81% in men without diabetes mellitus) compared with
3% (p0.001) for 35 patients in whom coronary bypass
as indicated but never performed (292,293). Fatal
ardiac events occurred within a mean of 4.6 years in 12%
nd 26% of these 2 subsets, respectively (p0.033).
hese later studies illustrate the importance of both
erioperative and long-term cardiac risk when one con-
iders whether to recommend coronary bypass surgery
efore noncardiac surgery.
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November 24, 2009:e13–118 2009 ACCF/AHA Perioperative GuidelinesA study by Fleisher et al. (294) of a cohort of Medicare
eneficiaries undergoing infrainguinal or abdominal aortic
econstructive surgery found that preoperative stress testing
ollowed by revascularization was associated with improved
hort- and long-term survival with the higher-risk aortic
urgery. However, this association may be confounded by
he fact that the cohorts referred for preoperative stress
esting were “healthier” patients, as evidenced by the finding
hat stress testing with or without coronary revascularization
as associated with greater short- and long-term survival.
n the other hand, a number of retrospective studies have
emonstrated that patients who previously have successfully
ndergone coronary bypass have a low perioperative mor-
ality rate in association with noncardiac procedures and
hat their mortality rate is comparable to the surgical risk for
ther patients who have no clinical indications of CAD
295–298).
The first large, randomized trial (CARP) was published
y McFalls et al. (143), who randomly assigned 510 patients
ith significant coronary artery stenosis among 5859 pa-
ients scheduled for vascular operations to either coronary
rtery revascularization before surgery or no revasculariza-
ion before surgery. Indications for vascular operations were
xpanding aortic abdominal aneurysm in 33% or peripheral
ascular occlusive disease in 67%. Patients needing emer-
ent or urgent surgery were excluded, as were patients with
nstable coronary syndromes, at least 50% stenosis of the
eft main coronary artery, LVEF less than 20%, or severe
ortic stenosis. One or more major coronary arteries had to
ave at least 70% stenosis and be suitable for revasculariza-
ion. Overall, 74% of the 510 patients had 3 or more of the
agle clinical risk criteria for CAD (44), 2 or more variables
s defined by the Revised Cardiac Risk Index (4), or a
oderate or large reversible defect on perfusion stress
maging. The remaining patients had angina or abnormal
esults on a stress test.
Two hundred fifty-eight patients were assigned to revas-
ularization, and of the 225 who actually received preoper-
tive coronary artery revascularization and had subsequent
ascular surgery, 59% had PCI (PTCA and bare-metal
tents) and 41% had CABG, at the discretion of the local
nvestigators. The average number of vessels revascularized
as 3.0 plus or minus 0.8 in the CABG patients and 1.3
lus or minus 0.8 in the PCI group. Thirty-three patients
ad coronary revascularization and did not undergo subse-
uent vascular surgery. Of these 33 patients, 10 died after
ABG or PCI, 18 declined vascular surgery, and 5 devel-
ped a severe coexisting condition. Of those proceeding to
ascular surgery, 4 deaths occurred in the revascularization
roup; 3 patients (2 after PCI and 1 after CABG) died after
ascular surgery, which was performed during the same
dmission as the coronary revascularization procedure. Four
ercent of the patients assigned to the nonrevascularization
roup underwent coronary revascularization because of a
hange in their cardiac status. In the revascularization
roup, a median of 48 days after CABG and 41 days after tCI elapsed before the vascular operation. The types of
ascular surgery procedures, anesthesia, and adjunctive
edical management were similar between the revascular-
zation and no-revascularization groups. Long-term medical
anagement was similar between the 2 groups.
At 30 days after the vascular operation and analyzing
reatment assigned, death had occurred in 3.1% of the
evascularization group and 3.4% of the nonrevasculariza-
ion group (p0.87). Within 30 days of the vascular
peration, postoperative MI by biomarker criteria had
ccurred in 12% of the revascularization group and 14% of
he nonrevascularization group (p0.37). At 2.7 years after
andomization, mortality was 22% in the revascularization
roup and 23% in the nonrevascularization group (RR 0.98,
5% CI 0.70 to 1.37; p0.92). Analysis with regard to
reatment received rather than treatment assigned did not
lter the long-term mortality findings. The authors con-
luded that routine coronary revascularization in patients
ith stable cardiac symptoms before elective vascular sur-
ery does not significantly alter the long-term outcome or
hort-term risk of death or MI.
In a subsequent publication from the CARP trial, the
uthors reported on the subset of 222 patients who under-
ent elective vascular surgery after coronary revasculariza-
ion (299). Prior CABG had been performed in 91 patients
nd prior PCI in 131 patients. Patients were not random-
zed between CABG and PCI; rather, the type of coronary
evascularization was left to the discretion of the local
nvestigator. Completeness of revascularization was defined
s the number of coronary vessels revascularized relative to
he total number of vessels with a stenosis of 70% or greater.
revascularization rate of greater than 100% could be
btained by this definition. Baseline clinical characteristics,
evised Cardiac Risk Index, results of stress imaging, and
edical treatment were similar in the CABG and PCI
roups. The CABG group had 3.0 (standard deviation 1.3)
ignificantly stenosed vessels compared with 2.2 (standard
eviation 1.4) in the PCI group (p0.001). Completeness
f revascularization was 117% (standard deviation 66%) in
he CABG group compared with 81% (standard deviation
7%) in the PCI group (p0.001). The incidence of death
as not significant between the CABG and PCI groups
2.2% versus 3.8%, respectively; p0.497). The incidence of
ny MI at 30 days and any MI after vascular surgery was
igher in the PCI group than in the CABG group (30 days,
6.8% versus 6.6%; p0.024; after vascular surgery, 32.7%
ersus 9.9%; p0.009). They also found that the longer the
elay between coronary revascularization and the vascular
peration, the higher the incidence of MI. In the entire
roup, MI was inversely related to the completeness of
evascularization (p0.02) and occurred more frequently in
bdominal than in infrainguinal vascular operations (19%
ersus 7.5%; p0.01). This study addressed outcomes after
ascular surgery in patients who received nonrandomized
oronary revascularization procedures and did not address
he relative benefit or risk of CABG compared with PCI for
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2009 ACCF/AHA Perioperative Guidelines November 24, 2009:e13–118reoperative coronary revascularization using intention-to-
reat analysis.
In patients in whom coronary revascularization is indi-
ated, timing of the procedure depends on the urgency of
he noncardiac surgical procedure balanced against the
tability of the underlying CAD. The decision to perform
evascularization on a patient before noncardiac surgery to
get them through” the noncardiac procedure is appropriate
nly in a small subset of very-high-risk patients when
ong-term outcomes are included.
The DECREASE-II trial (59) was designed to evaluate
he utility of cardiac testing in patients undergoing major
ascular surgery with intermediate cardiac risk factors and
dequate beta-blocker therapy. A composite end point of
eath and nonfatal MI was assessed at 30 days after vascular
urgery. The incidence of the primary end point in patients
ith extensive ischemia was 14.7%. Extensive ischemia was
dentified in 34 patients (8.8% of the population studied).
nly 12 of 34 patients with extensive ischemia were
onsidered to be candidates for coronary revascularization.
he authors found that “in intermediate-risk patients with
xtensive ischemia, no revascularization compared with
evascularization did not improve 30-day outcome (25.0%
ersus 9.1% events; OR 3.3, 95% CI 0.5 to 24; p0.32).”
he authors went on to state, “The effect of coronary
evascularization in intermediate-risk patients with exten-
ive stress-induced ischemia cannot be assessed, owing to
he insufficient number of patients studied.” This study
onfirms that extensive cardiac ischemia is a risk factor for
erioperative cardiac events, but it was too small to assess
he effect of revascularization.
The DECREASE-V pilot study (300) screened 1880
atients scheduled for major vascular surgery and identified
high-risk cohort by the presence of 3 or more clinical risk
actors. Of these, 101 showed extensive ischemia on DSE (5
r more ischemic segments, 88% of patients) or dobutamine
r dipyridamole perfusion scintigraphy (at least 3 ischemic
alls, 13% of patients). An LVEF of 35% or less was
bserved in 43% of these 101 patients. The 101 patients
ere randomized to best medical therapy and revasculariza-
ion or best medical therapy alone before vascular surgery.
est medical therapy included tight heart rate control with
eta blockers and continuation of antiplatelet therapy. The
evascularization group (n49) underwent catheterization,
hich revealed 2-vessel disease in 24%, 3-vessel disease in
7%, and left main disease in 8%. Revascularization with
CI was performed in 65% and CABG in 35%. Drug-
luting stents (DES) were used in 94% of the PCI patients,
nd dual-antiplatelet therapy was continued perioperatively.
here was no significant difference in perioperative trans-
usion requirement in patients with and without antiplatelet
herapy. Vascular surgery occurred a median of 29 (range 13
o 65) days after CABG and a median of 31 (range 19 to 39)
ays after PCI. Two patients died after CABG before
ascular surgery owing to ruptured aneurysms. The outcome
f 30-day all-cause death or nonfatal MI was similar netween the revascularization and medical therapy patients
t 43% versus 33% (OR 1.4, 95% CI 0.7 to 2.8; p0.30),
espectively. Postoperative troponin elevations occurred in
8.8% of revascularized patients versus 34.7% of medically
reated patients. The incidence of 1-year all-cause death or
I was high (47%) and similar in both groups at 49% for
evascularization and 44% for medical therapy (OR 1.2,
5% CI 0.7 to 2.3; p0.48). This study was not sized to
efinitively answer the question as to the value of preoper-
tive revascularization in high-risk patients; however, the
ndings are consistent with the previously published liter-
ture suggesting a lack of benefit of preoperative coronary
evascularization in preventing death or MI.
Patients undergoing elective noncardiac procedures who
re found to have prognostic high-risk coronary anatomy
nd in whom long-term outcome would likely be improved
y coronary bypass grafting (301) should generally undergo
oronary revascularization before a noncardiac elective vas-
ular surgical procedure or noncardiac operative procedures
f intermediate or high risk (Table 4). The cumulative
ortality and morbidity of both the coronary revasculariza-
ion procedure and the noncardiac surgery should be
eighed carefully in light of the individual patient’s overall
ealth, functional status, and prognosis. The indications for
reoperative surgical coronary revascularization, therefore,
re essentially identical to those recommended by the
CC/AHA 2004 Guideline Update for Coronary Artery
ypass Graft Surgery and the accumulated data on which
hose conclusions were based (302).
.1.3. Preoperative PCI
he role of prophylactic preoperative PCI in reducing
ntoward perioperative cardiac complications appears lim-
ted to patients with unstable active CAD who would be
ppropriate candidates for emergent or urgent revascular-
zation under the published ACC/AHA PCI and CABG
uidelines (302,303). Patients with ST-elevation MI, un-
table angina, and non–ST-elevation MI benefit from early
nvasive management, as outlined in the current ACC/
HA/SCAI (Society for Cardiovascular Angiography &
nterventions) 2005 Guideline Update for PCI (303). Ad-
itionally, in such patients in whom noncardiac surgery is
mminent, despite an increased risk in the peri-MI period,
strategy of balloon angioplasty or bare-metal stenting
hould be considered, as discussed below.
Patients with asymptomatic ischemia or stable Canadian
ardiovascular Society Class I or II angina do not appear to
e candidates for prophylactic preoperative coronary revas-
ularization unless cardiac catheterization reveals high-risk
urgical anatomy, as discussed above. The evidence for the
se and timing of PCI discussed below is summarized in
able 10.
It is unclear from the literature whether patients with
table but severe Canadian Cardiovascular Society Class III
ngina would benefit from prophylactic preoperative coro-
ary intervention. Indications for PCI for patients with this
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November 24, 2009:e13–118 2009 ACCF/AHA Perioperative Guidelinesable 10. Studies Reporting the Clinical Outcome (Death or Nonfatal MI) of Patients Undergoing Noncardiac Surgery After PCI
Study Authors
Year
Published
No. of Patients
Who
Underwent PCI
Time From PCI
to Surgery
Perioperative
Mortality, %
Perioperative
Infarction, % Comments
CI Without Stents (Coronary Balloon Angioplasty)
Allen et al.
(304)
1991 148 338 d (mean) 2.7 0.7 No increase in events if surgery
performed within 90 d of PTCA.
Huber et al.
(305)
1992 50 9 d (mean) 1.9 5.6 CABG needed after balloon angioplasty
in 10% of patients; no control group
for comparison.
Elmore et al.
(306)
1993 14 10 d (mean) 0 0% Very small study. Event rate in patients
treated with CABG or balloon
angioplasty less than in control
group. Angioplasty patients had
fewer risk factors than patients
undergoing CABG.
Gottleib et al.
(307)
1998 194 11 d (median) 0.5 0.5 Only vascular surgeries included.
Posner et al.
(308)
1999 686 1 year
(median)
2.6 2.2 Patients who had undergone PCI had a
similar frequency of death and MI
but half the angina and HF as
matched patients with CAD who had
not undergone PCI. Event rates were
much higher if PCI had been
performed within 90 d.
Brilakis et al.
(309)
2005 350 Within 2
months
0.3 0.6 All events occurred in patients who
underwent surgery within 2 weeks
of PTCA.
Leibowitz et al.
(310)
2006 216 Early (0 to
14 d)
Late (15 to
62 d)
19
11
4.7
7.2
56% had balloon angioplasty
44% had stents. No outcome
difference between balloon
angioplasty and stent groups.
CI With Coronary Stents
Kaluza et al.
(311)
2000 40 13 d (mean) 20 16.8 Mortality was 32% among patients
operated on less than 12 d after
stent placement versus 0 in patients
operated on 12 to 30 d after PCI.
Hassan et al.
(312)
2001 251 29 months
(median)
0.8 0.8 Among patients who received PCI in
BARI, outcome after noncardiac
surgery was equivalent to that of
BARI patients who had received
CABG.
McFalls et al.
(143)
2004 225 54 d (median) 3.1 (revascularization)
vs. 3.4% (control)
11.6 (revascularization)
vs. 14.3% (control)
Patients randomized to coronary
revascularization (PCI in 59%, CABG
in 41%) or not before vascular
surgery. No difference in short- or
long-term risk of MI or death.
Godet et al.
(313)
2005 78 5 to 8 weeks 4 9 Propensity analysis showed no benefit
for preoperative revascularization.
Vicenzi et al.
(314)
2006 103 12 months 5 12 Mix of bare-metal and drug-eluting
stents. Cardiac risk within 35 d of
stent implantation was increased
2.1-fold compared with after 35 d.
Schouten et al.
(315)
2007 192 Early
Late
13.3
0.6
0
0
Early surgery: 13.3% had MACE; late
surgery: 0.6% had MACE. Early
surgery and no thienopyridine:
30.7% had MACE.
Poldermans et al.
(300)
2007 32 PCI
17 CABG
31 d 22.5 at 30 d 34.7 at 30 d High-risk patients with significant CAD
randomized to revascularization
versus medical therapy. No
advantage to revascularization in
primary end point at 30 d or 1 year.ARI indicates Bypass Angioplasty Revascularization Investigation; CAD, coronary artery disease; CABG, Coronary artery bypass surgery; HF, heart failure; MACE, major adverse cardiovascular event(s);
I, myocardial infarction; PCI, percutaneous coronary intervention; and PTCA, percutaneous transluminal coronary angioplasty.
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HA/SCAI 2005 Guideline Update for PCI (303). The
alance of the evidence to date suggests that routine
reoperative coronary revascularization in patients with
table Class III angina will not alter perioperative risk.
igh-risk unprotected left main disease in a noncardiac
urgical candidate presents a special case for consideration.
he reported high rates of restenosis and acute events after
alloon angioplasty, atherectomy, and bare-metal stenting
n the left main artery suggest that these procedures would
e a poor preoperative strategy before noncardiac surgery
316). There have been reports of successful unprotected left
ain PCI with DES in this group of patients (317), but the
eed for prolonged and perhaps lifelong dual-antiplatelet
herapy to prevent catastrophic subacute thrombosis sug-
ests that this strategy would have limited utility in the
reoperative setting as well. Coronary artery bypass grafting
hould be considered in suitable patients with significant left
ain stenoses.
Percutaneous intervention as a prophylactic preopera-
ive coronary intervention in stable patients with prior
oronary bypass surgery before noncardiac surgery is of
nknown value. However, recurrent symptomatic isch-
mia early after CABG is a Class I indication for
ercutaneous revascularization.
In summary, the present review of the literature suggests
hat PCI before noncardiac surgery is of no value in
reventing perioperative cardiac events, except in those
atients in whom PCI is independently indicated for an
cute coronary syndrome. However, unscheduled noncar-
iac surgery in a patient who has undergone a prior PCI
resents special challenges, particularly with regard to man-
gement of the dual-antiplatelet agents required in those
ho have received coronary stents.
.1.4. PCI Without Stents: Coronary Balloon
ngioplasty
everal retrospective series of coronary balloon angioplasty
efore noncardiac surgery have been reported (Table 10). In
50-patient series reported from Mayo Clinic (305), PTCA
sing balloons without stents was performed before noncar-
iac surgery (52% vascular procedures) in patients at high
isk for perioperative complications (62% with greater than
anadian Cardiovascular Society Class III angina, 76%
ith multivessel disease, and all with positive functional
ests). Urgent CABG was required in 10% of patients after
TCA. The noncardiac operation was performed a median
f 9 days after PCI, and the perioperative MI rate was 5.6%,
hereas the mortality rate was 1.9%. Whether this result
iffers from what might have occurred without PTCA is
ncertain.
Elmore et al. (306) analyzed a cohort of 2452 patients
ho had abdominal aortic aneurysm surgery between 1980
nd 1990, of whom 100 patients (4.1%) required perioper-
tive coronary revascularization (86 had CABG, and 14 had
TCA). No deaths occurred in either group, and the aerioperative mortality rate for the 2452 patients was 2.9%.
he median number of days between the coronary revascu-
arization and surgery was 10 days for PTCA and 68 days
or CABG. At 3 years, no statistical difference in survival
as seen between the groups (82.8% for CABG and 92.3%
or PTCA). The 3-year cardiac event rates were 27.3% for
he CABG group and 56.5% for the PTCA group. The
mall numbers of patients in the PTCA group and the
etrospective analysis over a long period of time make
nterpretation of the results of this study difficult. It appears,
owever, that candidates for elective abdominal aortic an-
urysm surgery who have symptomatic disease (CAD) have
low operative mortality when revascularization is per-
ormed before surgery by either PTCA or CABG.
Allen et al. (304) performed a retrospective analysis of
48 patients who underwent angioplasty before noncar-
iac surgery (35% abdominal, 33% vascular, and 13%
rthopedic surgery). Surgery occurred within 90 days
fter angioplasty in 72 patients. There were 4 operative
eaths (1 cardiac), and 16 patients experienced cardiac
omplications during the noncardiac surgery. Cardiac
omplications were more common in patients older than
0 years. Little information can be gleaned from this
mall retrospective study except to note the low incidence
f cardiac death in patients who had coronary angioplasty
ometime before their noncardiac surgery.
Gottlieb et al. (307) studied 194 patients with CAD who
nderwent PTCA before vascular surgery (abdominal aor-
ic, carotid endarterectomy, or peripheral vascular surgery).
he median interval between PTCA and surgery was 11
ays (interquartile range 3 to 49 days) (307). Twenty-six
13.4%) of the patients had a cardiac complication, but only
patient died, and 1 had a nonfatal MI. The variable time
nterval over which PTCA was performed before surgery
nd the inability to know whether the clinical outcome of
hese patients would have been different had a prior PTCA
rocedure not been performed limit the conclusions that can
e drawn from this study.
Massie et al. performed a case-control study of 140
atients with abnormal dipyridamole myocardial perfusion
maging scans in 2 or more segments; 70 underwent
oronary angiography (of whom 25 were referred for revas-
ularization), and 70 (matched for age, sex, type of vascular
urgery, and number of myocardial segments that were
uggestive of ischemia on myocardial perfusion imaging
canning) did not (318). A trend toward late benefit
ssociated with preoperative revascularization was offset by a
rend toward an early hazard from the risk of the preoper-
tive invasive cardiac evaluation and treatment. There were
o significant differences between the angiography group
nd matched control subjects with respect to the frequency
f perioperative nonfatal MI (13% versus 9%) or fatal MI
4% versus 3%) or the frequency of late nonfatal MI (16%
ersus 19%) or late cardiac death (10% versus 13%).
In a retrospective cohort study by Posner et al. (308),
dverse events in the 30 days after noncardiac surgery were
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November 24, 2009:e13–118 2009 ACCF/AHA Perioperative Guidelinesompared among patients who had undergone preoperative
TCA at any time, patients with nonrevascularized CAD,
nd patients without known coronary disease (“normal
ontrols”). Patients with CAD had twice the risk of an
dverse outcome as normal controls (OR 1.98, p0.001);
owever, the risk of an adverse outcome among patients
ho had undergone PTCA was half that of patients with
onrevascularized CAD. The benefit was limited to a
eduction in angina and HF; there was no reduction in early
ostoperative MI or death associated with prior PTCA.
he investigators did not control for the severity of coronary
isease, comorbid illness, or the medical management used
n the PTCA and nonrevascularized CAD groups. No
enefit was seen in patients who had a PTCA 90 days or less
efore noncardiac surgery. The long time frame in which
TCA had been performed preoperatively limits the con-
lusions that can be drawn from this study.
Leibowitz et al. (310) performed a retrospective review of
16 patients who had PCI with balloon angioplasty alone or
CI with stenting within 3 months of noncardiac surgery.
dverse clinical events included acute MI, major bleeding,
nd death less than 6 months after noncardiac surgery.
verall, 11% of patients died, 12% in the balloon-only
roup (13/122) versus 14% in the stent group (13/94;
NS). There was no significant difference in either acute
I or bleeding between the balloon-only group (6% and
3%, respectively) and the stent group (7% and 16%,
espectively). More deaths occurred in both the balloon-
nly and stent groups if noncardiac surgery was performed
n days 0 to 14 after PCI (19%) than on days 15 to 62 after
CI (11%). However, the retrospective nature of the study
id not allow for standardization of medical therapy after
CI, and 46% of patients who died had an ejection fraction
ess than 30%.
A retrospective analysis by Brilakis et al. (309) of 350
atients who underwent balloon angioplasty between 1988
nd 2001 in the 2 months before noncardiac surgery found
(1.6%) had perioperative MI or death, and all these events
ccurred in the patients who underwent noncardiac surgery
ithin 2 weeks of balloon angioplasty. The authors con-
luded that the risk of perioperative death or MI in patients
ho undergo PCI before noncardiac surgery is low, and
TCA balloon angioplasty should be performed at least 2
eeks before noncardiac surgery.
There are data that permit comparison of the protective
ffects of revascularization with CABG and balloon angio-
lasty before noncardiac surgery. In the Bypass Angioplasty
evascularization Investigation, patients with multivessel
oronary disease were randomly assigned to undergo balloon
ngioplasty or CABG (319). In an ancillary study, the
esults of 1049 surgeries performed in 501 patients subse-
uent to randomization were analyzed; 250 patients had
ndergone CABG, and 251 had balloon angioplasty (312).
he median time from the most recent coronary revascu-
arization procedure to noncardiac surgery was 29 months.
he results of the study revealed that the frequency of death tr MI was low in patients with multivessel disease who had
ndergone either procedure (1.6% in both groups), and
here was no difference in the length of hospitalization or
ospital cost. The risk of death or MI was lower when the
oncardiac surgery was performed less than 4 years after
oronary revascularization (0.8% versus 3.6% in patients
ndergoing surgery 4 or more years after coronary revascu-
arization). These data do not provide insight into which
atients require preoperative coronary revascularization, but
hey do suggest that the risk of perioperative infarction or
eath is approximately equal in patients who have under-
one balloon angioplasty or CABG if they had been
ppropriate for and amenable to either type of coronary
evascularization procedure.
After balloon angioplasty, delaying noncardiac surgery for
ore than 8 weeks increases the chance that restenosis at
he angioplasty site will have occurred and theoretically
ncreases the chances of perioperative ischemia or MI.
owever, performing the surgical procedure too soon after
he PCI procedure might also be hazardous. Arterial recoil
r acute thrombosis at the site of balloon angioplasty is most
ikely to occur within hours to days after balloon coronary
ngioplasty. Delaying surgery for at least 2 to 4 weeks after
alloon angioplasty to allow for healing of the vessel injury
t the balloon treatment site is supported by the study by
rilakis et al. (309). Daily aspirin antiplatelet therapy should
e continued perioperatively. The risk of stopping the
spirin should be weighed against the benefit of reduction in
leeding complications from the planned surgery.
.1.5. PCI: Bare-Metal Coronary Stents
able 10 also provides data on several studies of PCI with
oronary stenting before noncardiac surgery. Godet et al.
313) performed an analysis of 1152 patients after abdom-
nal aortic surgery, 308 of whom underwent preoperative
oronary angiography and 78 of whom underwent PCI
bare-metal stents in 96%). Patients who underwent coro-
ary angiography without PCI fell into 2 groups: those with
inor coronary lesions (n13) and those with untreatable
evere CAD (n123). This latter group had a high cardiac
isk, with severe postoperative coronary events occurring in
4.5% and death in 8.1%. After aortic surgery, compared
ith a control group of patients without preoperative PCI,
he preoperative bare-metal coronary stent group showed no
ignificant differences in death (4% in the control group and
% in the stent group) or in severe postoperative coronary
vents (defined as new Q waves, prolonged ST-T changes,
r positive troponin I; 6% in the control group and 9% in
he stent group). Propensity analysis provided a similar
onclusion, with a predicted rate of severe postoperative
oronary events of 8.2% versus an observed rate in the
are-metal coronary stent group of 9.0% (nonsignificant)
nd a predicted rate of death of 6.9% versus an observed rate
f 5.1% (nonsignificant).
A retrospective study by Kaluza et al. (311) indicated thathe frequency of bare-metal stent thrombosis when elective
n
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lacement is very high, as is the frequency of MI and death.
n that study, there were 8 deaths, 7 MIs, and 11 major
leeding episodes in 40 patients who underwent coronary
are-metal stent placement less than 6 weeks (1 to 39 days,
verage 13 days) before noncardiac surgery. All deaths and
Is occurred in patients who were subjected to surgery less
han 14 days after bare-metal stenting, and stent thrombosis
ccounted for most of the fatal events.
Another retrospective analysis by Wilson et al. (320) of
atients who underwent major noncardiac surgery in the 2
onths after bare-metal coronary stent placement showed
eath, MI, or stent thrombosis in 8 (4%) of 207 patients,
ith death occurring in 6 patients (3%). Examination of the
nterval between coronary stenting and cardiac events re-
ealed that all adverse events occurred in patients who
nderwent noncardiac surgery within 6 weeks of coronary
tenting. Neither bleeding complications nor transfusion
ate appeared related to the antiplatelet regimen (320).
Reddy and Vaitkus (321) published a retrospective anal-
sis of 56 patients who received bare-metal coronary stents
efore noncardiac surgery that showed that 38% of patients
ho underwent surgery within 14 days of coronary stenting
xperienced a stent-related MI or cardiovascular death. No
atients who underwent noncardiac surgery more than 6
eeks after coronary stenting had stent-related MI or
ardiovascular death.
Sharma et al. (322) retrospectively reviewed 47 patients
ho underwent noncardiac surgery within 90 days of
are-metal coronary stent implantation. They noted a 26%
ortality rate in patients who had noncardiac surgery within
weeks of stent implantation compared with a 5% mortality
ate in those in whom noncardiac surgery occurred more
han 3 weeks after stent implantation. More importantly, in
he early-surgery group, death occurred in 1 (5%) of 20
atients who continued taking thienopyridines periopera-
ively compared with 6 (85.7%) of 7 patients in whom
hienopyridines were discontinued. There were no signifi-
ant differences in bleeding between those taking or not
aking thienopyridines.
If a coronary stent is used in the revascularization proce-
ure, as in the majority of percutaneous revascularization
rocedures, further delay of noncardiac surgery may be
eneficial. Bare-metal stent thrombosis is most common in
he first 2 weeks after stent placement and is exceedingly
are (less than 0.1% of most case series) more than 4 weeks
fter stent placement (323,324). Given that stent thrombo-
is will result in Q-wave MI or death in the majority of
atients in whom it occurs, and given that the risk of
are-metal stent thrombosis diminishes after endotheliali-
ation of the stent has occurred (which generally takes 4 to
weeks), it appears reasonable to delay elective noncardiac
urgery for 4 to 6 weeks to allow for at least partial
ndothelialization of the stent, but not for more than 12
eeks, when restenosis may begin to occur. cA thienopyridine (ticlopidine or clopidogrel) is generally
dministered with aspirin for 4 weeks after bare-metal stent
lacement. The thienopyridines and aspirin inhibit platelet
ggregation and reduce stent thrombosis but increase the
isk of bleeding. Rapid endothelialization of bare-metal
tents makes late thrombosis rare, and thienopyridines are
arely needed for more than 4 weeks after implantation of
are-metal stents. For this reason, delaying surgery 4 to 6
eeks after bare-metal stent placement allows proper thien-
pyridine use to reduce the risk of coronary stent thrombo-
is; then, after the thienopyridine has been discontinued, the
oncardiac surgery can be performed. However, once the
hienopyridine is stopped, its effects do not diminish imme-
iately. It is for this reason that some surgical teams request
1-week delay after thienopyridines are discontinued before
he patient proceeds to surgery. In patients with bare-metal
tents, daily aspirin antiplatelet therapy should be continued
erioperatively. The risk of stopping the aspirin should be
eighed against the benefit of reduction in bleeding com-
lications from the planned surgery. In the setting of
oncardiac surgery in patients who have recently received a
are-metal stent, the risk of stopping dual-antiplatelet
gents prematurely (within 4 weeks of implantation) is
ignificant compared with the risk of major bleeding from
ost commonly performed surgeries.
.1.6. PCI: DES
rug-eluting stents are designed to reduce neointimal
ormation, thus leading to lower restenosis rates. The
urrently available DES are coated with either sirolimus or
aclitaxel. Several additional agents are in clinical testing.
owever, the action of these drugs will delay endotheliali-
ation and healing and possibly induce hypersensitivity to
he drug or polymer and lead to an increased risk of
hrombosis (325,326). Thrombosis of DES may occur late
nd has been reported up to 1.5 years after implantation,
articularly in the context of discontinuation of antiplatelet
gents before noncardiac surgery (327,328).
Vicenzi et al. (314) reported a prospective observational
tudy of 103 patients who underwent noncardiac surgery
ithin 12 months of stent implantation. A mix of bare-
etal stents and DES was reported, but in a significant
umber of patients, the type of stent could not be identified.
ntiplatelet agents were either continued perioperatively or
iscontinued for fewer than 3 days preoperatively. All
atients received therapeutic unfractionated heparin or
noxaparin. The main outcome variable was the combined
erioperative complication rate at 30 days, which included
ardiac complications, bleeding, surgical complications, and
epsis. Cardiac complications included death, MI, repeat
evascularization, congestive HF, new unstable angina, new
ignificant arrhythmias, or myocardial cell injury, defined as
positive troponin T without ECG signs or symptoms.
ully 45% of the patients experienced complications, and
.9% died. The majority (329,330) of complications were
ardiac (5% cardiac death, 12% MI, and 22% myocardial cell
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November 24, 2009:e13–118 2009 ACCF/AHA Perioperative Guidelinesnjury). Only 4% had bleeding complications despite the use
f an anticoagulation regimen. Recently implanted stents
less than 35 days before surgery) resulted in a 2.1-fold
ncrease in adverse events compared with those implanted
ore than 90 days before surgery. Outcomes stratified by
ype of anticoagulation regimen, type of stent, and type of
peration were not reported. The authors estimated that 5%
f stented patients from their institutions underwent sub-
equent noncardiac surgery. This study raises concern that
oncardiac surgery, even with continued antiplatelet or
nticoagulation regimens, presents a substantial risk of
ardiac events in the year after stent implantation.
The CARP trial (143) and DECREASE-V pilot trial
300) used bare-metal stents and DES, respectively, in some
f the patients randomized to revascularization in those
rials, and neither trial showed an advantage of preoperative
CI with stents in preventing perioperative death or MI.
ee Section 7.1.2. for details.
Schouten et al. (315) reported a single-center registry
xperience of 192 patients who had noncardiac surgery
etween 1999 and 2005 who also had a successful PCI for
nstable coronary disease within the preceding 2 years.
atients with bare-metal stents received lifelong aspirin and
t least 1 month of clopidogrel, and patients with DES
eceived lifelong aspirin and clopidogrel for at least 3
onths (sirolimus) or 6 months (paclitaxel), according to
he existing guidelines. No protocol for continuation or
ithholding of antiplatelet agents before noncardiac surgery
as in force, and this decision was left to the care providers.
he composite end point of major adverse cardiac events
MACE, defined as nonfatal MI or death) at 30 days after
oncardiac surgery was analyzed. There was a Revised
ardiac Risk Index of 1 in 34%, 2 in 39%, and 3 or more in
8% of the patients. Beta blockers were being taken preop-
ratively by 68% of patients. Bare-metal stents were used in
8% and DES in 54% of the patients. The early-surgery
roup was defined as those whose noncardiac surgery
ccurred within the time frame when clopidogrel was
equired (bare-metal stent, 1 month; sirolimus stent, 3
onths; and paclitaxel stent, 6 months). Late surgery was
efined as noncardiac surgery that occurred after this time.
total of 2.6% of all patients experienced MACE (all fatal),
ith a 13.3% rate of MACE in the early-surgery group and
.6% in the late-surgery group. Interruption of antiplatelet
herapy was associated with a significantly higher rate of
ACE (5.5% versus 0%, p0.0023) in the entire group of
atients undergoing noncardiac surgery. Discontinuation of
ntiplatelet therapy in the early-surgery group resulted in a
0.7% incidence of MACE (all fatal) versus a 0% incidence
n early-surgery patients who continued dual-antiplatelet
herapy perioperatively. Overall, there was no difference in
ACE between patients with bare-metal stents and those
ith DES. The study reported that all patients with MACE
ad discontinued antiplatelet therapy before surgery,
hereas only 46% without MACE had done so. The studylso stated there was no difference in surgical risk between patients in whom antiplatelet agents were discontinued and
hose in whom they were not. Excessive blood loss occurred
n 2 patients, 1 of whom was receiving antiplatelet agents
nd 1 of whom was not. Transfusions were required in 24%
f patients taking antiplatelet therapy and in 20% of those in
hom antiplatelet therapy was discontinued (p0.50). The
uthors concluded that there was an increased rate of
ACE in patients undergoing early surgery and that
iscontinuation of antiplatelet agents may be a major cause
f this MACE. This study was reported as research corre-
pondence, and the authors cited the limitation of small
umbers in interpretation of the results. Nonetheless, these
ndings are concordant with other small series and support
he conclusion that early surgery and discontinuation of
ntiplatelet agents are risk factors for cardiac events at the
ime of noncardiac surgery after stent placement.
.1.7. Stent Thrombosis and DES
everal reports of stent thrombosis after discontinuation of
ntiplatelet therapy before noncardiac surgery have been
ublished and raise concern. Iakovou et al. (329) followed
p 2229 patients after DES implantation. Overall, 1.3% had
tent thrombosis, with a case fatality rate of 45%. Subacute
hrombosis within 30 days of implantation occurred in 0.6%
f patients, and late thrombosis, more than 30 days after
mplantation, occurred in 0.7%. Independent predictors of
tent thrombosis were premature discontinuation of anti-
latelet therapy (HR 90; p0.001), renal failure (HR 6.49;
0.001), bifurcation lesions (HR 6.42; p0.001), diabetes
ellitus (HR 3.71; p0.001), and lower ejection fraction
HR 1.09 for each 10% decrease; p0.001). Thrombosis
ccurred in 29% of patients who prematurely discontinued
ual-antiplatelet therapy. Moreno et al. (331) performed a
eta-analysis of DES trials and found no significant differ-
nce in the rate of stent thrombosis between DES (0.58%)
nd bare-metal stents (0.54%); however, they noted the
bsence of thienopyridine therapy to be associated with
ES thrombosis.
Ong et al. (332) reported on late angiographic DES
hrombosis, defined as occurring at least 1 month after stent
mplantation. They reported an incidence of late stent
hrombosis of 0.35% in patients treated with DES; how-
ver, of the 8 angiographically confirmed cases of late stent
hrombosis in their cohort of 2006 patients, 3 were related
o complete cessation of antiplatelet therapy, and 2 addi-
ional cases occurred within 1 month of cessation of
lopidogrel therapy.
McFadden et al. (327) reported 4 cases of stent throm-
osis that occurred 343 to 442 days after stent implantation
hortly after discontinuation of antiplatelet agents. Nasser et
l. (328) reported 2 cases in which aspirin was stopped for
oncardiac surgery 4 and 21 months after DES implanta-
ion; both patients suffered acute stent thrombosis and a
arge MI, and 1 died.
Spertus et al. (333) reported a 19-center study of 500
atients with acute MI designed to examine the prevalence
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2009 ACCF/AHA Perioperative Guidelines November 24, 2009:e13–118nd predictors of thienopyridine discontinuation 30 days
fter DES treatment. They found that 13.6% stopped
hienopyridine therapy within 30 days, and these patients
ere more likely to die (7.5% versus 0.7%; p0.0001) and
o be rehospitalized (23% versus 14%; p0.08) by 12
onths than those who continued thienopyridine therapy.
The BASKET-LATE (Basel Stent Cost-Effectiveness
rial–Late Thrombotic Events) study (334) reported a
ignificantly greater incidence of death and nonfatal MI in
atients who had received DES than in those who received
are-metal stents after clopidogrel had been discontinued at
months. A consecutive series of 746 patients with 1133
tented lesions randomly assigned in a 2:1 fashion to DES
r bare-metal stents and without events at 6 months were
ollowed up for 12 months after the discontinuation of
lopidogrel. Groups were well matched with regard to
aseline clinical characteristics, and the cohort included
onsecutive patients with indications for the procedure of
T-elevation MI in 21.1% and unstable angina in 36.7%.
verall, the 18-month rate of death or MI was not different
etween the DES and bare-metal stent groups. The rate of
eath or MI after clopidogrel discontinuation at 6 months
as 4.9% in the DES group and 1.3% in the bare-metal
tent group (HR 2.2; p0.03). Documented late stent
hrombosis was twice as frequent in the DES group as in the
are-metal stent group (2.6% versus 1.3%), and occurred
etween 15 and 362 days (median 116 days, interquartile
ange 53 to 313 days) after discontinuation of clopidogrel.
tent thrombosis was associated with an 88% risk of death
r nonfatal MI. Target-vessel revascularization was less
requent in the DES group than in the bare-metal stent
roup (7.5% versus 11.6%; p0.04). The authors concluded
hat after the discontinuation of clopidogrel, there is an
ncreased incidence of cardiac death and nonfatal MI in
atients receiving DES compared with bare-metal stents,
ossibly related to stent thrombosis.
A long-term observational study of 24-month clinical
utcomes in patients with stents and varying duration of
lopidogrel therapy was reported by Eisenstein et al. (335).
total of 4666 patients who received bare-metal stents
n3165) or DES (n1501) were followed up at 6, 12, and
4 months. Patients were stratified with regard to type of
tent and clopidogrel use. Landmark analysis was performed
n those patients who were event-free at 6 and 12 months
f follow-up and stratified as to clopidogrel use at that time.
djusted 24-month outcomes based on 6-month clopi-
ogrel use showed that DES patients without clopidogrel at
months had significantly higher rates of death (5.3%
ersus 2.0%; p0.03) and death or MI (7.2% versus 3.1%;
0.02) than patients in the DES group given clopidogrel.
he adjusted HR for death in the DES group without
lopidogrel was 2.43 (p0.03) compared with the DES
ith clopidogrel group. There were no significant differ-
nces in death or death and MI in patients with bare-metal
tents with or without clopidogrel at 6 months. There were
ewer events in patients with DES plus clopidogrel at 6 lonths (death or MI 3.1% versus 6.0%; p0.02) than in
atients with bare-metal stents without clopidogrel at 6
onths. Adjusted 24-month outcomes based on 12-month
lopidogrel use similarly showed that DES patients who did
ot take clopidogrel had significantly higher rates of death
3.5% versus 0%; p0.004) and death or MI (4.5% versus
%; p0.001) than DES patients who did take clopidogrel
t 12 months. There were no significant differences in death
r death and MI in patients with bare-metal stents with or
ithout clopidogrel use at 12 months. There were fewer
vents in patients with DES plus clopidogrel (death or MI
%; p0.001) than in patients with bare-metal stents with
4.7%) or without (3.6%) clopidogrel treatment at 12
onths. The authors concluded that the extended use of
lopidogrel (up to 12 months) in patients with DES is
ssociated with a reduced risk of death and death or MI at
4 months. They noted that the optimal duration of
lopidogrel use beyond 12 months after DES implantation
s not currently known.
On December 7 and 8, 2006, the US Food and Drug
dministration held advisory panel meetings in Washing-
on, DC, to discuss the safety and stent thrombosis rates
ssociated with DES (336). The panel report is yet to be
ublished, but initial conclusions were that 1) there appears
o be a numerical excess of late stent thrombosis with DES,
ut the magnitude is uncertain; 2) there does not appear to
e an increase in rates of death or MI when the products are
sed in accordance with indications listed on the label; 3)
he off-label use of DES, like bare-metal stents, is associated
ith increased risk compared with on-label use; and 4) more
ata are needed, which will entail studying outcomes in
ore patients for longer periods of time. The panel con-
urred with the AHA/ACC guideline recommendation for
2 months of dual-antiplatelet therapy after DES implan-
ation in patients who are not at high risk for bleeding.
The Swedish Coronary Angiography and Angioplasty
egistry (SCAAR) study group published a registry study of
033 patients treated with DES and 13 738 patients treated
ith bare-metal stents and followed up for 3 years (337).
ver the entire follow-up period, the 2 groups did not differ
n the composite outcomes of death or MI. At 6 months,
here was a trend toward a lower unadjusted event rate in
he DES group. However, after 6 months, patients with
ES had a higher event rate, with 12.7 more events per
000 patients per year than among patients given bare-
etal stents (adjusted RR 1.2%; 95% CI 1.05 to 1.37). At
years, mortality was higher in patients with DES (adjusted
R 1.18%; 95% CI 1.04 to 1.35). The relative rate of
linical restenosis was 60% lower in the DES patients. This
nalysis suggests an 18% increase in the RR of death in the
ong term with DES compared with bare-metal stents,
hich equates to an incremental absolute risk of death of
.5% per year and an incremental absolute risk of death or
I of 0.5% to 1.0% per year after the initial 6 months.
In January 2007, an AHA/ACC/SCAI/American Col-ege of Surgeons (ACS)/American Diabetes Association
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November 24, 2009:e13–118 2009 ACCF/AHA Perioperative GuidelinesADA) science advisory was issued regarding the prevention
f premature discontinuation of dual-antiplatelet therapy in
atients with coronary artery stents (338). The advisory
otes that the current recommendations of duration of
ual-antiplatelet regimens after bare-metal, sirolimus-
luting, and paclitaxel-eluting stent implantation were for-
ulated from trials designed to obtain Food and Drug
dministration approval and the anticipated time required
or the stent struts to become adequately endothelialized.
hese trials included low-risk lesions in low-risk patients. It
as been observed that only approximately 30% to 40% of
ES are implanted in such low-risk lesions in low-risk
atients (on-label indications). Approximately 60% to 70%
f patients receiving DES in most large contemporary series
f coronary intervention are in off-label populations that
nclude patients with multivessel coronary disease, left main
isease, aorto-coronary vein grafts, bifurcation lesions, pre-
iously stented lesions with in-stent restenosis, prior brachy-
herapy, small vessels, very long lesions, multiple or over-
apping stents, chronic total occlusions, and infarct-related
esions in acute MI. Additionally, reports have suggested
hat delayed or absent endothelialization (339), localized
ypersensitivity (326,340), and late stent thrombosis (see
bove) may occur with increased frequency in patients with
ES.
Several analyses of the randomized trials and postmarket-
ng registries of sirolimus and paclitaxel DES have been
ublished recently. Kastrati et al. (341) reported that 4958
atients randomized to DES or bare-metal stents and
ollowed up for 12 to 59 months had no significant
ifference in the incidence of death or MI, but there was a
ustained reduction in the need for reintervention with
ES. There was a slight increase in the risk of stent
hrombosis with sirolimus-eluting stents after the first year.
auri et al. (342) analyzed 878 patients treated with
irolimus-eluting stents, 1400 treated with paclitaxel-
luting stents, and 2267 patients treated with bare-metal
tents over 4 years of follow-up according to a hierarchical
lassification of stent thrombosis. The incidence of stent
hrombosis by any criterion was 3% and did not differ
etween DES and bare-metal stent patients. Stone et al.
343) analyzed randomized trials of DES versus bare-metal
tents and found that stent thrombosis occurred in 1.2% of
irolimus-eluting stent patients and 1.3% of paclitaxel-
luting stent patients, neither of which was significantly
ifferent from the bare-metal stent control group. Rates of
eath and MI were similar between the DES and bare-
etal stent groups over 4 years. After 1 year, stent throm-
osis was more common with DES patients. Spaulding et
l. (344) analyzed data from 1748 patients in 4 randomized
rials of sirolimus-eluting stents compared with bare-metal
tents with regard to survival at 4 years. The survival rate
as 93.3% in the DES group compared with 94.6% in the
are-metal stent group (pNS). In patients with diabetes
ellitus, the survival rate was better in the bare-metal stentroup (95.6% versus 87.8%; HR for death, sirolimus group a.9; p0.008). Rates of MI and stent thrombosis were
imilar between the 2 groups.
Stent thrombosis is usually a significant clinical event.
he incidence of death or MI was 64.4% in patients with
ngiographically documented bare-metal stent thrombosis
345). Mortality rates due to presumed or documented DES
hrombosis range from 20% to 45% (333–335).
The average reported incidence of subacute (within 1
onth of implantation) stent thrombosis is approximately
.5% to 1.0%. Late stent thrombosis at 1 to 12 months was
ot seen with bare-metal stents but was reported to occur in
.19% of patients in a large DES registry (346). In October
006, an independent patient-level meta-analysis of DES
rials was presented that demonstrated an increased rate of
ES thrombosis of approximately 0.2% per year between
ears 1 and 4 after stent implantation compared with
are-metal stents (347). Another meta-analysis (348) of all
he published DES trials that examined very late stent
hrombosis at more than 1 year after implantation found a
ate of 5.0 per 1000 patients (0.5%) compared with 0% in
atients with bare-metal stents (relative risk 5.02; p0.02).
he incidence of early stent thrombosis (within 30 days of
mplantation) was 4.4 per 1000 (0.44%) in DES patients
ompared with 5.0 per 1000 (0.5%) in bare-metal stent
atients (p0.74). The incidence of late stent thrombosis
more than 30 days after implantation) was 5.0 per 1000
ES patients compared with 2.8 per 1000 bare-metal stent
atients (p0.22). The median time to late sirolimus-
luting stent thrombosis was 15.5 months (range 173 to 773
ays), and the median time to paclitaxel-eluting stent
hrombosis was 18 months (range 40 to 548 days), whereas
he median time to bare-metal stent thrombosis was 3.5 to
.0 months. Very late stent thrombosis appears to be a
henomenon restricted to DES. These findings have clear
mplications for the duration of antiplatelet therapy.
Predictors of late stent thrombosis include the clinical
actors of advanced age, acute coronary syndrome, diabetes
ellitus, low ejection fraction, renal failure, and prior
rachytherapy and the angiographic factors of long stents,
ultiple lesions, overlapping stents, ostial or bifurcation
esions, small vessels, and suboptimal stent results (under-
xpansion, malapposition, or residual dissection). The op-
imal duration of clopidogrel therapy after 1 year has not
een established and should depend on the physician’s
udgment of the risk/benefit ratio for the individual patient.
urrent expert opinion suggests that continuation of thien-
pyridine (clopidogrel) therapy beyond 1 year may be
onsidered in patients undergoing DES placement.
A 2007 AHA/ACC/SCAI/ACS/ADA science advisory
eport (338) concludes that premature discontinuation of
ual-antiplatelet therapy markedly increases the risk of
atastrophic stent thrombosis and death or MI. To elimi-
ate the premature discontinuation of thienopyridine ther-
py, the advisory group recommends the following:
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discuss the need for dual-antiplatelet therapy. In patients
not expected to comply with 12 months of thienopyri-
dine therapy, whether for economic or other reasons,
strong consideration should be given to avoiding a DES.
. In patients who are undergoing preparation for PCI and
who are likely to require invasive or surgical procedures
within the next 12 months, consideration should be
given to implantation of a bare-metal stent or perfor-
mance of balloon angioplasty with provisional stent
implantation instead of the routine use of a DES.
. A greater effort by healthcare professionals must be made
before patient discharge to ensure that patients are
properly and thoroughly educated about the reasons they
are prescribed thienopyridines and the significant risks
associated with prematurely discontinuing such therapy.
. Patients should be specifically instructed before hospital
discharge to contact their treating cardiologist before
stopping any antiplatelet therapy, even if instructed to
stop such therapy by another healthcare provider.
. Healthcare providers who perform invasive or surgical
procedures and who are concerned about periprocedural
and postprocedural bleeding must be made aware of the
potentially catastrophic risks of premature discontinua-
tion of thienopyridine therapy. Such professionals who
perform these procedures should contact the patient’s
cardiologist if issues regarding the patient’s antiplatelet
therapy are unclear, to discuss optimal patient manage-
ment strategy.
. Elective procedures for which there is significant risk
of perioperative or postoperative bleeding should be
deferred until patients have completed an appropriate
course of thienopyridine therapy (12 months after
DES implantation if they are not at high risk of
bleeding and a minimum of 1 month for bare-metal
stent implantation).
. For patients treated with DES who are to undergo
subsequent procedures that mandate discontinuation of
thienopyridine therapy, aspirin should be continued if at
all possible and the thienopyridine restarted as soon as
possible after the procedure because of concerns about
late stent thrombosis.
Similar conclusions and recommendations were pub-
ished online in a clinical alert by the SCAI in January 2007
347). Given the above reports and recommendations, use
f a DES for coronary revascularization before imminent or
lanned noncardiac surgery that will necessitate the discon-
inuation of dual-antiplatelet agents is not recommended.
In conclusion, in patients with stable CAD, the indica-
ions for PCI in the preoperative setting should be identical
o those developed by the joint ACC/AHA Task Force that
rovided guidelines for the use of PCI in patients with
table angina and asymptomatic ischemia (303). There is no
vidence to support prophylactic preoperative percutaneous devascularization in patients with asymptomatic ischemia or
table angina.
Similarly, there is little evidence to show how long a more
istant PCI (i.e., months to years before noncardiac surgery)
rotects against perioperative MI or death. Because addi-
ional coronary restenosis is unlikely to occur more than 8 to
2 months after PCI (whether or not a stent is used), it is
easonable to expect ongoing protection against untoward
erioperative ischemic complications in currently asymp-
omatic, active patients who had been symptomatic before
omplete percutaneous coronary revascularization more
han 8 to 12 months previously.
.1.8. Perioperative Management of Patients With
rior PCI Undergoing Noncardiac Surgery
ccording to the 2005 PCI guidelines, “In patients who
ave undergone PCI, clopidogrel 75 mg daily should be
iven for at least 1 month after bare-metal stent implanta-
ion (unless the patient is at increased risk for bleeding, then
t should be given for a minimum of 2 weeks), 3 months
fter sirolimus stent implantation, and 6 months after
aclitaxel stent implantation, and ideally up to 12 months in
atients who are not at high risk of bleeding. (Level of
vidence: B)” (303). The newer recommendation by the
HA/ACC/SCAI/ACS/ADA Science Advisory Commit-
ee cited above (338) is for 12 months of dual-antiplatelet
herapy in patients who have undergone PCI with DES. If
here is a contraindication to 12 months of dual-antiplatelet
herapy, such as planned noncardiac surgery, then DES
hould not be implanted.
For patients who have undergone successful coronary
ntervention with or without stent placement before
lanned or unplanned noncardiac surgery, there is uncer-
ainty regarding how much time should pass before the
oncardiac procedure is performed. One approach is
utlined in Figure 2, which is based on expert opinion.
iven the reports of late DES thrombosis and the current
ecommendations discussed above, clinicians should re-
ain vigilant even beyond 365 days after DES place-
ent. The times of 14, 30 to 45, and 365 days for balloon
ngioplasty, bare-metal stents, and DES, respectively,
ecommended in Figure 2 are somewhat arbitrary because
f a lack of high-quality evidence.
Consideration should be given to continuing dual-
ntiplatelet therapy in the perioperative period for any
atient needing noncardiac surgery that falls within the time
rame that requires dual-antiplatelet therapy, particularly
hose who have received DES. In addition, consideration
hould be given to continuing dual-antiplatelet therapy
erioperatively beyond the recommended time frame in any
atient at high risk for the consequences of stent thrombo-
is, such as patients in whom previous stent thrombosis has
ccurred, after left main stenting, after multivessel stenting,
nd after stent placement in the only remaining coronary
rtery or graft conduit. Even after thienopyridines have been
iscontinued, serious consideration should be given to
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November 24, 2009:e13–118 2009 ACCF/AHA Perioperative Guidelinesontinuation of aspirin antiplatelet therapy perioperatively
n any patient with previous placement of a DES. The risk
f stopping antiplatelet therapy should be weighed against
he benefit of reduction in bleeding complications from the
lanned surgery. If thienopyridines must be discontinued
efore major surgery, aspirin should be continued and the
hienopyridine restarted as soon as possible. There is no
vidence that warfarin, antithrombotics, or glycoprotein
Ib/IIIa agents will reduce the risk of stent thrombosis after
iscontinuation of oral antiplatelet agents (338).
.1.9. Perioperative Management in Patients Who Have
eceived Intracoronary Brachytherapy
ntracoronary radiation with gamma or beta brachytherapy
as been used in the past to treat recurrent in-stent
estenosis. Brachytherapy delays the healing response and
nhibits endothelialization of the irradiated coronary seg-
ent. Late total occlusion and thrombosis of the irradiated
oronary segment occurs at a rate of 6% to 15%, especially
fter the placement of additional new bare-metal stents.
rolonged antiplatelet therapy is effective in preventing late
hrombosis of the irradiated coronary segment, in 1 study
educing the late thrombosis rate to 2.5% with 6 months of
herapy versus 9.6% with 1 month of dual-antiplatelet
herapy. Additional benefit was demonstrated with 12
onths of dual-antiplatelet therapy (late thrombosis rate of
.3%) (349,350). It is unclear when, if ever, antiplatelet
herapy can be safely discontinued in these patients.
Given the considerations above, antiplatelet therapy
hould be continued as per the “ACC/AHA/SCAI 2005
uideline Update for Percutaneous Coronary Intervention,”
igure 2. Proposed Approach to the Management of Patients With P
CI indicates percutaneous coronary intervention.ith a Class IIa recommendation: “It is reasonable that aatients undergoing brachytherapy be given daily chronic
lopidogrel 75 mg indefinitely and daily chronic aspirin 75
g to 325 mg indefinitely unless there is significant risk for
leeding. (Level of Evidence: C)” (303). Therefore, serious
onsideration should be given to continuing dual-
ntiplatelet therapy in the perioperative period for any
atient who has received brachytherapy for restenosis or
n-stent restenosis, particularly those in whom additional
tents (bare-metal or drug-eluting) were placed at the time
f or subsequent to the administration of brachytherapy.
he risk of stopping antiplatelet therapy should be weighed
gainst the benefit of reduction in bleeding complications
rom the planned surgery.
.1.10. Risks Associated With Perioperative Antiplatelet
gents
ual-antiplatelet therapy with aspirin and clopidogrel car-
ies a 0.4% to 1.0% increased absolute risk of major bleeding
ompared with aspirin alone (351). Some procedures carry a
ow risk of bleeding; for example, there is no indication to
nterrupt dual-antiplatelet therapy for dental procedures
352). The risk of surgical bleeding after administration of
spirin, thienopyridines, and glycoprotein IIb/IIIa inhibi-
ors has been reviewed (330,353). Increased blood loss in
atients taking aspirin has been reported in noncardiac
urgery, including general surgical, gynecologic, and uro-
ogic operations, and in dermatologic surgery in those
atients whose bleeding time was prolonged. One study
eported that patients taking aspirin who were undergoing
mergency general surgery operations did not demonstrate
us PCI Requiring Noncardiac Surgery (Based Upon Expert Opinion)revion increased risk of bleeding complications (354). Preoper-
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2009 ACCF/AHA Perioperative Guidelines November 24, 2009:e13–118tive aspirin use may not increase the risk of neuraxial
nesthesia or analgesia (355).
The authors of a review of this subject (330) concluded
hat monotherapy with aspirin need not be routinely dis-
ontinued for elective noncardiac surgery. Burger et al. (356)
eviewed the surgical literature with regard to the risks of
topping low-dose aspirin versus the risks of bleeding and
ound that in the majority of surgeries, low-dose aspirin may
esult in increased frequency of procedural bleeding (relative
isk 1.5) but not an increase in the severity of bleeding
omplications or perioperative mortality due to bleeding
omplications. Possible exceptions were intracranial surgery
nd prostatectomy. They recommended that aspirin should
nly be discontinued if the known bleeding risks are similar
r more severe than the observed cardiovascular risks of
spirin withdrawal.
In cardiac surgery, perioperative aspirin use results in
ncreased blood loss and need for reoperation but no
ncrease in mortality and is associated with improved saphe-
ous vein bypass graft patency. The “ACC/AHA 2004
uideline Update for Coronary Artery Bypass Graft Sur-
ery” reviewed this issue and stated: “In summary, aspirin is
he drug of choice for prophylaxis against early saphenous
raft thrombotic closure. Perioperative use and/or adminis-
ration of aspirin within 48 hours of operation should be the
tandard of care and should be continued indefinitely, given
ts benefit in the secondary prevention of subsequent clinical
vents” (302). In noncardiac vascular surgery, preoperative
spirin is routinely used and is associated with improved
eripheral bypass graft patency. Few data exist regarding the
isks and benefits of the use of aspirin perioperatively in
ther noncardiovascular surgery.
Likewise, monotherapy with clopidogrel or ticlopidine
ay not need to be discontinued in elective noncardiac
urgery; however, there is conflicting information about the
isks of bleeding in patients taking perioperative clopidogrel.
ongo et al. reported that a significant increased risk of
ajor perioperative bleeding was found in patients under-
oing CABG (357). Another study suggested no increased
isk of bleeding complications and mortality in patients
aking clopidogrel who were undergoing emergency CABG
ompared with those treated with aspirin and heparin alone
358). In the Clopidogrel in Unstable angina to prevent
ecurrent Events (CURE) trial (359), patients in whom
lopidogrel was stopped fewer than 5 days before CABG
urgery had a significantly increased (9.6% versus 6.3% in
he placebo arm) rate of major bleeding but no significant
ifference in perioperative mortality. Kapetanakis et al.
eported that patients receiving clopidogrel before off-pump
oronary artery bypass surgery had an OR of 5.1 (95% CI
.47 to 10.47; p0.01) with regard to the need for hemo-
tatic reoperation and a significant increase in the need for
acked red blood cell and platelet transfusions but no
ifference in surgical mortality (360). In a series of patients
ndergoing carotid endarterectomy, a reduction in transcra-
ial Doppler–determined emboli was seen with pretreat- pent with aspirin and clopidogrel, but no increase in
leeding complications or blood transfusions was seen (361).
Cannon et al. (362) suggest that for patients receiving
lopidogrel, a 5-day interval between stopping the drug and
lective surgery is optimal. This is reflected in the ACC/
HA recommendation that clopidogrel should be withheld
or at least 5 to 7 days in patients scheduled for elective
ABG surgery (302). For urgent and emergent surgery, a
elay of surgery until platelet function has recovered is
sually not a feasible option. Under these circumstances,
ome experts recommend platelet transfusions for treatment
f hemorrhage that continues despite usual hemostatic
echniques, even if platelet count is normal. However, no
ata demonstrate that transfused platelets reverse the clopi-
ogrel effect. For this reason, it may be more appropriate to
eserve platelet transfusion for patients with significant
linical bleeding after usual hemostatic methods are applied.
comprehensive approach for patients taking clopidogrel
nd aspirin who are undergoing emergent CABG surgery
ight include the use of aprotinin, aminocaproic acid, or
ranexamic acid to promote hemostasis during the early
eperfusion period. Early clinical experience suggested that
he intraoperative use of aprotinin or tranexamic acid may
ermit surgery to be conducted safely on patients presenting
hile taking aspirin and clopidogrel (363,364); however,
here is controversy regarding the safety of aprotinin in
ardiac surgery (365). Although this result is debated,
angano et al. found that aprotinin used in cardiac surgery
as associated with a doubling in the risk of renal failure
equiring dialysis among patients undergoing complex cor-
nary artery surgery compared with controls (365). Simi-
arly, the use of aprotinin in the primary surgery group was
ssociated with a 55% increase in the risk of MI or HF
p0.001) and a 181% increase in the risk of stroke or
ncephalopathy (p0.001). Neither aminocaproic acid nor
ranexamic acid was associated with an increased risk of
enal, cardiac, or cerebral events compared with controls. A
ater study found that the use of aprotinin was associated
ith a significant reduction in long-term survival (5-year
ortality 20.8% with aprotinin versus 12.7% for controls,
R 1.48; p0.005) that was not seen in CABG patients
reated with aminocaproic acid or tranexamic acid (366).
he applicability of this information to other types of
urgery is unknown.
.1.11. Strategy of Percutaneous Revascularization in
atients Needing Urgent Noncardiac Surgery
atients who require percutaneous coronary revasculariza-
ion in whom near-term noncardiac surgery is necessary
equire special consideration (338,367). A potential strategy
s outlined in Figure 3. Percutaneous coronary revascular-
zation should not be routinely performed in patients who
eed noncardiac surgery unless clearly indicated for high-
isk coronary anatomy, unstable angina, MI, or hemody-
amically or rhythmically unstable active CAD amenable to
ercutaneous intervention. If PCI is necessary, then the
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November 24, 2009:e13–118 2009 ACCF/AHA Perioperative Guidelinesrgency of the noncardiac surgery and the risk of bleeding
ssociated with the surgery in a patient taking dual-
ntiplatelet agents need to be considered. If there is little
isk of bleeding or if the noncardiac surgery can be delayed
2 months or more, then PCI with DES and prolonged
spirin and thienopyridine therapy could be considered if
he patient meets the criteria outlined in the AHA/ACC/
CAI/ACS/ADA science advisory group recommendations
utlined above (338). If the noncardiac surgery is likely to
ccur within 1 to 12 months, then a strategy of bare-metal
tenting and 4 to 6 weeks of aspirin and thienopyridine
herapy with continuation of aspirin perioperatively should
e considered. Although the risk of restenosis with this
trategy is higher than with DES, restenotic lesions are
sually not life-threatening, even though they may present
s an acute coronary syndrome (368), and can usually be
ealt with by repeat PCI if necessary. If the noncardiac
urgery is imminent (within 2 to 6 weeks) and the risk of
leeding is high, then consideration should be given to
alloon angioplasty and provisional bare-metal stenting plus
ontinued aspirin antiplatelet monotherapy, with restenosis
ealt with by repeat PCI if necessary. If the noncardiac
urgery is urgent or emergent, then cardiac risks, the risk of
leeding, and the long-term benefit of coronary revascular-
zation must be weighed, and if coronary revascularization is
bsolutely necessary, CABG combined with the noncardiac
urgery could be considered.
.2. Perioperative Medical Therapy (UPDATED)
.2.1. Recommendations for Perioperative Beta-Blocker
herapy (UPDATED)
LASS I
. Beta blockers should be continued in patients undergoing surgery
igure 3. Proposed Treatment for Patients Requiring Percutaneou
CS indicates acute coronary syndrome; and MI, myocardial infarction.who are receiving beta blockers for treatment of conditions with
r
cACCF/AHA Class I guideline indications for the drugs. (Level of
Evidence: C)
LASS IIa
. Beta blockers titrated to heart rate and blood pressure are probably
recommended for patients undergoing vascular surgery who are at
high cardiac risk owing to coronary artery disease or the finding of
cardiac ischemia on preoperative testing (88,246). (Level of Evi-
dence: B)
. Beta blockers titrated to heart rate and blood pressure are reason-
able for patients in whom preoperative assessment for vascular
surgery identifies high cardiac risk, as defined by the presence of
more than 1 clinical risk factor.‡‡ (Level of Evidence: C)
. Beta blockers titrated to heart rate and blood pressure are reason-
able for patients in whom preoperative assessment identifies coro-
nary artery disease or high cardiac risk, as defined by the presence
of more than 1 clinical risk factor,‡‡ who are undergoing
intermediate-risk surgery (369). (Level of Evidence: B)
LASS IIb
. The usefulness of beta blockers is uncertain for patients who are
undergoing either intermediate-risk procedures or vascular surgery
in whom preoperative assessment identifies a single clinical risk
factor in the absence of coronary artery disease.‡‡ (Level of Evi-
dence: C)
. The usefulness of beta blockers is uncertain in patients undergoing
vascular surgery with no clinical risk factors‡‡ who are not currently
taking beta blockers (370). (Level of Evidence: B)
LASS III
. Beta blockers should not be given to patients undergoing surgery
who have absolute contraindications to beta blockade. (Level of
Evidence: C)
‡Clinical risk factors include history of ischemic heart disease, history of compen-
ated or prior heart failure, history of cerebrovascular disease, diabetes mellitus, and
onary Intervention (PCI) Who Need Subsequent Surgerys Corenal insufficiency (defined in the Revised Cardiac Risk Index as a preoperative serum
reatinine of greater than 2 mg/dL) (4).
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dose titration is not useful and may be harmful to patients not
currently taking beta blockers who are undergoing noncardiac
surgery (371). (Level of Evidence: B)
he issue of perioperative beta-blocker therapy was last
ddressed by this committee in the “ACC/AHA 2007
uidelines on Perioperative Cardiovascular Evaluation and
are for Noncardiac Surgery” (2). As outlined in that
ocument, preoperative beta-blocker therapy should be
onsidered in the context of a full evaluation of each
atient’s clinical and surgical risk, including identification of
ctive cardiac conditions that require intensive management
nd may result in delay or cancellation of surgery unless the
urgery is emergent (Table 2). Clinical risk factors for
erioperative cardiovascular complications, as used in our
urrent recommendations, are unchanged from the prior
ocument and include the following:
• history of ischemic heart disease;
• history of compensated or prior heart failure;
• history of cerebrovascular disease;
• diabetes mellitus; and
• renal insufficiency (defined in the Revised Cardiac
Risk Index as a preoperative serum creatinine of
greater than 2 mg/dL) (4).
The surgery-specific cardiac risk of noncardiac surgery
Table 4) also remains relevant, with an important caveat
eing that limited data are available to guide beta-blocker
se in the presence of newer techniques (e.g., percutaneous
r endovascular vascular procedures) that may be associated
ith lower short-term risk.
The prior document outlined conflicting evidence regard-
ng the efficacy of beta blockers in reducing perioperative
ardiac events, as well as limitations in the evidence base.
hese included the relatively small number of randomized
rials on this issue and the dearth of studies comparing
ifferent beta-blocker agents or providing data to determine
he ideal target population, duration of preoperative titra-
ion, and route of administration. In addition, practical
oncerns, such as how, when, how long, and by whom
erioperative beta-blocker therapy should ideally or practi-
ally be prescribed, remained unaddressed. We advocated
or randomized controlled trials to explore the observation
hat there may be some harm associated with beta-blocker
herapy in low-risk patients (370). Moreover, there was a
ack of data regarding which beta blocker to use periopera-
ively. In summary, the best approach on how to reduce
ardiovascular complications medically during noncardiac
urgery was still unknown. Limitations in the perioperative
eta-blocker literature included the following:
• Most trials were inadequately powered.
• Few randomized trials of medical therapy to prevent
perioperative major adverse cardiac events had been
performed. c• Few randomized trials had examined the role of
perioperative beta-blocker therapy, and there was par-
ticularly a lack of trials that focused on high-risk
patients.
• Studies to determine the role of beta blockers in
intermediate- and low-risk populations were lacking.
• Studies to determine the optimal type, dose, timing,
duration, and titration of beta blockers were lacking.
• No studies addressed care-delivery mechanisms in the
perioperative setting, identifying how, when, and by
whom perioperative beta-blocker therapy should be
prescribed and monitored.
In addition, as outlined above, there is a paucity of
nformation to help guide beta-blocker use in the setting of
hifts in surgical techniques away from traditional open
rocedures that require general anesthesia and toward less
nvasive endovascular or percutaneous techniques, which
ay not require general anesthesia.
Since that guideline was published, important additional
nformation on some but not all of these issues has been
rovided by the POISE (PeriOperative ISchemic Evalua-
ion) trial (371), a large, randomized, controlled trial of fixed
igher-dose, extended-release metoprolol started the day of
urgery in more than 8000 patients undergoing noncardiac
urgery, which prompted this focused update on the subject
f perioperative beta-blocker therapy. This study, which will
e discussed in detail in Section 7.2.1.1, confirmed a
eduction in primary cardiac events such as cardiovascular
eath, myocardial infarction (MI), and cardiac arrest with
erioperative beta-blocker therapy. However, that benefit
as offset by an increased risk of stroke and total mortality,
hich suggests that routine administration of high-dose
eta blockers in the absence of dose titration is not useful
nd may be harmful to beta-blocker–naïve patients under-
oing surgery.
Current studies suggest that beta blockers reduce periop-
rative ischemia and may reduce the risk of MI and
ardiovascular death in high-risk patients. However, routine
dministration of higher-dose long-acting metoprolol in
eta-blocker–naive patients on the day of surgery and in the
bsence of dose titration is associated with an overall
ncrease in mortality. How should clinicians reconcile these
onflicting data? Importantly, the POISE results (371) do
ot address continuation of beta blockers in patients under-
oing surgery who are receiving beta blockers for ACCF/
HA Class I guideline indications; therefore, this continues
o be a Class I recommendation for beta-blocker therapy in
he present focused update. In addition, available evidence
uggests but does not definitively prove that when possible
nd where indicated, beta blockers should be started days to
eeks before elective surgery. The dose should be titrated
erioperatively to achieve adequate heart rate control to
ncrease the likelihood that the patient will receive the
enefit of beta blockade, while seeking to minimize the
onsiderable risks of hypotension and bradycardia seen in
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eta blockers should continue during the intraoperative and
ostoperative period, if possible, to maintain a heart rate of
0 to 80 bpm in the absence of hypotension, because this
egimen has demonstrated efficacy (59,88). However, rou-
ine administration of high-dose beta blockers in the ab-
ence of dose titration for patients undergoing noncardiac
urgery is not useful, may be harmful, and cannot be
dvocated, which results in a new Class III recommendation
or this practice. The committee continues to advocate for
dditional studies to address remaining issues regarding the
afety and efficacy of beta-blocker therapy as outlined above.
.2.1.1. EVIDENCE ON EFFICACY OF BETA-BLOCKER THERAPY (UPDATED)
tudies reviewed that provide primary data regarding the
fficacy and safety of beta-blocker therapy in noncardiac
urgery are summarized in Appendix 6. A more detailed
iscussion of these studies and of systematic reviews and
eta-analyses incorporating these data is provided in the
ections that follow. Several randomized trials examined the
ffect of perioperative beta blockers on cardiac events
urrounding surgery. Poldermans et al. (88) examined the
ffect of bisoprolol on patients undergoing vascular surgery
nd in patients at high risk for perioperative cardiac com-
lications who were scheduled for vascular surgery. Of 846
atients with risk factors for cardiac disease, 173 were found
o have new regional wall-motion abnormalities with stress
n dobutamine stress echocardiography. Of these patients,
1 were excluded from further study owing to large areas (5
r more segments) of regional wall-motion abnormalities on
obutamine stress echocardiography or because they were
lready taking beta blockers. The remaining 112 high-risk
atients were randomized to standard care or bisoprolol
tarted at least 7 days before surgery and titrated to maintain
eart rate less than 60 bpm preoperatively and less than 80
pm intraoperatively and postoperatively. The rates of
ardiac death (3.4% versus 17%; p0.02) and nonfatal MI
0% versus 17%; p0.001) were lower for the bisoprolol
roups than for the placebo groups, respectively. Impor-
antly, owing to the unblinded design and the inclusion of
nly high-risk patients in this study, the results cannot be
eneralized to all patients undergoing noncardiac surgery.
Boersma et al. (246) subsequently reanalyzed the total
ohort of 1351 consecutive patients considered for enroll-
ent in the aforementioned randomized trial of bisoprolol.
orty-five patients had perioperative cardiac death or non-
atal MI. Eighty-three percent of the 1351 patients had
ewer than 3 clinical risk factors, and in this subgroup,
atients taking beta blockers had a lower risk of cardiac
omplications (0.8% [2 of 263]) than those not taking beta
lockers (2.3% [20 of 855]). In patients with 3 or more risk
actors (17%), those taking beta blockers who had a dobut-
mine stress echocardiography examination that demon-
trated 4 or fewer segments of new wall-motion abnormal-
ties had a significantly lower incidence of cardiac
omplications (2.3% [2 of 86]) than those not receiving geta-blocker therapy (9.9% [12 of 121]). However, among
he small group of patients with more extensive ischemia on
obutamine stress echocardiography (5 or more segments),
here was no difference in the incidence of cardiac events (4
f 11 for those taking beta blockers versus 5 of 15 for those
ot taking beta blockers). Therefore, beta-blocker therapy
as beneficial in all but the subset of patients with more
xtensive ischemia. Nevertheless, one must be cautious
bout inferring a class effect from this observation.
Mangano et al. (87) reported on 200 patients undergoing
eneral surgery who were randomized to a combination of
ntravenous and oral atenolol versus placebo for 7 days.
lthough they found no difference in in-hospital perioper-
tive deaths (4 of 99 versus 2 of 101) or MI, they reported
ignificantly fewer episodes of ischemia by Holter monitor-
ng in the atenolol group than in the placebo group (24%
ersus 39%, respectively; p0.03). They then conducted
ollow-up on these patients after discharge and documented
ewer deaths in the atenolol group over the subsequent 6
onths (1% versus 10%; p0.001). Overall, 13 of 99
atients in the atenolol group and 23 of 101 patients in the
lacebo group died when both in-hospital and postdis-
harge events were considered. It is unclear why such a brief
ourse of therapy could exert such a delayed effect, and the
tudy did not control for other medications given either
efore or after surgery. Use of angiotensin-converting en-
yme inhibitors and beta blockers postoperatively differed
ignificantly between the study groups.
More recent randomized trials have examined beta block-
de for the prevention of perioperative cardiac complica-
ions during noncardiac surgery. Juul et al. (372) random-
zed 921 subjects with diabetes mellitus who were
ndergoing a range of noncardiac operations to either 100
g of extended-release metoprolol or placebo in the
IPOM (DIabetic POstoperative Mortality and morbidity)
tudy. There was no significant difference in the primary
omposite outcome of time to all-cause mortality, MI,
nstable angina, or congestive heart failure (CHF) (21%
ersus 20%) in patients randomized to higher-dose meto-
rolol versus placebo. Among those randomized, an equal
umber of deaths (16%) were observed in both groups. MI
ates were not reported separately. Yang et al. (373) reported
study of 496 subjects undergoing major vascular surgery
ho were randomized to dose-adjusted metoprolol or pla-
ebo. Exclusions in that study included those already taking
beta blocker. They reported similar MI rates (7.7% versus
.4%; p0.87) and death rates (0% versus 1.6%) at 30 days
n the beta-blocker and placebo groups, respectively. These
ere not noninferiority analyses but rather simply negative
tudy results. Most importantly for the purposes of these
uidelines, the patients included in the studies by Juul et al.
372) and Yang et al. (373) were patients with diabetes in 1
tudy and patients undergoing major vascular surgery in the
ther, who undoubtedly represent a heterogeneous risk
roup without documented coronary artery disease.
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2009 ACCF/AHA Perioperative Guidelines November 24, 2009:e13–118Additional studies have examined the use of perioperative
eta blockers but have used surrogate end points such as
lectrocardiographic ST changes, were not randomized, did
ot use general anesthesia, or had limited power to detect
ifferences in cardiac events. Stone et al. (76) randomized a
roup of patients with mild hypertension who underwent
redominantly (58%) vascular surgery either to oral beta
lockers 2 hours before surgery or to standard care. Control
ubjects had a higher frequency (28%) of ST-segment
epression (on intraoperative monitoring, as reported by the
uthors) than treated patients (2%). In a nonrandomized
tudy, Pasternack et al. (374) gave oral metoprolol imme-
iately before abdominal aortic aneurysm repair surgery,
ollowed postoperatively by intravenous metoprolol. Only
% of patients experienced an acute MI compared with 18%
or matched control subjects. Pasternack et al. (78) subse-
uently reported fewer episodes of intraoperative ischemia
n patients treated with oral metoprolol before peripheral
ascular surgery than in untreated patients. Yeager et al.
375) reported a case-control analysis of their experience
ith perioperative MI during vascular surgery, comparing
3 index cases of perioperative MI with 106 matched
ontrol subjects. They found a strong association of beta-
locker use with a decreased likelihood of MI (OR 0.43;
0.01). In 26 vascular surgery patients with documented
reoperative ischemia who were randomized to a protocol of
eart rate suppression with intravenous esmolol compared
ith standard care, Raby et al. (376) demonstrated that the
smolol group had fewer episodes of ischemia than control
ubjects (33% versus 73%; p0.055).
Zaugg et al. (377) randomized elderly noncardiac surgery
atients to preoperative and postoperative atenolol titrated
o heart rate, intraoperative atenolol titrated to heart rate, or
o beta blockers and detected no episodes of intraoperative
yocardial ischemia, electrocardiographic changes consis-
ent with MI, or death in any group. Three of 19 patients in
he no beta-blocker group developed significant elevations
f cardiac troponin I consistent with a perioperative MI
ompared with none of 40 patients who received 1 of the
tenolol regimens. In a follow-up study, Zaugg et al. (378)
andomized 219 patients undergoing spinal, rather than
eneral, anesthesia to bisoprolol or placebo. The composite
utcome of cardiovascular mortality, nonfatal MI, unstable
ngina, CHF, and cerebrovascular event was not signifi-
antly different over the 1-year follow-up period. Interest-
ngly, adrenergic-receptor genotype was associated with
utcome in this study, which raises the possibility that
enetic heterogeneity may be another important determi-
ant of outcome. Brady et al. (379) randomized patients
ndergoing elective vascular surgery to either metoprolol 50
g twice a day or placebo, from admission to the hospital
ntil 7 days after surgery. They found no difference in
ardiovascular events, which included MI, unstable angina,
entricular tachycardia, and stroke. This trial may have been
nderpowered (n103) to identify a difference in outcomes,
articularly hard outcomes of death and MI. Also, by trial sesign, therapy was initiated the day before vascular surgery,
nd it is quite possible that those randomized to metoprolol
eceived incomplete beta blockade in the early perioperative
eriod.
Perioperative beta-blocker therapy has also been reviewed
n several meta-analyses and in a very large cohort popula-
ion study before publication of the recent POISE trial.
uerbach and Goldman (380) undertook a review of this
opic in 2002. They reported on a MEDLINE search and
iterature review of 5 studies (all 5 studies are included in
able 11). They calculated an NNT on the basis of these
tudies of 2.5 to 6.7 to see improvement in measures of
yocardial ischemia and 3.2 to 8.3 in studies that reported
significant impact of beta blockers on cardiac or all-cause
ortality. They concluded that the literature supports a
enefit of beta blockers on cardiac morbidity and mortality.
A systematic review of the perioperative medical therapy
iterature by Stevens et al. (383) for noncardiac surgery
ncluded the results of 11 trials using beta blockers for
erioperative therapy. These authors concluded that beta
lockers significantly decreased ischemic episodes during
nd after surgery. Beta blockers significantly reduced the
isk of nonfatal MI; however, the results became nonsignif-
cant if the 2 most positive trials were eliminated. Likewise,
he risk of cardiac death was significantly decreased with
eta-blocker usage. These authors incorporated studies not
onsidered in other meta-analyses, including studies that
ere not blinded. Results to be quantified were limited to
hose in the 30-day perioperative period. The authors also
eported a direct relationship between the prevalence of
rior MI and the magnitude of risk reduction observed with
eta-blocker therapy, which suggests that higher risk con-
ers greater benefit. The NNT to prevent perioperative
schemia was 8 subjects, the NNT to prevent MI was 23,
nd 32 patients had to be treated to prevent cardiac death.
hese authors pointed out that given the observation that
igh-risk patients appeared to receive all the benefit, the
arget population for beta-blocker therapy is not clear. They
lso highlighted that schedules of beta-blocker administra-
ion varied significantly among the reported studies, and
hey acknowledged the potential for a single large, strongly
ositive study to skew the results of this meta-analysis (383).
In contrast, Devereaux et al. (384) published their opin-
on paper on the clinical evidence regarding the use of
eta-blocker therapy in patients undergoing noncardiac
urgery for the purpose of preventing perioperative cardiac
omplications. They expressed the opinion that the litera-
ure supporting the use of beta blockers during noncardiac
urgery is modest at best and is based on a few small,
nblinded studies with a focused patient population. In a
eview of the literature in 2005, Devereaux et al. (385)
iscussed 22 studies that randomized 2437 patients under-
oing noncardiac surgery to beta-blocker therapy or pla-
ebo. The POBBLE (PeriOperative Beta-BLockadE) study
379) was not included in this review. They found no
tatistically significant benefit with regard to any of the
Table 11. Perioperative Prophylactic Beta Blockers and Anti-Ischemic Medications
Study Procedure n Control Drug and Dosage
Myocardial Ischemia MI Death
Control Drug Control Drug Control Drug
Studies of Beta Blockers
Pasternack et al.,
1987 (374)
Abdominal aortic
aneurysmorrhaphy
83 Case-control Metoprolol 50 mg PO
preoperatively
17.6% (9/51) 3.1% (1/32)*
Pasternack et al.,
1989 (78)
Vascular 200 Unblinded Metoprolol 50 mg PO
preoperatively
1.83.2 episodes 0.81.6 episodes*
Stone et al.,
1988 (75)
Noncardiac 128 Placebo Labetalol
Atenolol
Alprenolol
PO preoperatively
28.2% (11/39) 2.2% (2/89)* 0% (0/39) 0% (0/89)
Poldermans et al.,
1999 (88)
Vascular 112 Unblinded Bisoprolol 5 to 10 mg
PO
17% (9/53) 0% (0/59)* 17% (9/53) 3.4% (2/59)*
Raby et al.,
1999 (376)
Vascular 26 Placebo IV esmolol 72.7% (8/11) 33.3% (5/15)*
Wallace et al.,
1998 (381)
and Mangano
et al.,
1996 (87)
Noncardiac 200 Placebo Atenolol 10 to 20 mg IV
or 50 to 100 mg PO
39/101 (38.6%) 24/99 (24.2%)* (At 6 months)
10/101 (9.9%)
1/99 (1.0%)*
Urban et al.,
2000 (382)
Noncardiac 107 Placebo IV esmolol on the day of
surgery, followed by
metoprolol starting at
25 mg PO BID and
increased to maintain
an HR less than 80
bpm, and continued
for the next 48 h
14.5% (8/55) 5.8% (3/52) 5.4% (3/55) 1.9% (1/52)
Brady et al.,
2005 (379)
Vascular 103 Placebo Metoprolol 50 mg PO
BID preoperatively
until 7 d after surgery
9% (4/44) 9.4% (5/53) 11.3% (5/44) 5.6% (3/53) 2.2% (1/44) 5.6% (3/53)
Perioperative Prophylactic Anti-Ischemic Medications and Cardiac Morbidity
Juul et al.,
2006 (372)
Noncardiac 921 Placebo Metoprolol 100 mg
sustained release 1 d
preoperatively, until
up to 8 d
postoperatively
16% (72/459) 16% (74/462)
Yang et al.,
2006 (373)
Vascular 496 Placebo Weight-adjusted
metoprolol, 50, 75, or
100 mg
21/250 (8.4%) 19/246 (7.7%) 4/250 (1.6%) 0/246 (0%)
*p0.05 for drug versus control.
BID indicates twice per day; bpm, beats per minute; HR, heart rate; IV, intravenous; MI, myocardial infarction; n, number of patients; NTG, nitroglycerin; and PO, by mouth.
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2009 ACCF/AHA Perioperative Guidelines November 24, 2009:e13–118ndividual outcomes and a “nominally” statistically signifi-
ant benefit (RR 0.44, 99% CI 0.16 to 1.24) for the
omposite outcome of cardiovascular mortality, nonfatal
I, and nonfatal cardiac arrest. The authors believed that
hese data were inadequate to draw conclusions without a
arger, controlled study. This review, however, included a
ide variety of studies, patient populations, and beta-
locker regimens. Many of the studies described only a
ingle or double dose of beta blockers preoperatively or at
nduction of anesthesia. Many of the data, therefore, do not
ertain to perioperative beta blockade for the purpose of
ardiac risk reduction or are focused on a low-risk popula-
ion. Additionally, the largest studies included, those re-
orted by Miller et al. (386) and preliminary data from Yang
t al. (373), which together account for almost as many
ubjects as all the other studies combined, may not have
een appropriate to include in this analysis. The first, by
iller et al. (386), was a study of a single intravenous dose
f beta blocker for the purpose of blood pressure control
uring intubation, not reduction of perioperative events. It
ncluded follow-up only to the point of discharge from the
ecovery room. The second was Yang et al. (373), an
bstract of a paper that has now published. The studies
ncluded in this review also varied widely in length of
ollow-up.
McGory et al. (387) performed a meta-analysis of 6
andomized trials of perioperative beta blockade and con-
luded that therapy was associated with significant reduc-
ions in perioperative myocardial ischemia (from 33% to
5%), MI, cardiac mortality, and long-term cardiac mortal-
ty (from 12% to 2%). These authors used the combined
ata to derive ORs and CIs for several outcomes. For
erioperative overall mortality, the OR for beta-blocker
herapy was 0.52 (95% CI 0.20 to 1.35), and for perioper-
tive cardiac mortality, the OR was 0.25 (95% CI 0.07 to
.87). Neither the POBBLE (379) study nor the unpub-
ished findings included in the Devereaux article were
ncluded, which explains the marked difference in findings
rom the other meta-analysis.
More recently, Wiesbauer et al. (388) published a sys-
ematic review of randomized trials through 2005 of peri-
perative beta-blocker use in both cardiac and noncardiac
urgery. The authors concluded that beta blockers reduced
erioperative arrhythmias and myocardial ischemia, but they
ere unable to show an effect on mortality or perioperative
I. A cohort study by Lindenauer et al. (370) reviewed
dministrative records from more than 600 000 patients
ndergoing noncardiac surgery at 329 hospitals in the
nited States. Participant hospitals in this cohort study
ere members of a consortium database measuring quality
f care and healthcare use. These authors evaluated all
oncardiac surgical cases and compared those who received
eta blockers within the first 2 days of hospitalization with
hose who did not. The authors used propensity-score–
atching techniques in an attempt to reduce confoundingnd selection bias. These authors found that for a Revised (ardiac Risk Index score (4) of 3 or more (based on the
resence of history of ischemic heart disease, cerebrovascu-
ar disease, renal insufficiency, diabetes mellitus, or a patient
ndergoing high-risk surgery), patients who received beta
lockers were significantly less likely to die while in the
ospital. This was not true for those with a Revised Cardiac
isk Index of 2, l, or 0. Those with a risk index of 0 were
ore likely to die in the hospital if given a beta blocker on
ay 1 or day 2 of hospitalization. This study was retrospec-
ive and not randomized and is therefore subject to potential
ias. This is particularly true in terms of reporting bias,
ecause the documentation was based entirely on adminis-
rative data sets, with arbitrary definitions of “on” or “off”
erioperative beta blockers that were based solely on hospi-
al day of use. Nonetheless, there appears to be an associa-
ion between improved outcomes and the use of beta
lockers in clinically high-risk patients, whereas lower-risk
atients had worse outcomes, which raises concerns regard-
ng the routine use of beta blockers perioperatively in
ower-risk patients.
One observational cohort study examined the question of
hich beta blocker may be best for perioperative medical
herapy. Redelmeier et al. (389) retrospectively reviewed
rescription records and administrative data related to
lective surgery in Ontario, Canada, from April 1992 to
pril 2002. They limited their analysis to patients older
han 65 years of age who were receiving prescriptions for
ither atenolol or short-acting metoprolol before and after
urgery (although actual beta-blocker use perioperatively
as not ascertained) and identified 37 151 subjects. A total
f 1038 either had a perioperative MI or died, and the rate
f MI or death was significantly lower among those patients
eceiving atenolol than among those given metoprolol (2.5%
ersus 3.2%; p0.001). This difference persisted even after
djustment for demographic, clinical, and surgical factors.
he inclusion of other long-acting beta blockers in the
nalysis yielded an identical risk reduction. Although lim-
ted by several methodological issues, these data suggest that
ong-acting beta blockade (when therapy is initiated before
urgery) might be superior to short-acting beta blockade,
ut clinical trial evaluation is awaited to confirm this.
.2.1.1.1. RECENT DATA REGARDING PERIOPERATIVE BETA-BLOCKER
HERAPY (NEW). Since the publication of the 2007 update, the
OISE trial group has published the results of their study
371). Patients were randomly assigned to receive extended-
elease metoprolol succinate or placebo starting 2 to 4 hours
efore surgery and continued for 30 days with a primary end
oint of a composite of cardiovascular death, nonfatal MI,
nd nonfatal cardiac arrest. Patients were eligible if they
ere undergoing noncardiac surgery, were 45 years or older,
ad an expected length of hospital stay of at least 24 hours,
nd fulfilled any 1 of the following criteria: history of
oronary artery disease; peripheral vascular disease; stroke;
ospitalization for CHF within previous 3 years; undergo-
ng major vascular surgery; or any 3 of 7 risk criteria
undergoing intrathoracic or intraperitoneal surgery, history
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November 24, 2009:e13–118 2009 ACCF/AHA Perioperative Guidelinesf CHF, transient ischemic attack, diabetes mellitus, serum
reatinine greater than 175 micromoles/L, age greater than
0 years, or undergoing emergency or urgent surgery).
atients who were previously receiving a beta blocker or
ho had coronary artery bypass graft surgery in the preced-
ng 5 years and no cardiac ischemia since that time were
xcluded. Patients received the first dose of the study drug
metoprolol succinate 100 mg or placebo) 2 to 4 hours
efore surgery. Study drug administration required a heart
ate of 50 bpm or higher and a systolic blood pressure of 100
m Hg or greater; these parameters were checked before
ach administration. If at any time during the first 6 hours
fter surgery heart rate was 80 bpm or more and systolic
lood pressure was 100 mm Hg or higher, patients received
heir first postoperative dose (extended-release metoprolol
00 mg or matched placebo) orally. If the study drug was
ot given during the first 6 hours, patients received their
rst postoperative dose at 6 hours after surgery. Twelve
ours after the first postoperative dose, patients started
aking oral extended-release metoprolol 200 mg or placebo
very day for 30 days. If a patient’s heart rate was consis-
ently below 45 bpm or their systolic blood pressure dropped
elow 100 mm Hg, study drug was withheld until their
eart rate or systolic blood pressure recovered; the study
rug was then restarted at 100 mg once daily. Patients
hose heart rate was consistently 45 to 49 bpm and whose
ystolic blood pressure exceeded 100 mm Hg delayed taking
he study drug for 12 hours. Patients who were unable to
ake medications orally received the study drug by intrave-
ous infusion (slow infusion of 15 mg of study drug over 60
inutes or rapid infusion of 5 mg over 2 minutes every 5
inutes up to a total of 15 mg as long as hemodynamic
riteria were met) until they could resume oral medications.
The final analysis included 8351 patients from 190
ospitals in 23 countries. Several hundred more participants
ere excluded because of fraudulent activity at their sites. A
otal of 8331 patients (99.8%) completed the 30-day follow-
p. Fewer patients in the metoprolol group than in the
lacebo group reached the primary end point of cardiovas-
ular death, nonfatal MI, and nonfatal cardiac arrest (244
5.8%] in the metoprolol group versus 290 [6.9%] in the
lacebo group; HR 0.84, 95% CI 0.70 to 0.99; p0.0399).
ewer patients in the metoprolol group than in the placebo
roup had an MI (176 [4.2%] versus 239 [5.7%]; HR 0.73,
5% CI 0.60 to 0.89; p0.0017). However, more people
eceiving metoprolol died than did individuals receiving
lacebo (HR 1.33, 95% CI 1.03 to 1.74; p0.0317); the
aplan-Meier mortality estimates started separating on day
0. The only reported cause of death for which there was a
ignificant difference between groups was sepsis or infection,
hich was more common among patients allocated to
etoprolol. More patients in the metoprolol group than in
he placebo group had a stroke (41 [1.0%] versus 19 [0.5%]
atients; HR 2.17, 95% CI 1.26 to 3.74; p0.0053). Most
atients who had a nonfatal stroke subsequently required
elp to perform everyday activities or were incapacitated. iultiple predefined subgroup analyses were performed,
lthough the study was underpowered to detect modest
ifferences in subgroup effects. The cohort that developed
linically significant hypotension had the largest population
ttributable risk for death and the largest intraoperative or
ostoperative risk for stroke. In the wake of POISE, a
eta-analysis of trials investigating the use of beta blockers
round the time of noncardiac surgery and incorporating the
OISE results was published (390). The authors found that
eta blockers were associated with a significant reduction in
onfatal MI (OR 0.65) and ischemia (OR 0.36) at the
xpense of an increased risk of stroke (OR 2.01), as well as
radycardia and hypotension. As the largest of the included
rials by far, these results are largely driven by the POISE
esults. The results point to a need to understand more fully
he causes for the increased risk of stroke and death seen in
OISE and their relation to the potential hemodynamic
ffects of beta blockade. Because of limitations inherent in
eta-analysis, these analyses could not be adjusted for type
nd duration or dosage of beta blockers used in treatment
rotocols.
Several nonrandomized studies have also been published.
aafarani et al. (391) published a retrospective, single-
enter experience assessing outcomes in those who received
eta blockers perioperatively (n238) compared with a
ontrol group (n408) that did not. In this study, unlike
OISE, beta-blocker use was associated with an increased
isk of MI at 30 days (2.94% versus 0.74%; p0.03) and
eath (2.52% versus 0.25%; p0.007), and patients who
ied had significantly higher preoperative heart rates, but
hese data are difficult to interpret in light of methodological
imitations. Matyal et al. (392) analyzed retrospective data
rom 960 patients (594 men, 366 women) undergoing
rimarily infrainguinal vascular surgery. They reported that
se of beta blockers was associated with a lower risk of
dverse outcome (including MI, CHF, death, significant
rrhythmia, and renal failure) in men (12.6% versus 18.9%,
0.04) but not in women (17.8% versus 13.7%; p0.37),
hich raises the question of sex difference in response to
erioperative beta blockade.
Finally, the results of a large (n1066), randomized,
ontrolled trial of bisoprolol and fluvastatin use in
ntermediate-risk patients undergoing noncardiac surgery
DECREASE-IV) were presented at the 2008 American
eart Association Annual Scientific Sessions and were
ublished recently (369). Patients were enrolled who were at
east 40 years of age, were scheduled for elective noncardiac
urgery, and had an estimated risk of perioperative death
nd MI of 1% to 6%. Exclusion criteria included the use of
eta blockers; a contraindication for beta blocker use; the
se of statins before randomization; a contraindication for
tatin use; unstable coronary heart disease or evidence of
-vessel disease or left main disease; elevated cholesterol
ccording to the National Cholesterol Consensus; emer-
ency surgery; inability or unwillingness to provide written
nformed consent; and previous participation in the same
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2009 ACCF/AHA Perioperative Guidelines November 24, 2009:e13–118rial. Participants were randomized according to an open-
abel, factorial design to 1) beta-blocker therapy (bisopro-
ol), 2) statin (fluvastatin XL 80 mg daily), 3) a combination
f a beta blocker and a statin (bisoprolol and fluvastatin), or
) neither a beta blocker or a statin (control group). By
esign, study medication could be started up to the day of
urgery (median 34 days before the procedure, interquartile
ange 21 to 53 days) and was to be continued until 30 days
fter surgery. The starting dose of bisoprolol was 2.5 mg
rally per day if resting heart rate was greater than 50 bpm.
uring hospitalization, resting heart rate was evaluated on a
aily basis, and drug dose was modified in steps of 1.25 or
.5 mg per day, up to a maximum dose of 10 mg, aiming for
heart rate of 50 to 70 bpm. The primary efficacy end point
as a composite of cardiac death and nonfatal MI until 30
ays after surgery. The study was terminated early owing to
low enrollment linked to widespread use of 1 or both types
f medications in the population screened. Patient charac-
eristics were as follows: median age 64 years; 60% male;
1% with diabetes mellitus; 6% with angina pectoris; 5%
ith prior MI; and 4% with prior stroke. The most common
ypes of surgery were general (39%), urological (19%),
rthopedic (16%), and ear-nose-throat (12%). Patients ran-
omized to bisoprolol (n533) had a lower incidence of
erioperative cardiac death and nonfatal MI than those who
id not receive bisoprolol (2.1% versus 6.0% events; HR
.34, 95% CI 0.17 to 0.67; p0.002). Ischemic stroke
ccurred in 7 patients (0.7%), of whom 4 (0.8%) were
andomized to bisoprolol treatment and 3 (0.6%) were
andomized to the group which did not receive bisoprolol
p0.68). In total, 3 patients (0.6%) randomized to biso-
rolol reached 1 other beta-blocker–related safety end point
heart failure, clinically significant bradycardia, or hypoten-
ion) compared with 2 patients (0.4%) in the group which
id not receive bisoprolol (p0.65). The authors also
eported a stroke rate of 0.4% in all the DECREASE
tudies combined, with no difference between treatment
roups.
This research demonstrated a cardioprotective effect of
erioperative beta-blocker use in the intermediate-risk
roup, without an increased incidence of perioperative
troke or mortality, although power for these end points was
imited. Importantly, beta blockers were generally started
ell in advance of surgery and were titrated to heart rate
tarting at a low dose (369).
.2.1.2. TITRATION OF BETA BLOCKERS (UPDATED)
eta-blocker therapy is commonly used to reduce adverse
ardiac events in conditions such as MI and CHF. Titration
f the dose is a well-recognized part of using this class of
edication. For example, the “ACC/AHA 2007 Guidelines
or the Management of Patients With Unstable Angina/
on–ST-Elevation Myocardial Infarction” (187) and the
ACC/AHA Guidelines for the Management of Patients
ith ST-Elevation Myocardial Infarction” (49) recom-
end dose titration of beta blockers to a goal heart rate of (0 to 60 bpm. Titration to goal heart rate in this case is
ssociated with more benefit than the fixed-dose application
f the medication alone. Cucherat (393) evaluated 17 trials
f beta blockers in patients with MI that reported change in
eart rate, showing that each 10-bpm reduction in the heart
ate is estimated to reduce the RR of cardiac death by 30%.
n patients with MI, the use of fixed, higher-dose therapy
as associated with increases in cardiogenic shock that offset
eductions in reinfarction and ventricular fibrillation (394).
n CHF, the “ACC/AHA 2005 Guideline Update for the
iagnosis and Management of Chronic Heart Failure in
he Adult” (189) also suggested that beta blockers should be
itrated up to high-dose therapy in patients who could
olerate these doses. Recent data suggest that high-dose
herapy, in patients who tolerate the dose, reduces event
ates more than low-dose therapy (5).
Similarly, in the management of perioperative patients,
xed-dose beta-blocker administration has not shown suf-
cient benefit to warrant routine use. POISE, as the largest
rial to date, and the only trial with enough power to
onfirm a null result, makes this clear. Several potential
roblems can arise from a fixed-dose management strategy.
irst, fixed-dose strategies cannot account for the variability
n response to medications within a population and may
rovide doses that are inadequate for some patients, ade-
uate for some, and clearly too much for others, as evi-
enced by increased hypotension and bradycardia. Second,
ong-acting oral medications may not provide the flexibility
equired for the dynamic postoperative clinical condition.
hird, fixed-dose regimens presuppose a constant require-
ent for beta blockade in the postoperative setting. Small
hysiological trials have made clear that sympathetic ner-
ous system tone increases after operation and returns to
aseline within 4 to 5 days (395), which suggests variation
n the required dose within individual patients.
In contrast to the fixed-dose studies, beta-blocker dose
itration may provide benefit in high-risk patients. Feringa
t al. (396) performed an observational cohort study of 272
ascular surgery patients. The beta-blocker dose was con-
erted to a percentage of the maximum recommended
herapeutic dose. In multivariable analysis, higher beta-
locker doses (per 10% increase) were significantly associ-
ted with a lower incidence of myocardial ischemia (HR
.62, 95% CI 0.51 to 0.75), troponin T release (HR 0.63,
5% CI 0.49 to 0.80), and long-term mortality (HR 0.86,
5% CI 0.76 to 0.97). Higher heart rates during electrocar-
iographic monitoring (per 10-bpm increase) were signifi-
antly associated with an increased incidence of myocardial
schemia (HR 2.49, 95% CI 1.79 to 3.48), troponin T
elease (HR 1.53, 95% CI 1.16 to 2.03), and long-term
ortality (HR 1.42, 95% CI 1.14 to 1.76). An absolute
ean perioperative heart rate less than 70 bpm was associ-
ted with the best outcome.
Poldermans et al. (59) randomly assigned 770 intermediate-
isk patients to cardiac stress testing (n386) or no testing
n384). All patients received beta blockers, and the
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November 24, 2009:e13–118 2009 ACCF/AHA Perioperative Guidelineseta-blocker dose was adjusted preoperatively to achieve a
esting heart rate of 60 to 65 bpm. In patients with
schemia, physicians aimed to control heart rate below the
schemic threshold. Patients assigned to no testing had a
imilar incidence of the cardiac events as those assigned to
esting. Patients with a heart rate less than 65 bpm had
ower risk than the remaining patients (1.3% versus 5.2%;
R 0.24, 95% CI 0.09 to 0.66; p0.003). The authors
oncluded that cardiac testing can safely be omitted in
ntermediate-risk patients, provided that beta blockers
imed at tight heart rate control are prescribed. The
mportance of heart rate control in reducing perioperative
yocardial ischemia is further supported by a study by Raby
t al. (376).
Meta-analyses addressing this subject have had mixed
esults. Beattie et al. (397) identified 10 trials enrolling 2176
ubjects. Trials associated with an estimated maximal heart
ate of less than 100 bpm showed cardioprotection for MI
OR 0.23, 95% CI 0.08 to 0.65; p0.005), whereas those
ith higher maximal heart rates did not (OR 1.17, 95% CI
.79 to 1.80; p0.43). Biccard et al. (398) identified 8
tudies of perioperative beta blockade around the time of
oncardiac surgery and found no correlation between heart
ate and cardiac complications at 30 days, although postop-
rative heart rate was not a primary end point in these
tudies. Overall, available evidence suggests that beta block-
rs, if used, should be appropriately titrated throughout the
reoperative, intraoperative, and postoperative period to
chieve effective heart rate control while avoiding frank
ypotension and bradycardia.
.2.1.3. WITHDRAWAL OF BETA BLOCKERS (UPDATED)
eta-blocker withdrawal has been associated with an in-
reased risk of MI and chest pain. Psaty et al. (399) showed
hat hypertensive patients who stopped taking their beta
lockers had a transient 4-fold increase in the RR of first
vents associated with coronary heart disease (RR 4.5, 95%
I 1.1 to 18.5). More recently, Teichert et al. (400) showed
hat selective beta-blocker discontinuation resulted in a
igher risk of MI in the first 30 days (RR 2.70, 95% CI 1.06
o 6.89) and between 30 and 180 days (RR 2.44, 95% CI
.07 to 5.59) after cessation, although older data from Croft
t al. (401) suggest the short-term risk of discontinuation
uring MI is modest and does not result in a significant
ncrease in infarct size or worsened in-hospital outcomes.
Concerns regarding the discontinuation of beta-blocker
herapy in the perioperative period have existed for several
ecades (402). Shammash et al. (403) retrospectively stud-
ed a total of 140 patients who received beta blockers
reoperatively. Mortality in the 8 patients who had beta
lockers discontinued postoperatively (50%) was signifi-
antly greater than in the 132 patients in whom beta
lockers were continued (1.5%; OR 65.0; p0.001). Hoeks
t al. (404) studied 711 consecutive peripheral vascular
urgery patients. After adjustment for potential confounders
nd the propensity of its use, continuous beta-blocker use semained significantly associated with a lower 1-year mor-
ality than among nonusers (HR 0.4, 95% CI 0.2 to 0.7). In
ontrast, beta-blocker withdrawal was associated with an
ncreased risk of 1-year mortality compared with nonusers
HR 2.7, 95% CI 1.2 to 5.9).
Thus, although data are limited, perioperative beta-
locker withdrawal should be avoided unless necessary. As
oted in the recommendations, continuation of beta-
locker therapy in the perioperative period is a Class I
ndication, and accumulating evidence suggests that titra-
ion to maintain effective heart rate control while avoiding
rank hypotension and bradycardia should be the goal.
.2.1.4. RISKS AND CAVEATS (NEW)
erioperative beta blockade is associated with risk. All of the
reviously discussed studies have incorporated lower limits
f heart rate and blood pressure with regard to holding or
iscontinuing the study medication. In the POISE trial, the
ral study medication was held if the heart rate was
onsistently below 45 bpm or the systolic blood pressure was
elow 100 mm Hg (371). If a patient’s heart rate was
onsistently 45 to 49 bpm, there was a delay of 12 hours in
dministering the study drug. If the patient was on an
ntravenous infusion, the study medication was held if the
atient’s heart rate dropped below 50 bpm or systolic blood
ressure dropped to below 100 mm Hg. Similarly, Polder-
ans et al. (88) held beta-blocker medication if the heart
ate was less than 50 bpm or the systolic blood pressure was
ess than 100 mm Hg. Several meta-analyses have examined
he rates of bradycardia and hypotension. Stevens et al.
383) reported an OR of 3.76 (95% CI 2.45 to 5.77; number
eeded to harm6) for bradycardia, although the definition
f bradycardia varied from study to study. In the more
ecent meta-analysis, the risk ratio for postoperative brady-
ardia was 2.22 (95% CI 1.50 to 3.29), and the risk ratio for
radycardia that required treatment was 2.34 (95% CI 1.62
o 3.37) (405). Postoperative hypotension was also signifi-
ant, with a risk ratio of 1.29 (95% CI 1.10 to 1.51). Beattie
t al. (397) analyzed 10 randomized trials with 2176 patients
nd found that perioperative beta blockade was associated
ith an increased incidence of bradycardia (OR 3.49, 95%
I 2.4 to 5.9) and CHF (OR 1.68, 95% CI 1.00 to 2.8).
mportantly, administration of beta blockers did not reliably
ecrease HRs in all patients. In the POISE trial (371), the
R in the metoprolol group for clinically significant hypo-
ension was 1.55 (95% CI 1.38 to 1.74), and the HR for
linically significant bradycardia was 2.74 (95% CI 2.19 to
.43); in addition, clinically significant hypotension was
ssociated with an adjusted OR of death and stroke of 4.97
95% CI 3.62 to 6.81), whereas clinically significant brady-
ardia was associated with an adjusted OR for death and
troke of 2.13 (95% CI 1.37 to 3.12). Given the association
etween hypotension or bradycardia and morbidity or mor-
ality from the POISE trial, the hemodynamic effects of
erioperative beta blockade must be incorporated and con-
idered in any beta-blocker protocol, with the goal of
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2009 ACCF/AHA Perioperative Guidelines November 24, 2009:e13–118voidance of bradycardia and hypotension. The association
f death due to sepsis and beta-blocker use in POISE also
uggests that a thorough search for alternate causes of
achycardia, such as infection, is important. Indeed, patients
ith persistent tachycardia may have alternative causes, such
s sepsis, hypovolemia, pulmonary embolism, and anemia
hat would warrant short-term down titration or even
iscontinuation of beta-blocker therapy. Available evidence
herefore supports an ongoing examination and reexamina-
ion of the indication and contraindications to beta-blocker
herapy throughout the postoperative period.
.2.1.5. SUMMARY (NEW)
his focused update incorporates important new informa-
ion regarding the risks and benefits of perioperative beta
lockade, as well as expert consensus. In this update, a Class
indication for perioperative beta-blocker use exists, for
ontinuation of a beta blocker in patients already taking the
rug. In addition, several Class IIa recommendations exist
or patients with inducible ischemia, coronary artery disease,
r multiple clinical risk factors who are undergoing vascular
i.e., high-risk) surgery and for patients with coronary artery
isease or multiple clinical risk factors who are undergoing
ntermediate-risk surgery. Initiation of therapy, particularly
n lower-risk groups, requires careful consideration of the
isk:benefit ratio for an individual patient. Initiation well
efore a planned procedure with careful titration periopera-
ively to achieve adequate heart rate control while avoiding
rank bradycardia or hypotension is also suggested. In light
f the POISE results, routine administration of periopera-
ive beta blockers, particularly in higher fixed-dose regimens
egun on the day of surgery, cannot be advocated. Ongoing
nd future studies in this area should continue to address
imitations in our evidence base on this subject and provide
urther guidance regarding this important topic.
.2.2. Perioperative Statin Therapy
ecommendations for Statin Therapy
LASS I
. For patients currently taking statins and scheduled for noncardiac
surgery, statins should be continued. (Level of Evidence: B)
LASS IIa
. For patients undergoing vascular surgery with or without clinical risk
factors, statin use is reasonable. (Level of Evidence: B)
LASS IIb
. For patients with at least 1 clinical risk factor who are undergoing
intermediate-risk procedures, statins may be considered. (Level of
Evidence: C)
ipid lowering has proven to be highly effective in the
econdary prevention of cardiac events. Numerous studies
ave demonstrated that many patient groups (high-risk
atients with a history of MI, high-risk patients without a
istory of MI, and patients who are simply at high risk) have
lower incidence of MI, stroke, and death when treated
ith lipid-lowering agents. Specifically, the bulk of thisvidence applies to hydroxymethylglutaryl coenzyme A tHMG-CoA) reductase inhibitors, or statin therapy
406,407).
The effectiveness of this class of medications in prevent-
ng cardiovascular events among high-risk patients has
uggested to many that these agents might similarly improve
erioperative cardiac risk. Certainly, the growing evidence
hat statin therapy improves endothelial function, reduces
ascular inflammation, and stabilizes atherosclerotic plaque
ll supports the concept that these agents may reduce the
ncidence of cardiovascular events brought on by the stress
f surgery in the setting of known atherosclerotic disease.
The evidence relating to statin use in the perioperative
eriod to date is primarily in the form of observational
tudies (Table 12) (251,408–415). Hindler et al. conducted
meta-analysis to evaluate the overall effect of preoperative
tatin therapy on postoperative outcomes (416). Preopera-
ive statin therapy was associated with 59% reduction in
he risk of mortality after vascular (1.7% versus 6.1%;
0.0001) surgery. When including noncardiac surgery, a
4% reduction in mortality (2.2% versus 3.2%; p0.0001)
as observed.
One randomized controlled trial has been performed to
valuate the effectiveness of statin therapy for perioperative
ardiovascular risk protection. Durazzo et al. randomized
00 patients who were to undergo vascular surgery to
torvastatin 20 mg per day or placebo (418). Subjects in the
tudy received atorvastatin for an average of 30 days before
ndergoing vascular surgery. The end point studied was a
omposite of death due to a cardiac cause, MI, unstable
ngina, and stroke. Cardiac events occurred in 13 patients
26%) in the placebo group at 6-month follow-up compared
ith only 4 (8%) in the atorvastatin group (p0.31).
lthough this study was small, with few end points, and
ncluded a composite end point, the investigators did have
omplete follow-up, and the difference in event rates be-
ween the 2 groups was statistically significant.
Poldermans et al. evaluated the association between
erioperative death and statin use in a case-control study
409). They identified all patients who died during hospi-
alization for vascular surgery from among 2816 patients
ho underwent vascular surgery at Erasmus University
etween 1991 and 2000 (409). For each of the 160 cases of
n-hospital death, they matched 2 control subjects based on
imilar year and type of surgery. Statin use was significantly
ess in those who died during hospitalization for vascular
urgery, with an adjusted OR of 0.22 (95% CI 0.10 to 0.47).
nly 65% of the cases in this study died of vascular causes,
lthough the authors point out that there was no association
etween statin use and death among those patients who
ied of bleeding complications. The authors did adjust for
edication use, including beta blockers and statins. Al-
hough retrospective and observational, these data certainly
rgue for an association between a lack of statin use and
ncreased mortality after major vascular surgery.
In another similar study, O’Neil-Callahan et al. evaluated
he association between statin use and cardiac complications
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ion on all patients undergoing major vascular surgery
carotid endarterectomy, aortic surgery, or lower-extremity
evascularization) between January 1999 and December
000 at a single tertiary referral center. The composite end
oint for this study included death, MI, ischemia, conges-
ive HF, and ventricular tachyarrhythmias. The primary end
oint occurred in 157 of 1163 patients, significantly more
requently in patients not receiving statin therapy (16.5%)
han in those receiving statins (9.9%, p0.001). After
djustment for other predictors of perioperative cardiac
vents, statin use remained associated with a decreased risk
OR 0.52, 95% CI 0.35 to 0.76, p0.001). These authors
ound that statin use was associated with beta-blocker use,
ut a propensity score analysis suggested that the effect of
tatins was independent of that association.
A large administrative database combining patient infor-
ation from 4 western Canadian provinces was used to
xamine the relationship between statin use and outcomes
n patients undergoing carotid endarterectomy (412). In this
tudy, the authors identified all patients undergoing open
urgical treatment for symptomatic carotid disease, examin-
ng the association between statin use and perioperative
eath, perioperative stroke or death, or perioperative car-
iovascular outcomes. They found a significant inverse
orrelation between statin use and perioperative death (OR
.25, 95% CI 0.07 to 0.90) and between statin use and
erioperative stroke or death (OR 0.55, 95% CI 0.32 to
.95) but not cardiovascular outcomes (OR 0.87, 95% CI
.49 to 1.54). Interestingly, this group showed no benefit for
ny of these outcomes in asymptomatic patients undergoing
arotid endarterectomy, which suggests that benefit, as
able 12. Published Studies of Perioperative Statin Use and Ou
Study Design n (Statin/Tota
indenauer et al.,
2004 (408)
Retrospective/administrative 77 082/780,59
oldermans et al.,
2003 (409)
Case-control 160 Cases, 320
controls
’Neil-Callahan et al.,
2005 (410)
Retrospective 526/1163
ertai et al.,
2004 (411)
Retrospective 162/570
andesberg et al.,
2003 (417)
Retrospective 502
ennedy et al.,
2005 (412)
Retrospective/administrative 815/2031
Symptomatic
665/1252
Asymptomati
ard et al.,
2005 (413)
Retrospective 72/446
cGirt et al.,
2005 (414)
Retrospective 657/1566
AA indicates abdominal aortic aneurysm; CI, confidence interval; MI, myocardial infarction; n, nxpected, is proportional to risk. Similarly, McGirt et al. r414) reviewed the results of carotid endarterectomy in 1566
atients at a major academic medical center, documenting a
educed rate of perioperative stroke (OR 0.35, 95% CI 0.15
o 0.85) and death (OR 0.20, 95% CI 0.04 to 0.99).
Le Manach prospectively collected data in patients
ndergoing infrarenal aortic surgery and compared a
ohort when there were no guidelines for perioperative
ontinuation of statins (discontinuation group, n491)
ompared with when guidelines were instituted whereby
tatin therapy was continued starting as soon as possible
fter surgery (continuation group, n178) (419). Post-
perative statin withdrawal (more than 4 days) was an
ndependent predictor of postoperative myonecrosis (OR
.9, 95% CI 1.6 to 5.5).
Finally, in the largest such observational study, Linde-
auer et al. reviewed the hospital and pharmacy records of
80 591 patients over 18 years of age who were undergoing
oncardiac surgery (408). These data came from adminis-
rative databases in 329 hospitals participating in a quality
nd benchmarking program. The authors defined statin use
s recorded use of statin therapy during the first 2 days of
ospitalization. Use after the first 2 days was coded as
onuse of statins. These authors used propensity matching
o adjust for baseline demographic and risk factor differ-
nces. Hospital mortality was the primary end point and was
nalyzed in association with statin use, stratified by each
atient’s calculated Revised Cardiac Risk Index score based
n Lee et al. (4). Patients who received statins had a lower
rude mortality rate (2.13% versus 3.05%, p0.001) and a
ower mortality rate with matching by propensity score
2.18% versus 3.15%, p0.001). Mortality remained lower
fter adjustment for differences with conditional logistic
es in Noncardiac Surgery
Surgery
Adjusted OR (95% CI)
Perioperative
Complications
Perioperative
Mortality
Major noncardiac 0.62 (0.58 to 0.67)
Major vascular 0.22 (0.10 to 0.47)
Major vascular 0.52 (0.35 to 0.77)
AAA surgery 0.24 (0.10 to 0.70)
(Death or MI)
Major vascular 0.54 (0.26 to 1.11)
Carotid endarterectomy 0.55 (0.32 to 0.95)
(Stroke or death)
0.25 (0.07 to 0.90)
Carotid endarterectomy 0.54 (0.13 to 2.24)
(Stroke or death)
1.34 (0.61 to 2.93)
Infrainguinal vascular
surgery
0.36 (0.14 to 0.93)
Carotid endarterectomy 0.35 (0.15 to 0.85)
(Stroke)
0.20 (0.04 to 0.99)
of patients; and OR, odds ratio.tcom
l)
1
cegression (adjusted OR 0.62, 95% CI 0.58 to 0.67). The
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tatin therapy to prevent in-hospital death was 85 (95% CI
7 to 98), varying from 186 in the lowest-risk group to 30
n the highest-risk group.
Several other reports also lend support to the association
etween perioperative statin use and perioperative out-
omes. Some of these studies are analyses of reports that
ncluded statin use among the independent variables asso-
iated with outcomes after noncardiac surgery (415) or are
eanalyses of data already discussed (420,421) Additionally,
chouten et al. (421) studied 981 patients undergoing major
ascular surgery and did not find an association between
erioperative statin use and an increased risk of myopathy or
ny cases of rhabdomyolysis.
In summary, the evidence so far accumulated suggests a
rotective effect of perioperative statin use on cardiac
omplications during noncardiac surgery. Most of these data
re observational and identify patients in whom time of
nitiation of statin therapy and duration of statin therapy are
nclear. Furthermore, statin dose, target or achieved low-
ensity lipoprotein levels, and indications for statin therapy
re also largely unclear. Sufficiently powered randomized
rials are needed to determine whether these observed
ssociations translate into a benefit for statin therapy pre-
cribed perioperatively for the purpose of lowering cardiac
vent rates surrounding noncardiac surgery. Utilizing the
erioperative period as an opportunity to impact long-term
ealth, consideration should be given to starting statin
herapy in patients who meet National Cholesterol Educa-
ion Program criteria (407,422).
.2.3. Alpha-2 Agonists
LASS IIb
. Alpha-2 agonists for perioperative control of hypertension may be
considered for patients with known CAD or at least 1 clinical risk
factor who are undergoing surgery. (Level of Evidence: B)
LASS III
. Alpha-2 agonists should not be given to patients undergoing surgery
who have contraindications to this medication. (Level of Evidence: C)
everal studies examined the role of alpha-agonists
clonidine and mivazerol) for perioperative cardiac protec-
ion. Oliver et al. (423) reported a large, randomized,
lacebo-controlled, multicenter trial of the alpha-2 agonist
ivazerol in perioperative use. They randomized 2854
atients with known CAD or significant risk factors who
ere undergoing noncardiac surgery to a 1.5 mcg per kg per
our infusion of mivazerol or placebo. Among patients with
n established history of CAD who were undergoing
eneral surgical procedures, the rate of MI was no different
etween the mivazerol and placebo groups, but the cardiac
eath rate was reduced (13 of 946 versus 25 of 941;
0.04). Among patients undergoing vascular procedures,
oth cardiac death rate (6 of 454 versus 18 of 450; p0.017)
nd the combined end point of death or MI (44 of 454
ersus 64 of 450; p0.037) were significantly reduced. Theulticenter Study of Perioperative Ischemia Research troup (424) also reported the results of a placebo-
ontrolled, randomized, double-blind study of perioperative
ivazerol. Three hundred patients with known CAD un-
ergoing noncardiac surgery were randomized to high-dose
1.5 mcg per kg per hour) or low-dose (0.75 mcg per kg per
our) mivazerol or placebo. No differences in perioperative
eath or MI were observed, but the high-dose group had
ignificantly less myocardial ischemia than the placebo
roup (20 of 98 versus 35 of 103; p0.026). Two random-
zed, placebo-controlled studies of clonidine for periopera-
ive myocardial protection were performed in 297 patients
ndergoing vascular surgery (425) and 61 patients under-
oing general surgery (426). Both demonstrated a signifi-
ant decrease in the incidence of myocardial ischemia (35 of
45 versus 59 of 152; p0.01, and 1 of 28 versus 5 of 24,
0.05, respectively).
Wijeysundera et al. (427) performed a meta-analysis of
erioperative alpha-2 agonist administration through 2002
omprising 23 trials enrolling 3395 patients. Alpha-2 ago-
ists reduced mortality (RR 0.76, 95% CI 0.63 to 0.91) and
I (RR 0.66, 95% CI 0.46 to 0.94) during vascular surgery.
More recently, Wallace et al. (428) conducted a prospec-
ive, double-blinded, clinical trial on patients with or at risk
or CAD to investigate whether prophylactic clonidine
educed perioperative myocardial ischemia and long-term
eath in patients undergoing noncardiac surgery. Patients
ere randomized to clonidine (n125) or placebo (n65).
lonidine (0.2 mg orally and by patch) or placebo (tablet
nd patch) were administered the night before surgery, and
lonidine (0.2 mg orally) or placebo (tablet) was adminis-
ered on the morning of surgery. Patches were left on for 4
ays. Prophylactic clonidine administered perioperatively
ignificantly reduced myocardial ischemia during the intra-
perative and postoperative period (clonidine 18 of 125 or
4% versus placebo 20 of 65 or 31%; p0.01). Moreover,
dministration of clonidine had minimal hemodynamic
ffects and reduced postoperative mortality for up to 2 years
clonidine 19 of 125 or 15% versus placebo 19 of 65 or 29%;
R 0.43, 95% CI 0.21 to 0.89; p0.035).
.2.4. Perioperative Calcium Channel Blockers
meta-analysis of perioperative calcium channel blockers
n noncardiac surgery that was published in 2003 identified
1 studies involving 1007 patients (429). Calcium channel
lockers significantly reduced ischemia (RR 0.49, 95% CI
.30 to 0.80; p0.004) and supraventricular tachycardia
RR 0.52, 95% CI 0.37 to 0.72; p0.0001). Calcium
hannel blockers were associated with trends toward re-
uced death and MI. In post hoc analyses, calcium channel
lockers significantly reduced death/MI (RR 0.35, 95% CI
.15 to 0.86; p0.02). The majority of these benefits were
ttributable to diltiazem. Dihydropyridines and verapamil
id not decrease the incidence of myocardial ischemia,
lthough verapamil decreased the incidence of supraventric-
lar tachycardia. The authors concluded that a large-scale
rial was needed to define the value of these agents.
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oncardiac Surgery
here is little information about the appropriateness of
alvular repair or replacement before a noncardiac surgical
rocedure is undertaken. Clinical experience indicates that
atients with valvular heart disease severe enough to warrant
urgical treatment should have valve surgery before elective
oncardiac surgery. It has been suggested that patients with
evere mitral or aortic stenosis who require urgent noncar-
iac surgery, such as intestinal resection for lesions causing
erious gastrointestinal bleeding, may benefit from catheter
alloon valvuloplasty at least as a temporizing step to reduce
he operative risk of noncardiac surgery (430–433). Unfor-
unately, there are no controlled studies, and the risks of
alloon aortic valvuloplasty in older patients are significant
430), although mitral valvuloplasty performed by experi-
nced operators has been shown to be safe and effective.
xperience with managing valvular heart disease during
abor and delivery provides insights into the approach to
anagement of the patient for noncardiac surgery. The vast
ajority of women with regurgitant valvular heart disease
an be managed medically during the course of pregnancy,
ncluding labor and delivery, because the decrease in periph-
ral vascular resistance that occurs with pregnancy tends to
ecrease regurgitant lesions (434). Increased arterial after-
oad is not well tolerated in patients with aortic and mitral
egurgitation. Therefore, increases in blood pressure should
e prevented, and LV afterload should be optimized with
asodilators. In contrast, patients with significant aortic or
itral stenosis often do not do well with the increased
emodynamic burden of pregnancy. If the stenosis is severe,
ercutaneous catheter balloon valvotomy should be consid-
red as definitive therapy or as a bridge to care for the
atient through pregnancy, labor, and surgical delivery.
xcessive changes in intravascular volume should be avoided
see also Section 3.5., Valvular Heart Disease).
.4. Perioperative Arrhythmias and Conduction
isturbances
n the perioperative setting, cardiac arrhythmias or conduc-
ion disturbances often reflect the presence of underlying
ardiopulmonary disease, drug toxicity, or metabolic de-
angements. In patients with documented hemodynamically
ignificant or symptomatic arrhythmias, electrophysiologic
esting and catheter ablation, particularly for supraventric-
lar arrhythmias, may be indicated to prevent arrhythmia
ecurrence (435–437). In patients with documented hemo-
ynamically significant or symptomatic arrhythmias, acute
reatment is indicated. Sustained supraventricular arrhyth-
ias may require electrical or pharmacological cardiover-
ion. Alternatively, in atrial fibrillation or atrial flutter, a
ate-control strategy can be accomplished with beta-
drenergic blockers, calcium channel blockers, or digoxin
oral or intravenous). Of these 3 types of medications,
igitalis is the least effective agent and beta blockers are the aost effective agent for controlling the ventricular response
uring atrial fibrillation (438). An additional benefit of beta
lockers is that they have been shown to accelerate the
onversion of postoperative supraventricular arrhythmias to
inus rhythm compared with diltiazem (439). In select cases,
lectrophysiologic testing and catheter ablation, particularly
or supraventricular arrhythmias, may be indicated.
Patients with chronic atrial fibrillation or a history of
aroxysmal atrial fibrillation before surgery often take
hronic oral anticoagulants. It may be necessary to
iscontinue this anticoagulation from a few to several
ays before surgery. Bridging anticoagulation with either
ow-molecular-weight or unfractionated heparin may be
ndicated if the thromboembolic risk assessment war-
ants. If time does not allow and it is important that the
atient not be taking anticoagulants, the effect of warfa-
in can be reversed by parenteral vitamin K or fresh
rozen plasma (440).
Ventricular arrhythmias, whether simple premature ven-
ricular contractions, complex ventricular ectopy, or nonsus-
ained tachycardia, usually do not require therapy unless
hey are associated with hemodynamic compromise or occur
n the presence of ongoing or threatened myocardial isch-
mia or LV dysfunction. Studies have shown that although
early half of all high-risk patients undergoing noncardiac
urgery have frequent premature ventricular contractions or
symptomatic nonsustained ventricular tachycardia, the
resence of these ventricular arrhythmias is not associated
ith an increase in nonfatal MI or cardiac death (36,37).
evertheless, the presence of an arrhythmia in the preop-
rative setting should provoke a search for underlying
ardiopulmonary disease, ongoing myocardial ischemia or
nfarction, drug toxicity, or metabolic derangements. Phy-
icians should also have a low threshold at which they
nstitute prophylactic beta-blocker therapy in patients at
ncreased risk of developing a perioperative or postoperative
rrhythmia (including those in whom arrhythmias are
resent during the preoperative evaluation).
Several studies have demonstrated that beta-blocker ther-
py can reduce the incidence of arrhythmias during the
erioperative period (86,115). Sustained or symptomatic
entricular tachycardia should be suppressed preoperatively
ith intravenous lidocaine, procainamide, or amiodarone,
nd a thorough search should be conducted for underlying
auses and appropriate short- and long-term therapy.
The indications for temporary pacemakers are almost
dentical to those previously stated for long-term permanent
ardiac pacing (441). Patients with intraventricular conduc-
ion delays, bifascicular block (right bundle-branch block
ith left anterior or posterior hemiblock), or left bundle-
ranch block with or without first-degree atrioventricular
lock do not require temporary pacemaker implantation in
he absence of a history of syncope or more advanced
trioventricular block (116).
7
W
I
i
m
p
g
i
a
p
c
a
(
A
h
t
t
f
a
p
s
t
d
v
c
p
a
c
r
1
n
m
t
a
r
e
m
c
A
t
a
r
a
o
i
d
w
p
t
f
p
w
m
t
p
e
i
w
b
t
p
a
t
a
b
t
i
w
d
n
r
p
i
s
p
w
a
c
w
T
d
d
d
i
g
o
d
v
r
s
t
fi
h
c
w
m
g
w
d
m
m
T
i
e
i
d
o
e72 Fleisher et al. JACC Vol. 54, No. 22, 2009
2009 ACCF/AHA Perioperative Guidelines November 24, 2009:e13–118.5. Intraoperative Electromagnetic Interference
ith Implanted Pacemakers and ICDs
t is important to be aware of the potential for adverse
nteractions between electrical/magnetic activity and pace-
aker or ICD function that may occur during the operative
eriod. These interactions result from electrical current
enerated by electrocautery or cardioversion, as well as the
mpact of metabolic derangements, antiarrhythmic agents,
nd anesthetic agents on pacing and sensing thresholds. The
robability of these adverse interactions can be minimized if
ertain precautions are taken. Although this topic has been
nalyzed in a number of review articles and book chapters
442–445), no formal guidelines have been developed by the
CC, the AHA, or the Heart Rhythm Society. Of note,
owever, is a practice advisory that has been published by
he American Society of Anesthesiology (446).
Electrocautery involves the use of radiofrequency current
o cut or coagulate tissues. It is usually applied in a unipolar
ashion between the cautery device and an indifferent plate
ttached to the patient’s skin. The indifferent plate is often
laced on the patient’s thigh. Although bipolar cautery
ystems are available, they are not widely used. The poten-
ial for electromagnetic interference with an implanted
evice is related to the amount of current generated in the
icinity of the pacemaker or ICD device. In general, high
urrent is generated if the cautery device is close to the
acemaker, particularly if the current path of the cautery lies
long the axis of the pacemaker or ICD lead. The electrical
urrent generated by electrocautery can cause a variety of
esponses by the implanted device, including the following:
) temporary or permanent resetting to a backup, reset, or
oise-reversion pacing mode (e.g., a dual-chamber pace-
aker may be reset to VVI pacing at a fixed rate); 2)
emporary or permanent inhibition of pacemaker output; 3)
n increase in pacing rate due to activation of the rate-
esponsive sensor; 4) ICD firing due to activation by
lectrical noise; or 5) myocardial injury at the lead tip that
ay cause failure to sense and/or capture. Cardioversion
an have similar effects on pacemaker or ICD function.
lthough the probability of any of these adverse interac-
ions occurring has fallen dramatically owing to the
lmost universal use of bipolar leads (which greatly
educes the probability of electromagnetic interference)
nd improved pacemaker and ICD design, they still may
ccur (442– 445,447).
The likelihood and potential clinical impact of adverse
nteractions occurring in patients with ICDs and pacemaker
evices will be influenced by a number of factors, including
hether the patient is pacemaker dependent, whether the
acemaker has unipolar or bipolar leads, whether the elec-
rocautery is bipolar or unipolar, and the relative distance
rom and orientation of the electrocautery relative to the
acemaker and pacemaker lead. These factors, combined
ith the urgency and type of surgery (interactions are far
ore likely to occur with surgical procedures that involve flhe chest or abdomen) and the availability of expertise in
acing and/or ICDs, will ultimately determine the type and
xtent of evaluation that is performed in a particular
nstitution. Patients with pacemakers must be assessed as to
hether they are pacer dependent. This may be determined
y a chart review and examination of the ECG, as opposed
o requiring the interrogation of the device. When the
atient is not pacer dependent and/or the cautery is remote
nd will be administered in brief bursts, and the operative
eam can monitor the ECG and pulse oximeter (which
llows pulse determination even when electrical interference
y cautery interferes with the ECG), it may be unnecessary
o interrogate the pacer at all.
Several general recommendations can be made concern-
ng the preoperative and operative management of patients
ith implanted devices who are undergoing surgical proce-
ures (448). Patients with implanted ICDs or pacemakers
eed to be identified before surgery so that appropriate
ecords from the device clinic that is monitoring the
atient’s device can be obtained. In addition, the original
ndication for device placement should be identified before
urgery. Patients with permanent pacemakers, who are
acemaker dependent, should have their device evaluated
ithin 3 to 6 months before significant surgical procedures,
nd also after surgery. Significant surgical procedures in-
lude major abdominal or thoracic surgery, particularly
hen the surgery involves large amounts of electrocautery.
his evaluation should include 1) determining the type of
evice, 2) determining whether the patient is pacemaker
ependent for antibradycardia pacing, and 3) determining
evice programmed settings and battery status. If a patient
s pacemaker dependent, the device should be repro-
rammed to an asynchronous mode during surgery (VOO
r DOO), or a magnet should be placed over the device
uring surgery. Implantable cardioverter defibrillator de-
ices should have their tachyarrhythmia treatment algo-
ithms programmed off before surgery and turned on after
urgery to prevent unwanted shocks due to spurious signals
hat the device might interpret as ventricular tachycardia or
brillation. During the period of time when device therapy
as been inactivated, the patient should be monitored
ontinuously for a life-threatening arrhythmia. All patients
ith implanted devices should have both continuous ECG
onitoring and continuous pulse monitoring during sur-
ery. This reflects the fact that electrocautery may interfere
ith ECG monitoring and make it difficult or impossible to
etermine the patient’s rhythm. Efforts should be made to
inimize the chance for interactions by careful manage-
ent of potential sources of electromagnetic interference.
hese include 1) the use of a bipolar electrocautery system
f possible, 2) the use of short and intermittent bursts of
lectrocautery at the lowest possible energy levels, 3) max-
mization of the distance between the electrocautery and the
evice, and 4) if a unipolar cautery is to be used, placement
f the ground patch in a position so as to minimize current
ow through the pacemaker or ICD device. Finally, if
e
p
o
t
f
d
e
b
s
p
a
s
v
f
r
a
a
t
m
w
a
c
b
p
o
m
t
t
t
i
i
m
t
o
a
I
(
n
t
s
7
C
1
P
c
i
d
i
h
o
c
r
n
i
m
(
9
p
o
e
c
1
1
d
r
7
A
T
p
e
p
s
s
b
a
v
t
e
t
a
s
b
c
c
a
t
v
T
t
p
t
v
(
w
e
m
d
t
m
e73JACC Vol. 54, No. 22, 2009 Fleisher et al.
November 24, 2009:e13–118 2009 ACCF/AHA Perioperative Guidelinesmergency cardioversion is required, the paddles should be
laced as far from the implanted device as possible and in an
rientation likely to be perpendicular to the orientation of
he device leads (anterior-posterior paddle position is pre-
erred). After the surgery, the function of the implanted
evice should be assessed and in some cases formally
valuated. If the pacemaker or ICD was reprogrammed
efore surgery, it should be programmed back to its original
ettings after surgery. In the case of an ICD, an interrogated
rogrammer printout should be produced to verify that its
ntitachycardia function has been restored to its active
tatus.
Placement of a magnet over an implanted device has
ariable effects depending on the type of device, its manu-
acturer, and its model. Most bradycardia pacemakers will
espond to magnet application with asynchronous pacing at
pre-prescribed rate. However, this magnet function can, in
minority of pacemaker models, be programmed off, and
herefore, a magnet may not elicit a response from those
odels. If a magnet will be used during surgery in a patient
ith a pacemaker who is pacemaker dependent, it should be
pplied before surgery to be certain that appropriate asyn-
hronous pacing is triggered by the magnet. Unlike with
radycardia pacemakers, a magnet will not change the
acing function of an ICD. Magnet application will affect
nly the antitachycardia function of an ICD. With some
odels of ICDs, the magnet will first suspend the anti-
achycardia (shocking) function and then actually turn the
herapy off. With other ICD models, the magnet will only
emporarily disable the shock function (while the magnet is
n place), and the therapy will then become active again on
ts removal (either intentional or unintentional). Program-
ing the shock function off with an ICD programmer (and
urning it back on after the surgery) is the preferred method
f addressing these issues. Because some patients with ICDs
re also pacemaker dependent, the pacing function of the
CD may need to be programmed to an asynchronous mode
e.g., VOO or DOO) during surgery to prevent electromag-
etic interference–induced inhibition. Communication of
he status of the pacemaker or ICD to the anesthesiologist,
urgeon, and intensivist is imperative.
.6. Preoperative Intensive Care
LASS IIb
. Preoperative intensive care monitoring with a pulmonary artery
catheter for optimization of hemodynamic status might be consid-
ered; however, it is rarely required and should be restricted to a very
small number of highly selected patients whose presentation is
unstable and complex and who have multiple comorbid conditions.
(Level of Evidence: B)
reoperative invasive monitoring in an intensive care setting
an be used to optimize and even augment oxygen delivery
n patients at high risk. It has been proposed that indices
erived from the pulmonary artery catheter (PAC) andnvasive blood pressure monitoring can be used to maximize temodynamic function which may lead to a reduction in
rgan dysfunction or morbidity.
There are limited numbers of studies evaluating intensive
are monitoring before noncardiac surgery. Two prospective
andomized trials evaluating the use of PACs and hemody-
amic optimization arrived at different conclusions regard-
ng its impact on morbidity and mortality (449,450). A
eta-analysis of hemodynamic optimization by Poeze et al.
451) found an overall decreased mortality rate (RR 0.75,
5% CI 0.54 to 0.81) in all studies. Kavarana et al. (452)
erformed a retrospective analysis investigating preoperative
ptimization of cardiovascular function using a PAC in
lderly patients (greater than 65 years) undergoing elective
olon resection and found reduced mortality (5% versus
5.8%) only in patients with a cardiac risk index greater than
0. Kern and Shoemaker’s (453) meta-analysis of 21 ran-
omized controlled trials with various approaches found
educed mortality with hemodynamic optimization.
.7. Venothromboembolism/Peripheral
rterial Disease
wo peripheral vascular disorders that merit attention
reoperatively are venous thromboembolism and, in the
lderly, chronic occlusive peripheral arterial disease. Pro-
hylactic measures need to be planned and in some cases
tarted preoperatively for persons with clinical circum-
tances associated with postoperative venous thromboem-
olism. These correlates of thromboembolic risk include
dvanced age; prolonged immobility or paralysis; prior
enous thromboembolism; malignancy; major surgery, par-
icularly operations involving the abdomen, pelvis, or lower
xtremities; obesity; varicose veins; HF; MI; stroke; frac-
ures of the pelvis, hip, or leg; congenital or acquired
berrations in hemostatic mechanisms (hypercoagulable
tates); and, possibly, high-dose estrogen use as suggested
y the American College of Chest Physicians (112). The
hoice of prophylactic measure or agent— graded-
ompression elastic stockings, low-dose subcutaneous hep-
rin, low-molecular-weight heparin, warfarin, or intermit-
ent pneumatic compression—will depend on the risk of
enous thromboembolism and the type of surgery planned.
able 13 provides published recommendations for various
ypes of surgical procedures (454).
The noninvasive techniques—impedance plethysmogra-
hy and real-time compression ultrasonography—are effec-
ive objective tests to exclude clinically suspected deep
enous thrombosis and are best used for this purpose
455,456). Routine screening of all postoperative patients
ith a noninvasive technique is not as cost-effective or
fficient as appropriate antithrombotic prophylaxis for
oderate- and high-risk patients (457,458).
The prevalence of chronic occlusive peripheral arterial
isease rises with increasing age, affecting more than 10% of
he general population older than 65 years (459) and as
any as half of all persons with CAD (460). Patients withhis condition may be at increased risk of perioperative
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isease (461). This may warrant particular attention to the
reoperative evaluation and intraoperative therapy of such
atients. Protection of the limbs from trauma during and
fter surgery is as important for those with asymptomatic
rterial disease as for those with claudication.
. Anesthetic Considerations and
ntraoperative Management
he pathophysiological events that occur with the trauma of
urgery and the perioperative administration of anesthetic
nd pain-relieving drugs often affect the physiology of
ardiac function and dysfunction to great degrees. Specific
ntegration of these changes with the consultative evaluation
s a field unto itself and beyond the scope of these guide-
ines. The information provided by the cardiovascular con-
ultant needs to be integrated by the anesthesiologist,
urgeon, and postoperative caregivers in preparing an indi-
idualized perioperative management plan. The diagnosis of
n MI has been redefined by the Joint European Society of
ardiology/ACC Committee for the Redefinition of MI,
ut the definition of a perioperative MI in noncardiac
urgery was not specifically addressed (462).
There are many different approaches to the details of the
nesthetic care of the cardiac patient, including the use of
pecific anesthetic agents (Table 14) or anesthetic tech-
iques (e.g., general, regional, or monitored anesthesia
are). Each has implications regarding anesthetic and intra-
perative monitoring. In addition, no study has clearly
able 13. Levels of Thromboembolism Risk in Surgical Patients
Level of Risk
Deep Vein
Thrombosis, %
Calf Proximal
ow
Minor surgery in patients less than 40 years
old with no additional risk factors
2 0.4
oderate
Minor surgery in patients with additional
risk factors
Surgery in patients aged 40 to 60 years
with no additional risk factors
10 to 20 2 to 4
igh
Surgery in patients more than 60 years old
or aged 40 to 60 years with additional
risk factors (prior VTE, cancer, molecular
hypercoagulability)
20 to 40 4 to 8
ighest
Surgery in patients with multiple risk
factors (age greater than 40 years,
cancer, prior VTE)
Hip or knee arthroplasty, HFS
Major trauma; SCI
40 to 80 10 to 20
dapted with permission from Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thr
004;126:338S–400S (112).
GCS indicates graduated compression stocking; HFS, hip fracture surgery; INR, internationa
MWH, low-molecular-weight heparin; SCI, spinal cord injury; U, unit; VKA, vitamin K antagonist;emonstrated a change in outcome from the routine use of ihe following techniques: a PAC, ST-segment monitor,
ransesophageal echocardiography (TEE), or intravenous
itroglycerin. Therefore, the choice of anesthetic technique
nd intraoperative monitors is best left to the discretion of
he anesthesia care team. Intraoperative management may
e influenced by the perioperative plan, including the need
or postoperative monitoring, ventilation, analgesia, and the
erioperative use of anticoagulants or antiplatelet agents.
herefore, a discussion of these issues before the planned
urgery will allow for a smooth transition through the
erioperative period.
.1. Choice of Anesthetic Technique and Agent
ecommendations for Use of Volatile Anesthetic Agents
LASS IIa
. It can be beneficial to use volatile anesthetic agents during noncar-
diac surgery for the maintenance of general anesthesia in hemody-
namically stable patients at risk for myocardial ischemia. (Level of
Evidence: B)
ultiple studies have examined the influence of anesthetic
rugs and techniques on cardiac morbidity. In a large-scale
tudy of unselected patients, coexisting disease and surgical
rocedure were important determinants of outcome (478).
ll anesthetic techniques and drugs are associated with
nown effects that should be considered in the perioperative
lan. Opioid-based anesthetics were previously popularized
ecause of the cardiovascular stability associated with their
se. The use of high doses of opioids, however, is associated
ith the need for prolonged postoperative mechanical
entilation, and their use may increase length of stay in the
hout Prophylaxis
Pulmonary Embolism, %
Successful Prevention Strategiesnical Events Fatal Events
0.2 Less than 0.01 No specific prophylaxis; early and
“aggressive” mobilization
1 to 2 0.1 to 0.4 LDUH (every 12 h), LMWH (less than or
equal to 3400 U daily), GCS, or IPC
2 to 4 0.4 to 1.0 LDUH (every 8 h), LMWH (more than
3400 U daily), or IPC
4 to 10 0.2 to 5.0 LMWH (more than 3400 U daily),
fondaparinux, oral VKAs (INR 2 to 3),
or IPC/GCS plus LDUH/LMWH
mbolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest
lized ratio; IPC, intermittent pneumatic compression; LDUH, low-dose unfractionated heparin;
E, venous thromboembolism.Wit
Cli
omboentensive care unit (ICU).
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November 24, 2009:e13–118 2009 ACCF/AHA Perioperative GuidelinesAll inhaled volatile anesthetic agents have cardiovascular
ffects, including depression of myocardial contractility and
fterload reduction. The similarities between the agents are
reater than their differences. Early studies demonstrated
hat volatile anesthetic agents did not influence outcome
ompared with high-dose opioid techniques (463–465).
owever, as summarized in Table 14, randomized clinical
rials in patients undergoing CABG surgery indicate that
olatile anesthetics decrease troponin release and enhance
V function compared with propofol, midazolam, or bal-
nced anesthesia techniques with opioids. These data can
ikely be generalized to patients with CAD who are
ndergoing noncardiac surgery. Of the 15 trials per-
ormed (463– 474,476,477,479), the use compared with
he nonuse of volatile anesthetics was associated with a
ecrease in troponin release in 6 trials, preservation of
arly LV function in 5, decreased ICU length of stay in
, and decreased late cardiac events in 1. Although
ecreases in troponin levels reflect the cardioprotective
ctions of volatile anesthetics, none of the trials were
owered to evaluate MI or death as an outcome. Volatile
able 14. Randomized Clinical Trials of Volatile Anesthetics in
Study n Anesthetic
logoff & Keats,
1989 (463)
1012 Enflurane
Halothane
Isoflurane
eung et al.,
1991 (464)
186 Isoflurane
elman et al.,
1992 (465)
200 Desflurane
elhomme et al.,
1999 (466)
20 Isoflurane before aortic
cross-clamping
enta de Peppo et al.,
1999 (467)
22 Enflurane before CPB
omai et al.,
1999 (468)
40 Isoflurane before CPB
aroun-Bizri et al.,
2001 (469)
49 Isoflurane before CPB
e Hert et al.,
2002 (470)
20 Sevoflurane
e Hert et al.,
2003 (471)
45 Sevoflurane
Desflurane
ulier et al.,
2003 (472);
arcia et al.,
2005 (473)
72 Sevoflurane before
aortic cross-clamping
onzen et al.,
2003 (474)
20 Sevoflurane
e Hert et al.,
2004 (475)
320 Sevoflurane or
desflurane
orlani et al.,
2004 (476)
60 Isoflurane before CPB
ein et al.,
2005 (477)
52 Sevoflurane
NP indicates brain natriuretic peptide; CK-MB, MB isoenzyme of creatine kinase; CPB, cardiop
I, myocardial infarction; MIDCAB, minimally invasive direct coronary artery bypass; n, numbernesthetics have been shown in animal studies to precon- hition and postcondition the heart against infarction by
ctivating specific intracellular signal transduction path-
ays (480). Decreased troponin levels in cardiac surgery
atients receiving volatile anesthetics may reflect this
reconditioning or postconditioning effect. De Hert et al.
475) demonstrated that sevoflurane administered
hroughout surgery decreased troponin and ICU length
f stay compared with patients who received propofol,
hereas no differences in troponin levels were observed in
atients receiving sevoflurane when this volatile anes-
hetic was administered solely as either a preconditioning
r postconditioning agent. Similarly, low doses (0.25 to
.5 minimum alveolar concentration) of sevoflurane and
soflurane have been demonstrated to provide cardioprotec-
ion in animal models; however, the dose dependence or
lass effect of volatile anesthetics to produce cardioprotec-
ion in humans has not been specifically investigated.
Neuraxial anesthetic techniques include spinal and epi-
ural approaches. Both techniques can result in sympathetic
lockade, resulting in decreases in both preload and after-
oad. The decision to use neuraxial anesthesia for the
ents Undergoing Coronary Artery Surgery
Control
Surgical
Technique End Point
igh-dose
sufentanil
CPB No difference in ischemia, MI,
or death
igh-dose
sufentanil
CPB No difference in ischemia
igh-dose
sufentanil
CPB Increased ischemia during
induction of anesthesia
o volatile
anesthetic
CPB No difference in TnI activation
of PKC
o volatile
anesthetic
CPB Improved LV function
o volatile
anesthetic
CPB Decreased TnI in subset of
patients with EF less than
50%
o volatile
anesthetic
CPB Improved LV function
ropofol CPB Decreased TnI; improved LV
function
ropofol CPB; elderly; EF
less than 50%
Decreased TnI; improved LV
function
o volatile
anesthetic
CPB No difference in TnI at 72 h;
decreased BNP; decreased
late cardiac events in the
same study population
ropofol OPCAB Decreased TnI
ropofol or
midazolam
CPB Decreased TnI; decreased ICU
and hospital LOS
o volatile
anesthetic
CPB Decreased TnI and CK-MB
ropofol MIDCAB Improved LV function
ry bypass; EF, ejection fraction; ICU, intensive care unit; LOS, length of stay; LV, left ventricle;
nts; OPCAB, off-pump coronary bypass; PKC, protein kinase C; and TnI, troponin I.Pati
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ures can be performed under spinal or epidural anesthesia
ith minimal hemodynamic changes if neuraxial blockade is
imited to those dermatomes. Abdominal procedures can
lso be performed with neuraxial techniques; however, high
ermatomal levels of anesthesia may be required and may be
ssociated with significant hemodynamic effects. High der-
atomal levels can potentially result in hypotension if
reload becomes compromised or blockade of the cardioac-
elerators occurs. A meta-analysis reviewed the impact of
entral neuraxial analgesia on outcome after coronary artery
ypass surgery (481). The use of thoracic epidural analgesia
ecreased postoperative pulmonary complications but did
ot influence the incidence of MI or overall mortality. Seven
andomized clinical trials conducted in patients undergoing
ascular surgery demonstrated no differences in outcome
hen regional and general anesthesia techniques were com-
ared (482–488). One trial of 168 patients undergoing
bdominal aortic surgery specifically examined the relative
mportance of intraoperative versus postoperative epidural
nesthesia and analgesia compared with general anesthesia
n outcomes (487). No differences in major morbidity,
ength of stay, or mortality rate were observed. There was no
verall difference in death or major complications in 1021
atients randomized to receive general anesthesia/opioid
nalgesia or combined general/epidural anesthesia and an-
lgesia for intra-abdominal aortic, gastric, biliary, or colon
urgery (489). In the subgroup of patients undergoing aortic
urgery, the incidence of MI was decreased (p0.05) from
.9% in the general anesthesia/opioid analgesia group to
.7% in the general/epidural anesthesia group; however, the
se of beta blockers in the 2 groups was not reported. The
ASTER (Multicenter Australian Study of Epidural An-
sthesia) trial randomized 915 patients undergoing major
bdominal surgery to receive either combined general and
pidural anesthesia/epidural analgesia or general anesthesia
ith opioid analgesia (490). Epidural anesthesia/analgesia
id not decrease death or cardiovascular outcomes but
odestly improved pulmonary outcomes compared with the
eneral anesthesia group. In a subgroup analysis of patients
ndergoing aortic surgery, there was no effect of perioper-
tive epidural analgesia on major outcomes (488).
“Monitored anesthesia care” by an anesthesia caregiver
ncludes the use of local anesthesia supplemented with
ntravenous sedation/analgesia. In a large-scale study, mon-
tored anesthesia care was associated with the highest
ncidence of 30-day mortality (478). This finding may
eflect a strong selection bias in which patients with signif-
cant coexisting disease were selected for surgery with
onitored anesthesia care rather than other anesthetic
echniques. Although this technique can eliminate some of
he undesirable effects of general or neuraxial anesthesia, it
rovides poor blockade of the stress response unless the local
nesthetic provides profound anesthesia of the affected area.
f the local anesthetic block is less than satisfactory or
annot be used at all, monitored anesthesia care could result ln an increased incidence of myocardial ischemia and cardiac
ysfunction compared with general or regional anesthesia.
o achieve the desired effect, excess sedation can occur.
herefore, there may be no significant difference in overall
afety with monitored anesthesia care, and general or
egional anesthesia may be preferable. In general, the
ardiovascular consultant should be aware of these issues,
ut it is the role of the anesthesiologist to select the best
pproach with integration and consideration of all medical
erspectives and sometimes even patient preference.
.2. Perioperative Pain Management
rom the cardiac perspective, pain management may be a
rucial aspect of perioperative care. Because the majority of
ardiac events in noncardiac surgical patients occur postop-
ratively, the postoperative period may be the time during
hich ablation of stress, adverse hemodynamics, and hyper-
oagulable responses are most critical. Although no ran-
omized controlled study specifically addressing analgesic
egimens has demonstrated improvement in outcome,
atient-controlled analgesia techniques are associated with
reater patient satisfaction and lower pain scores. Epidural
r spinal opiates are becoming more popular and have
everal theoretical advantages. Several studies have evaluated
iffering combinations of general and epidural anesthesia
nd intravenous and epidural analgesia (482–486). Patients
aving epidural anesthesia/analgesia have demonstrated
ower opiate dosages, better ablation of the catecholamine
esponse, and a less hypercoagulable state (491,492). In 1
tudy of patients undergoing lower-extremity vascular by-
ass procedures (483), the use of epidural anesthesia/
nalgesia was associated with a lower incidence of cardiac
orbidity; however, this finding was not confirmed in 2
ther studies (484,486). In a study of 124 patients under-
oing aortic surgery, there was no difference in the incidence
f myocardial ischemia in patients randomized to postop-
rative intravenous analgesia versus epidural analgesia (485).
n effective analgesic regimen must be included in the
erioperative plan and should be based on issues unique to
given patient undergoing a specific procedure at a specific
nstitution.
.3. Prophylactic Intraoperative Nitroglycerin
LASS IIb
. The usefulness of intraoperative nitroglycerin as a prophylactic
agent to prevent myocardial ischemia and cardiac morbidity is
unclear for high-risk patients undergoing noncardiac surgery, partic-
ularly those who have required nitrate therapy to control angina. The
recommendation for prophylactic use of nitroglycerinmust take into
account the anesthetic plan and patient hemodynamics and must
recognize that vasodilation and hypovolemia can readily occur
during anesthesia and surgery. (Level of Evidence: C)
itroglycerin has been shown to reverse myocardial isch-
mia intraoperatively; however, the intraoperative prophy-
actic use of nitroglycerin in patients at high risk may have
n
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ation through decreases in preload. Topical nitroglycerin
ay have uneven absorption intraoperatively, so when
linically indicated, it is reasonable to administer nitroglyc-
rin intravenously. The venodilating and arterial dilating
ffects of nitroglycerin are mimicked by some anesthetic
gents, so that the combination of agents may lead to
ignificant hypotension and myocardial ischemia. There-
ore, nitroglycerin should be used only when the hemody-
amic effects of other agents being used and intravascular
olume status have been considered.
Four controlled studies have evaluated prophylactic ni-
roglycerin infusions for high-risk patients, including 2
tudies in noncardiac surgery patients (493–496). Only 1
tudy, performed in patients with stable angina undergoing
arotid endarterectomy, demonstrated a reduced incidence
f intraoperative myocardial ischemia in the group receiving
mcg of nitroglycerin per kilogram of weight per minute.
either of the 2 small studies demonstrated any reduction
n the incidence of MI or cardiac death. In a retrospective
nalysis of patients with rest anginal symptoms who were
ndergoing CABG surgery, preoperative use of intravenous
itroglycerin had no effect on outcomes such as MI, death,
r use of an intra-aortic balloon pump (497).
.4. Use of TEE
LASS IIa
. The emergency use of intraoperative or perioperative TEE is reason-
able to determine the cause of an acute, persistent, and life-
threatening hemodynamic abnormality. (Level of Evidence: C)
ransesophageal echocardiography has become increasingly
ommon in the operating room for cardiac surgery but is less
requently used in noncardiac surgery. Multiple investiga-
ions have documented the improved sensitivity of TEE for
etection of myocardial ischemia compared with ECG or
ulmonary capillary wedge pressure measurements. Most
tudies have used offline analysis of the TEE images,
owever, and automated, online detection may increase its
alue.
There are few data regarding the value of TEE-detected
all-motion abnormalities to predict cardiac morbidity in
oncardiac surgical patients. In 2 studies from the same
roup, intraoperative wall-motion abnormalities were poor
redictors of cardiac morbidity (498,499). In 1 study involv-
ng 322 men undergoing noncardiac surgeries, TEE dem-
nstrated an OR of 2.6 (95% CI 1.2 to 5.7) for predicting
erioperative cardiac events (498). Although regional wall-
otion abnormalities in a high-risk patient suggest myo-
ardial ischemia, resolution of myocardial ischemia may not
esult in improvement of wall motion.
There is emerging evidence demonstrating the utility of
EE to alter the management of patients undergoing
ardiac surgery; however, interpretation of TEE requires
dditional education. Many anesthesiologists are expert in
his technique, but others have limited or no training.
urrently, there is insufficient evidence to determine the aost-effectiveness of TEE for its use as a diagnostic monitor
r to guide therapy during noncardiac surgery; therefore, the
outine use of TEE in noncardiac surgery does not appear
arranted. In contrast, emergent use of intraoperative or
erioperative TEE to determine the cause of an acute,
ersistent, and life-threatening hemodynamic abnormal-
ty is indicated. Guidelines for the appropriate use of
EE have been developed by the American Society of
nesthesiologists and the Society of Cardiovascular An-
sthesiologists (500).
.5. Maintenance of Body Temperature
ecommendations for Maintenance of Body
emperature
LASS I
. Maintenance of body temperature in a normothermic range is
recommended for most procedures other than during periods in
which mild hypothermia is intended to provide organ protection
(e.g., during high aortic cross-clamping). (Level of Evidence: B)
ypothermia is common during the perioperative period in
he absence of active warming of patients. In a retrospective
nalysis of a prospective randomized trial comparing 2
ifferent anesthetic techniques for infrainguinal revascular-
zation surgery, hypothermia (temperature less than 35
egrees Celsius) was associated with an increased risk of
yocardial ischemia compared with patients who had a core
emperature greater than or equal to 35 degrees Celsius
normothermic group) in the postanesthesia care unit (501).
everal methods of maintaining normothermia are available
n clinical practice, the most widely studied being forced-air
arming.
One randomized clinical trial was performed in 300
igh-risk patients undergoing noncardiac surgery in which
atients were randomized to active warming via forced air
normothermic group) or routine care (hypothermic group)
502). Perioperative morbid cardiac events (unstable angina/
schemia, cardiac arrest, and MI) occurred less frequently in
he normothermic group than in the hypothermic group
1.4% versus 6.3%; p0.02). In addition, ventricular tachy-
ardia occurred less frequently in the normothermic group
2.4% versus 7.9%; p0.04) (502). Hypothermia was an
ndependent predictor of morbid cardiac events by multiva-
iable analysis (RR 2.2, 95% CI 1.1 to 4.7, p0.04),
ndicating a 55% reduction in risk when normothermia was
aintained.
.6. Intra-Aortic Balloon Counterpulsation Device
lacement of an intra-aortic balloon counterpulsation de-
ice has been suggested as a means of reducing perioperative
ardiac risk in noncardiac surgery. Several case reports have
ocumented its use in patients with unstable coronary
yndromes or severe CAD who are undergoing urgent
oncardiac surgery (503–506). Although the rate of cardiac
omplications is low compared with other series of patients
t similarly high risk, there are no randomized trials to
ssess its true effectiveness. Additionally, the use of intra-
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ions, particularly in patients with peripheral vascular dis-
ase. There is currently insufficient evidence to determine
he benefits versus risks of prophylactic placement of an
ntra-aortic balloon counterpulsation device for high-risk
oncardiac surgery.
.7. Perioperative Control of Blood Glucose
oncentration
ecommendations for Perioperative Control of Blood
lucose Concentration
LASS IIa
. It is reasonable that blood glucose concentration be controlled§§
during the perioperative period in patients with diabetes mellitus or
acute hyperglycemia who are at high risk for myocardial ischemia or
who are undergoing vascular and major noncardiac surgical proce-
dures with planned ICU admission. (Level of Evidence: B)
LASS IIb
. The usefulness of strict control of blood glucose concentration§§
during the perioperative period is uncertain in patients with diabetes
mellitus or acute hyperglycemia who are undergoing noncardiac
surgical procedures without planned ICU admission. (Level of Evi-
dence: C)
yperglycemia is an independent predictor of cardiovascu-
ar risk, and severity of hyperglycemia is directly related to
ortality rate during MI. The impact of perioperative
ontrol of blood glucose concentration on morbidity and
ortality has been investigated recently. Table 15 summa-
izes the results of 13 clinical trials evaluating the relation-
hip between blood glucose concentration and outcome in
ritically ill patients with and without diabetes mellitus
507–519). Eight retrospective analyses conducted in pa-
ients undergoing coronary artery surgery and in patients
dmitted to a medical-surgical ICU for a variety of surgical
nd nonsurgical conditions indicated that increased blood
lucose concentration was an important predictor of mor-
idity and mortality. These results were confirmed by a
andomized clinical trial of critically ill patients (63% cardiac
urgical patients) admitted to a surgical ICU who received
ntensive treatment with intravenous insulin to control
lood glucose concentrations between 80 and 110 mg per
L, who were compared with conventionally treated pa-
ients who received insulin only if blood glucose exceeded
15 mg per dL (507). Aggressively treated patients with a
rolonged length of stay in the ICU demonstrated signifi-
ant decreases in morbidity and mortality. Glucose-insulin-
otassium was also shown to improve outcomes in cardiac
urgery patients when blood glucose concentrations were
ell controlled (508) but not when blood glucose concen-
rations were inadequately controlled (509). The benefit of
lucose-insulin-potassium to produce cardioprotection in
onhyperglycemic cardiac surgery patients is controversial
nd may not be similar to the use of insulin to specificallym§Blood glucose less than 150 mg per dL appears to be beneficial.ontrol blood glucose concentration (516). The role of
ntraoperative glycemic control with a standardized insulin
rotocol to modulate outcomes was investigated in a pro-
pective observational study of patients with diabetes mel-
itus undergoing CABG surgery. Although postoperative
lood glucose concentrations were similar, those patients
ho achieved tight control of blood glucose concentrations
ntraoperatively demonstrated decreased morbidity and
ortality compared with patients whose blood glucose was
oorly controlled (4 consecutive blood glucose measure-
ents exceeding 200 mg per dL despite insulin therapy)
520). A retrospective analysis similarly identified intraop-
rative blood glucose concentration as an independent
redictor of adverse outcome in cardiac surgery patients
512). The risks of stroke, MI, and death were also shown
o be independently increased 3- to 4-fold by preoperative
yperglycemia (glucose concentration in excess of 200 mg
er dL) in patients undergoing carotid endarterectomy
511). Although clinical trials demonstrated the deleterious
ffects of perioperative hyperglycemia, the ideal target for
nd cardiovascular benefit of intraoperative and postopera-
ive glycemic control are not entirely clear. Results of
egression analyses (510) suggest that blood glucose con-
entrations controlled to less than 150 mg per dL in the
erioperative period may improve outcome and minimize
he risk of severe hypoglycemia in anesthetized patients
521,522). The American College of Endocrinology re-
ently published a position statement recommending that
reprandial glucose concentration should be less than 110
g per dL, with maximal glucose not to exceed 180 mg per
L in hospitalized patients and that blood glucose concen-
ration should be controlled to less than 110 mg per dL in
he ICU (522). The use of intravenous insulin therapy to
aintain glycemic control in the perioperative period was
ecommended.
. Perioperative Surveillance
lthough much attention has been focused on the preop-
rative preparation of the high-risk patient, intraoperative
nd postoperative surveillance for myocardial ischemia and
nfarction, arrhythmias, and venous thrombosis should also
ead to reductions in morbidity. Postoperative myocardial
schemia has been shown to be the strongest predictor of
erioperative cardiac morbidity and is rarely accompanied
y pain (121). Therefore, it may go untreated until overt
ymptoms of cardiac failure develop.
The diagnosis of a perioperative MI has both short- and
ong-term prognostic value. Traditionally, a perioperative
I has been associated with a 30% to 50% perioperative
ortality and reduced long-term survival (42,523–525).
herefore, it is important to identify patients who sustain a
erioperative MI and to treat them aggressively, because it
ay reduce both short- and long-term risk.
Table 15. Impact of Perioperative Blood Glucose Concentration on Outcomes
Study Study Type No. of Pts Study Design Mean Glucose, mg/dL
% of Pts
With
Diabetes Major Findings
van Den Berghe et al.,
2001 (507)
RCT 1548 Surgical ICU
pts
Intensive intravenous insulin
vs. conventional
treatment
Intensive 103  19 vs.
conventional 153  33
13 vs. 13 Intensive insulin compared with conventional treatment
decreased mortality (8.0% to 4.6%) and major morbidity.
Lazar et al.,
2004 (508)
RCT 141 On-pump
CABG pts
GIK vs. SQ insulin GIK 134  4 vs. SQ
insulin 267  6
100 GIK improved 5-year survival and decreased major morbidity.
Lell et al., 2002 (509) RCT 46 Off-pump
CABG pts
GIK vs. saline GIK 386  152 vs. saline
211  75
28 vs. 45 No differences in TnI or CK-MB between groups; study
terminated owing to concerns of persistent hyperglycemia
in the GIK group.
Finney et al.,
2003 (510)
Prospective
observational
531 ICU pts Intravenous insulin N/A 16 Increased administration of insulin was an independent
predictor of ICU mortality; regression models
demonstrated a mortality benefit if blood glucose was
maintained less than 144 to 200 mg/dL.
Ouattara et al.,
2005 (520)
Prospective
observational
200 On-pump
CABG pts
Insulin by standardized
protocol
Tightly controlled 147 
42 vs. poorly controlled
208  54
100 Poor intraoperative control of blood glucose was an
independent predictor of severe morbidity; mortality rate
was increased in pts with poorly controlled glucose
(11.4%) vs. those with tightly controlled glucose (2.4%).
McGirt et al.,
2006 (511)
Retrospective 1201 Pts
undergoing CEA
Postoperative insulin use
was nonstandardized
N/A 27 Multivariate analysis demonstrated that preoperative glucose
greater than 200 mg/dL was an independent predictor of
2.8-, 4.3-, and 3.3-fold increases in risk of stroke/TIA, MI,
or death.
Gandhi et al.,
2005 (512)
Retrospective 409 Cardiac
surgery pts
Nonstandardized
intraoperative use of
insulin in 6%
Any adverse event 141 
37 vs. no events
127  25
28.6 vs. 18 Multivariate analysis demonstrated that mean and maximal
intraoperative glucose predicted increased mortality. A
20-mg/dL increase in mean intraoperative glucose was
associated with a 30% increase in adverse events.
Krinsley 2004 (513) Retrospective 1600 Med-Surg
ICU pts
Historical control vs.
standardized glucose
control protocol
Historical 152  93 vs.
protocol 131  55
16 vs. 18 Decreased mortality, renal insufficiency, and ICU length of
stay were observed in the standardized insulin protocol
compared with the historical group.
Hill et al., 2000 (514) Retrospective 2862 CABG pts Nonstandardized glucose
management
79–653 31 Univariate analysis showed no association between
maximum blood glucose concentration and mortality.
Krinsley 2003 (515) Retrospective 1826 Med-Surg
ICU pts
Nonstandardized glucose
management
Survivors 138 vs.
nonsurvivors 172
22 Progressive increase in in-hospital mortality rate as blood
glucose concentration increased, up to 42.5% among
patients with mean glucose values in excess of
300 mg/dL.
Furnary et al.,
2003 (516)
Retrospective 3554 CABG pts SQ insulin vs. continuous
intravenous insulin
SQ 213  41 vs.
intravenous 177  30
100 Continuous intravenous insulin was an independent predictor
of survival.
Estrada et al.,
2003 (517)
Retrospective 1574 CABG pts Nonstandardized glucose
management
Diabetes 214  47 vs. no
diabetes 157  37
35 Hyperglycemia did not predict increased mortality but was
associated with increased resource utilization.
McAlister et al.,
2003 (518)
Retrospective 1574 CABG pts 92% received intravenous
insulin by protocol
164–209 100 Hyperglycemia was an independent predictor of adverse
outcomes.
CABG indicates coronary artery bypass graft; CEA, carotid endarterectomy; CK-MB, creatine kinase MB fraction; GIK, glucose insulin potassium; ICU, intensive care unit ; Med-Surg, medical-surgical; MI, myocardial infarction; N/A, not available; pts, patients; RCT,
randomized, controlled trial ; SQ, subcutaneous; TIA, transient ischemic attack; and TnI, troponin I. e79
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ecommendations for Perioperative Use of PACs
LASS IIb
. Use of a PAC may be reasonable in patients at risk for major
hemodynamic disturbances that are easily detected by a PAC.
However, the decision must be based on 3 parameters: patient
disease, surgical procedure (i.e., intraoperative and postoperative
fluid shifts), and practice setting (experience in PAC use and inter-
pretation of results), because incorrect interpretation of the data
from a PAC may cause harm. (Level of Evidence: B)
LASS III
. Routine use of a PAC perioperatively, especially in patients at low
risk of developing hemodynamic disturbances, is not recom-
mended. (Level of Evidence: A)
se of a PAC may provide significant information critical to
he care of the cardiac patient; however, the potential risk of
omplications and cost associated with catheter insertion
nd use must be considered. Practice guidelines for PAC, as
ell as methods to perform perioperative optimization of
he high-risk surgical patient, have been developed and
eported elsewhere (526,527). Several studies have evaluated
he benefit of PAC use in both randomized trials and those
sing historical controls. In patients with prior MI, when
erioperative care included PAC and intensive care moni-
oring for 3 days postoperatively, there was a lower inci-
ence of reinfarction than in historical controls (523). Other
hanges in management occurred during the period under
tudy, however, including the increased use of beta-
drenergic sympathetic blockade. In particular, patients
ith signs and symptoms of HF preoperatively, who have a
ery high (35%) postoperative incidence of HF, might
enefit from invasive hemodynamic monitoring (114).
Although a great deal of literature has evaluated the
tility of the PAC during the perioperative period in
oncardiac surgery, relatively few controlled studies have
valuated PAC use in relation to clinical outcomes. Evi-
ence of benefit of PAC use from controlled trials is
quivocal, and a large-scale cohort study demonstrated
otential harm (528). Nevertheless, PAC use may benefit
igh-risk patients. Berlauk et al. (449), in comparing
utcomes associated with PAC insertion 12 hours before
urgery, 3 hours before surgery, or no planned insertion,
ound the PAC group had fewer adverse intraoperative
vents and less postoperative cardiac morbidity (p0.05 for
oth). However, Bender et al. (450) found no decrease in
orbidity or mortality with routine PAC use in elective
urgery. In studies using appropriate patient selection, no
ifferences in cardiac morbidity (MI or cardiac death) were
etected (450,529–532). A meta-analysis by Poeze et al.
451) found that hemodynamic optimization of critically ill
atients decreased mortality (RR 0.75, 95% CI 0.62 to 0.90)
hen all studies were combined, and this effect was attrib-
ted to the decreased mortality observed in studies specifi-
ally conducted to evaluate the benefit of perioperative
nterventions (RR 0.66, 95% CI 0.54 to 0.81). aPolanczyk et al. performed an observational study of 4059
atients aged 50 years or older who underwent major
lective noncardiac procedures with an expected length of
tay of 2 or more days (533). Major cardiac events occurred
n 171 patients (4.2%); those who underwent right heart
atheterization had a 4-fold increased incidence of major
ostoperative cardiac events (34 [15.4%] versus 137 [3.6%];
0.001). In a case-control analysis of a subset of 215
atched pairs of patients in this trial who did and did not
ndergo right heart catheterization, adjusted for propensity
f right heart catheterization and type of procedure, patients
ho underwent perioperative right heart catheterization
lso had increased risk of postoperative congestive HF (OR
.9, 95% CI 1.4 to 6.2) and major noncardiac events (OR
.2, 95% CI 1.4 to 4.9) (533).
A randomized, multicenter clinical trial of goal-directed
herapy with a PAC in 1994 elderly patients (American
ociety of Anesthesiologists Class 3 or 4) who underwent
ajor noncardiac surgery demonstrated no differences in
urvival or cardiovascular morbidity compared with a stan-
ard care group (77% had a central venous catheter placed)
526). Although mortality and hospital length of stay were
imilar in both groups, the PAC group demonstrated higher
ates of pulmonary embolism (0 events in the standard care
roup versus 8 events in the PAC group; p0.004) (534).
Several surveys have shown physician and nurse under-
tanding of PAC catheterization data are extremely variable,
hich may account for the higher rate of postoperative
ongestive HF and greater perioperative net fluid intake
bserved in some studies. This finding led some to recom-
end re-evaluation of current accreditation and teaching
ractices (535–538). The American Society of Anesthesiol-
gists Task Force on Pulmonary Artery Catheterization has
ecently provided an update to the practice guidelines for
ulmonary artery catheterization (526). Given the above-
escribed studies and the accumulating data from the
onsurgical arena, in which the use of a PAC has not shown
enefit, the decision to place a PAC should carefully weigh
he potential for harm with any potential benefit from the
nformation obtained from the monitor.
.2. Intraoperative and Postoperative Use of
T-Segment Monitoring
LASS IIa
. Intraoperative and postoperative ST-segment monitoring can be
useful to monitor patients with known CAD or those undergoing
vascular surgery, with computerized ST-segment analysis, when
available, used to detect myocardial ischemia during the perioper-
ative period. (Level of Evidence: B)
LASS IIb
. Intraoperative and postoperative ST-segment monitoring may be
considered in patients with single or multiple risk factors for CAD
who are undergoing noncardiac surgery. (Level of Evidence: B)
he presence of intraoperative and postoperative ST-
egment changes has been associated with cardiac morbidity
nd mortality in high-risk patients undergoing noncardiac
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November 24, 2009:e13–118 2009 ACCF/AHA Perioperative Guidelinesurgery. Most contemporary operating rooms and ICU
onitors incorporate algorithms that perform real-time
nalysis of the ST segment. Numerous studies have dem-
nstrated the limited ability of physicians to detect signifi-
ant ST-segment changes compared with computerized or
ffline analysis. Computerized ST-segment trending is su-
erior to visual interpretation in the identification of ST-
egment changes. Because the algorithms used to measure
T-segment shifts are proprietary, variability in accuracy
etween the different monitors has been evaluated in several
tudies compared with offline analysis of standard Holter
ecordings (539–541). ST-segment trending monitors were
ound to have an average sensitivity and specificity of 74%
range 60% to 78%) and 73% (range 69% to 89%), respec-
ively, compared with Holter ECG recordings (540). Sev-
ral factors have been identified that decreased the accuracy
f the monitors and have been discussed in detail elsewhere.
dditionally, the lead system used affects the incidence of
schemia detected, with leads II and V5 detecting only 80%
f all episodes detected by a 12-lead ECG in 1 study (542),
hereas another study found that V4 was the most sensitive
ead (83.3%) (543).
Virtually all studies examining the predictive value of
ntraoperative and postoperative ST-segment changes have
een performed with ambulatory ECG recorders. Using
etrospective analysis, investigators have found postopera-
ive ST-segment changes indicative of myocardial ischemia,
rimarily ST-segment depression, to be an independent
redictor of perioperative cardiac events in high-risk non-
ardiac surgery patients in multiple studies, with changes of
rolonged duration (greater than 30 minutes per episode or
reater than 2 hours cumulative duration in different stud-
es) being particularly associated with increased risk
42,71,288,544,545). In a review of studies involving more
han 2400 patients between the years 1990 and 2003,
andesberg reported a sensitivity of perioperative ischemia
n predicting postoperative cardiac events of 55% to 100%;
he specificity was 37% to 85%, the positive predictive value
as 7% to 57%, the negative predictive value was 89% to
00%, and the RR of suffering a postoperative cardiac
vent, including cardiac death, in patients with ischemia
anged between 2.2% and 73% (546). Postoperative
T-segment changes, particularly of a prolonged dura-
ion, have been shown to predict worse long-term sur-
ival in high-risk patients (288,524).
In a cohort of patients older than 45 years with 1 risk
actor but without known CAD, the presence of intraoper-
tive and postoperative ST-segment changes was not asso-
iated with either ischemia on an exercise stress test or
ardiac events within 1 year (547). The total cohort of
atients was small, which may limit the ability to generalize
hese findings.
Intraoperative ST-segment changes may also occur in
ow-risk populations. ST-segment depression has been
hown to occur during elective cesarean sections in healthy
atients (548,549). Because these changes were not associ- sted with regional wall-motion abnormalities on precordial
chocardiography, in this low-risk population, such ST-
egment changes may not be indicative of myocardial
schemia and CAD.
Thus, although there are data to support the contention
hat ST-segment monitoring detects ischemia, no studies
ave addressed the issue of the effect on outcome when
herapy is based on the results of ST-segment monitoring.
owever, general consensus is that early treatment, such as
ontrol of tachycardia, could lead to a reduction in cardiac
orbidity.
.3. Surveillance for Perioperative MI
LASS I
. Postoperative troponin measurement is recommended in patients
with ECG changes or chest pain typical of acute coronary syndrome.
(Level of Evidence: C)
LASS IIb
. The use of postoperative troponin measurement is not well estab-
lished in patients who are clinically stable and have undergone
vascular and intermediate-risk surgery. (Level of Evidence: C)
LASS III
. Postoperative troponin measurement is not recommended in
asymptomatic stable patients who have undergone low-risk surgery.
(Level of Evidence: C)
ultiple studies have evaluated predictive factors for a
erioperative MI. The presence of clinical evidence of
oronary artery or peripheral vascular disease has been
ssociated with an increased incidence of perioperative MI.
actors that increase the risk of a perioperative MI have
een discussed previously. Because of the increased risk of
oth short- and long-term mortality from a perioperative
I, accurate diagnosis is important.
Perioperative MI can be documented by assessing clinical
ymptoms, serial ECGs, cardiac-specific biomarkers, com-
arative ventriculographic studies before and after surgery,
adioisotopic or magnetic resonance studies specific for
yocardial necrosis, and autopsy studies. The criteria used
o diagnose infarction in various studies differ not only in
he level of cardiac biomarkers that determine abnormality
ut also in the frequency with which these biomarkers are
ampled after noncardiac surgery. The cardiac biomarker
rofile after infarction exhibits a typical rise and fall that
iffers among different biomarkers. Daily sampling may
iss detection of a cardiac biomarker rise (such as the MB
soenzyme of creatine kinase [CK-MB]), thus underesti-
ating the incidence of perioperative infarction. The ECG
riteria used to define infarction may also differ not only in
he definition of a Q wave but also with respect to the
agnitude of ST-T wave shifts that determine an abnormal
esponse. In the analysis of cardiac biomarker criteria,
umerous assays are available to measure CK-MB, cTnI,
nd, to a lesser extent, cardiac troponin T. Creatine
inase-MB may be released from noncardiac sources in
atients with ischemic limbs or those undergoing aortic
urgery, the group at highest risk for a perioperative MI.
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2009 ACCF/AHA Perioperative Guidelines November 24, 2009:e13–118dditionally, other tissues may release CK-MB into the
irculation, such as many from the gastrointestinal tract.
enal insufficiency may affect the ability to clear these
nzymes and therefore decrease the specificity of an abnor-
al result. The use of cTnI or cardiac troponin T offers the
otential for enhanced specificity (550–555).
An increasing number of studies have examined the
utcome using protocol-specific criteria for perioperative
I after noncardiac surgery. The topic of surveillance for
erioperative MI was reviewed in 2005 and a set of criteria
roposed (126). Charlson et al. (556) reported on 232
atients, most of whom were hypertensive or had diabetes
ellitus, who were undergoing elective noncardiac surgery.
erial ECGs and CK-MB were collected for 6 days post-
peratively. The incidence of perioperative MI varied
reatly depending on the diagnostic criteria used. A strategy
f using an ECG immediately after the surgical procedure
nd on the first and second days postoperatively had the
ighest sensitivity. Two studies have demonstrated the
rognostic significance of a postoperative 12-lead ECG.
infret et al, examining the same population set as de-
cribed above in the study by Lee et al. (553), investigated
he information provided by a postoperative ECG per-
ormed in the recovery room after operation (557). Of the
750 patients evaluated, 7.5% had significant ECG
hanges. Significant changes included ST-segment eleva-
ion, ST-segment depression, and T-wave changes. The
resence of these changes conferred a 2.2-fold increase in
ajor cardiac complications, increasing the rate from 1.9%
n patients who did not have these signs to 6.7% in those
ho did (p0.001). The increase in event rate was main-
ained when stratified by the author’s Revised Cardiac Risk
ndex (4). In fact, the RR of an adverse event associated
ith ECG changes was higher in the lower-risk group,
ncreasing the events more than 4-fold compared with
-fold in the high-risk subset. Bottiger et al. (558) investi-
ated the value of 12-lead ECGs obtained 15 minutes, 20
ours, 48 hours, 72 hours, and 84 hours after operation in
5 patients. For study entry, patients had operations that
equired more than 1 hour of anesthesia and a history of
AD or 2 cardiovascular disease risk factors. Of the 55
atients, 19 had perioperative ischemia, and 2 required
ardiac catheterization. Electrocardiographic changes of
schemia were noted in 24 patients, of which 88% were
oted in the first postoperative evaluation. Moreover, early
CG changes were concordant with cardiac biomarker
vidence of myocardial damage.
Strategies that included the serial measurement of
K-MB had higher false-positive rates (i.e., lower specific-
ty) without higher sensitivities. In contrast, Rettke et al.
eported that overall survival was associated with the degree
f CK-MB elevation in 348 patients undergoing abdominal
ortic aneurysm repair, with higher levels associated with
orse survival (559). Yeager et al. evaluated the prognostic
mplications of a perioperative MI in a series of 1561 major
ascular procedures (525). These authors found that the tncidence of subsequent MI and coronary artery revascular-
zation was significantly higher in patients who had a
erioperative MI, except in the subset who only demon-
trated an elevated CK-MB without ECG changes or
ardiovascular symptoms.
Over the last decade, the diagnosis of myocardial damage
as become more sensitive with the application of cardiac
iomarkers. Measurement of troponin T or I facilitates the
ecognition of myocardial damage with much smaller
mounts of injury. Because of the augmentation of sensitiv-
ty, the threshold to diagnosis of an MI is lower and the
requency greater (288). On the basis of the increase in
ensitivity, many studies have been performed to determine
hether screening troponin measurements convey impor-
ant prognostic information.
The largest screening study by Lee et al. evaluated
roponin T measured in 1175 noncardiac surgical patients
553). Troponin T was measured in the recovery room after
peration and on the next 2 postoperative mornings. In this
opulation, an MI was diagnosed in 1.4% (n17) of the
atients using CK-MB fraction and ECG for diagnosis.
roponin T was elevated in 87% of the patients with MI
nd 16% of the patients without MI.
Martinez et al. studied 467 high-risk patients requiring
oncardiac surgery (560). The diagnosis of myocardial
njury was determined by biomarkers combined with either
ostoperative changes on 12-lead ECG or 1 of 3 clinical
ymptoms consistent with MI (chest pain, dyspnea, or
equirement for hemodynamic support). The incidence of
I was 9.0% by the criterion of cTnI greater than or equal
o 2.6 ng per mL, 19% by cTnI greater than or equal to 1.5
g per mL, 13% by CK-MB mass, and 2.8% by CK-MB%.
f surveillance of cTnI greater than or equal to 2.6 ng per
L was used to detect MI, then the strategy with the
ighest diagnostic yield was surveillance on postoperative
ays 1, 2, and 3.
The pattern of cardiac specific troponin elevation may
lso be important. Le Manach et al. performed intense
ardiac cTnI surveillance after abdominal aortic surgery in
136 consecutive patients to better evaluate the incidence
nd timing of postoperative MI (cTnI greater than or equal
o 1.5 ng per mL) or myocardial damage (abnormal cTnI
ess than 1.5 ng per mL) (561). Abnormal cTnI concentra-
ions were noted in 163 patients (14%), of whom 106 (9%)
ad myocardial damage and 57 (5%) had perioperative MI.
n 34 patients (3%), perioperative MI was preceded by a
rolonged (greater than 24 hours) period of increased cTnI
delayed perioperative MI), and in 21 patients (2%), the
ncrease in cTnI lasted less than 24 hours (early periopera-
ive MI). The authors concluded that abnormal but low
ostoperative cTnI is associated with increased mortality
nd may lead to delayed perioperative MI.
Data like these highlight the difficulty of using cardiac
pecific troponin to distinguish myocardial damage from
nfarction. The variability in the rate of MI based on
roponin cutoff and other studies highlights the fact that
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November 24, 2009:e13–118 2009 ACCF/AHA Perioperative Guidelineshere is a poor relationship between cardiac-specific tropo-
in elevation and postoperative ECG changes (562). It is
lready known that one third of coronary arterial ischemic
vents occur distal to areas of noncritical stenosis and that
ritical stenoses are uncommon in the pathogenesis of MI
289). Although the extent of coronary artery atherosclero-
is, as determined by the number of vessels with significant
tenoses, predicts frequency of perioperative MI, individual
esion stenosis does not (563).
Studies regarding the predictive value of postoperative
ardiac specific troponin elevations for long-term out-
ome have been inconsistent. Investigations have shown
hat postoperative elevations in cardiac specific troponin
re associated with increased cardiovascular morbidity
nd mortality at 30 days (564,565), 6 months (554,566),
year (567), and beyond 1 year (565,568). However,
ther studies have shown no association with intermedi-
te or long-term cardiovascular outcomes (569), and none
f the studies above demonstrate a relationship at the
ther time points.
On the basis of the available literature, routine measure-
ent of cardiac-specific troponin after surgery is more likely
o identify patients without acute MI than with MI.
oreover, studies of cardiac specific troponin elevations
either consistently show associations with adverse cardio-
ascular outcomes at any time point nor provide insight into
he effect of treatment on outcomes in patients with an
levated cardiac-specific troponin level. Although it is
nown that elevations in cardiac specific troponin are more
ikely to occur in patients with more extensive CAD, the
ole of revascularization in patients with an elevated cardiac-
pecific troponin level but no other manifestation of MI
emains unclear. Until each of these issues has been ad-
ressed, routine cardiac-specific troponin measurement can-
ot be recommended. Perioperative surveillance for acute
oronary syndromes with routine ECG and cardiac serum
iomarker measurement is unnecessary in clinically low-risk
atients undergoing low-risk operative procedures.
Further evaluation regarding the optimal strategy for
urveillance and diagnosis of perioperative MI is re-
uired. On the basis of current evidence, in patients
ithout documented CAD, surveillance should be re-
tricted to those who develop perioperative signs of
ardiovascular dysfunction. In patients with high or
ntermediate clinical risk who have known or suspected
AD and who are undergoing high- or intermediate-risk
urgical procedures, the procurement of ECGs at base-
ine, immediately after the surgical procedure and daily
n the first 2 days after surgery appears to be the most
ost-effective strategy. The use of cardiac specific tropo-
in measurements to supplement the diagnosis in these
ymptomatic patients is warranted. Additional research is
eeded to correlate long-term outcome results to the mag-
itude of isolated cardiac-specific troponin elevations. c.4. Postoperative Arrhythmias and
onduction Disorders
ostoperative arrhythmias are often due to remedial non-
ardiac problems such as infection, hypotension, metabolic
erangements, and hypoxia. The approach taken to the
cute management of postoperative tachycardias varies de-
ending on the likely mechanism. If the patient develops a
ustained, regular, narrow-complex tachycardia, which is
ikely due to atrioventricular nodal re-entrant tachycardia or
trioventricular reciprocating tachycardia, the tachycardia
an almost always be terminated with vagal maneuvers
Valsalva maneuver or carotid sinus massage) or with
ntravenous adenosine. Most antiarrhythmic agents (espe-
ially beta blockers, calcium channel blockers, and type 1a or
c antiarrhythmic agents) can be used to prevent further
ecurrences in the postoperative setting. A somewhat dif-
erent approach is generally recommended for atrial fibril-
ation and atrial flutter. The initial approach to management
enerally involves the use of intravenous digoxin, diltiazem,
r a beta blocker in an attempt to slow the ventricular
esponse. Among these 3 types of medications, digitalis is
east effective and beta blockers are most effective for
ontrolling the ventricular response during atrial fibrillation
438). An additional benefit of beta blockers is that they
ave been shown to accelerate the conversion of postoper-
tive supraventricular arrhythmias to sinus rhythm com-
ared with diltiazem (439). Cardioversion of atrial fibrilla-
ion/flutter is generally not recommended for asymptomatic
r minimally symptomatic arrhythmias until correction of
he underlying problems has occurred, which frequently
eads to a return to normal sinus rhythm. Also, cardiover-
ion is unlikely to result in long-term normal sinus rhythm
f the underlying problem is not corrected. The avoidance of
n electrolyte abnormality, especially hypokalemia and hy-
omagnesemia, may reduce the perioperative incidence and
isk of arrhythmias, although acute preoperative repletion of
otassium in an asymptomatic individual may be associated
ith greater risk than benefits (570–573). Unifocal or
ultifocal premature ventricular contractions do not merit
herapy. Very frequent ventricular ectopy or prolonged runs
f nonsustained ventricular tachycardia may require antiar-
hythmic therapy if they are symptomatic or result in
emodynamic compromise. Patients with an ischemic or
onischemic cardiomyopathy, particularly those with an
jection fraction of less than 35%, a history of HF, and
onsustained ventricular tachycardia in the perioperative
eriod, may benefit from ICD therapy for primary preven-
ion of sudden cardiac death (evaluation by an electrophysi-
logist may be indicated) (574–576). Ventricular arrhyth-
ias may respond to intravenous beta blockers, lidocaine,
rocainamide, or amiodarone (374,577–579). Electrical
ardioversion should be used for sustained supraventric-
lar or ventricular arrhythmias that cause hemodynamic
ompromise.
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2009 ACCF/AHA Perioperative Guidelines November 24, 2009:e13–118Bradyarrhythmias that occur in the postoperative period
re usually secondary to some other cause, such as certain
edications, an electrolyte disturbance, hypoxemia, or isch-
mia. On an acute basis, many will respond to intravenous
edication such as atropine, and some will respond to
ntravenous aminophylline. Bradyarrhythmias due to sinus
ode dysfunction and advanced conduction abnormalities
uch as complete heart block will respond to temporary or
ermanent transvenous pacing or permanent pacing. The
ndications are the same as those for elective permanent
acemaker implantations.
0. Postoperative and Long-Term
anagement
dvances in preoperative risk assessment, surgical and
nesthetic techniques, and better implementation of medi-
al therapy have served to decrease the frequency of cardio-
ascular complications associated with noncardiac surgery.
ppropriate use of therapies that decrease the frequency of
ardiovascular complications in patients with CAD, includ-
ng beta-adrenergic blockers, antiplatelet therapies, statins,
nd modifiers of the renin-angiotensin system (ACE inhib-
tors and/or angiotensin receptor blockers), directed nonin-
asive evaluations of the coronary anatomy, and selective use
f coronary artery revascularization have resulted in reduced
ates of perioperative MI and death compared with out-
omes in recent decades (580).
Despite these advances, cardiovascular complications rep-
esent the most common and most treatable adverse conse-
uences of noncardiac surgery. Those patients who have a
ymptomatic MI after surgery have a marked increase in the
isk of death, reaching as high as 40% to 70% (581). Because
he consequences of infarction are so severe, management of
atients must continue after risk assessment in the postop-
rative setting. As described in sections above, postoperative
CG changes suggestive of MI predict poor outcome, and
ostoperative management is an active process that requires
requent intervention.
0.1. MI: Surveillance and Treatment
n contrast to clinically silent elevations in troponin, the
evelopment of coronary artery plaque rupture that results
n thrombotic coronary artery occlusion requires rapid
ntervention. Among eligible patients, rapid reperfusion
herapy is the cornerstone of therapy (582). Fibrinolytic
herapy markedly reduces mortality when administered to
atients who have MI unrelated to a surgical procedure.
owever, because of the substantial risk of bleeding at the
urgical site, patients who have recently undergone surgery
ave been excluded from all trials of fibrinolytic therapy, and
ecent surgery is generally considered a strong contraindi-
ation to fibrinolytic therapy. Although fibrinolytic therapy
as been administered to patients for life-threatening pul-
onary embolus shortly after noncardiac surgery, the fi- srinolytic dosage has generally been less and has been
dministered over a longer time interval than is standard for
he treatment of acute MI (583,584). Immediate coronary
ngioplasty has been favorably compared with fibrinolytic
herapy in the treatment of acute MI (585), but of greater
mportance is that the risk of bleeding at the surgical site is
elieved to be less with direct angioplasty than with fibrino-
ytic therapy. Only a single small study (586) has evaluated
he role of immediate angiography and angioplasty among
8 patients who were believed able to take aspirin and
ntravenous heparin and to undergo immediate angiography
nd PCI. This study suggested that such a strategy is
easible and may be beneficial. However, time to reperfusion
s a critical determinant of outcome in acute MI, and any
ope of benefiting patients who have a perioperative acute
I due to an acute coronary occlusion requires that angiog-
aphy and revascularization be performed rapidly (i.e.,
ithin 12 hours of symptom onset) (586,587). In addition,
hese reperfusion procedures should not be performed
outinely on an emergency basis in postoperative patients in
hom MI is not related to an acute coronary occlusion. For
nstance, in cases of increased myocardial demand in a
atient with postoperative tachycardia or hypertension,
owering the heart rate or blood pressure is likely to be of
reater benefit and is certain to carry less risk. Moreover,
ecause of the requirements for periprocedural anticoag-
lation and postrevascularization antiplatelet therapy, the
enefits of revascularization must be weighed against the
isk of postoperative bleeding, individualizing the deci-
ion for referral.
Although reperfusion therapy is an important therapy in
cute ST-segment elevation MI, the emphasis on reperfu-
ion therapy should not detract from pharmacological ther-
py, which is also very important and has been shown to
educe adverse events in such patients, as well as in patients
ith non–ST-elevation acute coronary syndromes. Therapy
ith aspirin, a beta blocker, and an ACE inhibitor, partic-
larly for patients with low ejection fractions or anterior
nfarctions, may be beneficial, whether or not the patients
re rapidly taken to the catheterization laboratory (49). An
xtensive evidence-based review of therapy for ST-segment
levation MI can be found in the ACC/AHA Guidelines
or the Management of Patients With ST-Segment Eleva-
ion Myocardial Infarction (49). Although not intended
pecifically for patients who have a postoperative MI, these
uidelines are nonetheless appropriate for these high-risk
atients. Similarly, the ACC/AHA Guidelines for Unstable
ngina and Non–ST-Segment Elevation Myocardial In-
arction represent an important template for management of
his condition in the postoperative setting (187).
In the approach to the long-term postoperative manage-
ent of noncardiac surgery patients, one should first appre-
iate that the occurrence of an intraoperative nonfatal MI
arries a high risk for future cardiac events that are often
ominated by cardiovascular death (524,589). Patients who
ustain a perioperative MI should have evaluation of LV
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ostinfarction medical therapy should be prescribed as
efined in the ACC/AHA Guidelines for the Management
f Patients With ST-Elevation Myocardial Infarction (49).
he ACC/AHA guidelines for post-MI evaluation in these
ypes of patients should be followed as soon as possible after
urgical recovery. The use of pharmacological stress (590) or
ynamic exercise (if feasible) for risk stratification should
lso be a priority in patients to help determine who would
enefit from coronary revascularization. In all cases, the
ppropriate evaluation and management of complications
nd risk factors such as angina, HF, hypertension, hyper-
ipidemia, cigarette smoking, diabetes mellitus (hyperglyce-
ia), and other cardiac abnormalities should commence
efore hospital discharge. It is also important to communi-
ate these new observations and determinations of cardiac
tatus and risk to the physician and nonphysician providers
ho will be responsible for arranging subsequent medical
are and follow-up.
0.2. Long-Term Management
lthough the occasion of noncardiac surgery brings a period
f increased cardiovascular risk, physicians should also use
he opportunity to ensure appropriate cardiovascular medi-
al therapy. Indeed, the requirement for vascular surgery
ndicates a high cardiovascular risk alone. In a trial of 1404
atients with critical limb ischemia that investigated the
ossible benefit of a molecular therapy to reduce bypass graft
ailure, there was a 16% mortality rate at 1 year (415).
edical therapy was lacking in many patients at study entry:
3% were not taking antiplatelet therapy, 54% were not
eceiving lipid-lowering therapy, and 52% were not pre-
cribed beta-blocker medications.
Other risk factors may provide additional prognostic
nsight. In studies of vascular surgery patients who had
ollow-up for 40 to 48 months, cardiac events were signif-
cantly more frequent in those who had a reduced LVEF of
ess than 35% or 40% and who demonstrated at least a
oderate area of ischemia on dipyridamole myocardial
erfusion imaging (589,591). Therefore, the perioperative
ardiovascular risk represents the most visible but not the
argest portion of morbidity and mortality that can be
meliorated by the institution of recommended medical
herapy.
These types of observations should encourage us to pay
loser attention to the medical outcome of patients seen for
erioperative evaluations, especially in the context of vascu-
ar surgery. In the ACC/AHA guidelines for the manage-
ent of patients with peripheral arterial disease, treatment
ith a statin to achieve a low-density lipoprotein level of less
han 100 mg per dL, control of blood pressure to less than
40/90 mm Hg, cigarette smoking cessation, and antiplate-
et therapy all received Class 1 indications (592). Institution
f medical therapy in the hospital is associated with in-
reased compliance (593), which makes early initiation
referable. aIn other noncardiac surgical populations, it is clear that
reoperative clinical risk assessment, as determined by the
linical criteria, LVEF, coronary angiography, dipyridamole
yocardial perfusion imaging, and dobutamine echocardi-
graphy, provides information concerning a patient’s long-
erm cardiac risk. Cardiac mortality in the postoperative
eriod increases with higher clinical risk, lower LVEF (less
han 35%), multivessel CAD, abnormal myocardial perfu-
ion imaging scans, or multiple ischemic segments on
obutamine echocardiography studies. Other studies
41,276,594) also confirm the value of semiquantitative
nalysis of myocardial perfusion imaging when these types
f perioperative tests are used to predict future cardiac
vents. All of these studies have the ability to combine an
ssessment of myocardial ischemia and LV function into a
ore useful clinical index; however, the extent of ischemia
r reduction in ventricular function achieves the best level of
rognostic utility for future cardiac events (208,261,595).
verall, a normal or near-normal stress imaging study
uggests a relatively small risk, but the positive predictive
ccuracy of abnormal studies is greatly enhanced by the
stablishment of a progressive gradient for that abnormality.
In general, the indications for additional screening or
esting in postoperative patients depend on individual pa-
ient characteristics. It is important that the care team
esponsible for the long-term care of the patient be provided
ith complete information about any cardiovascular abnor-
alities or risk factors for CAD identified during the
erioperative period.
1. Conclusions
uccessful perioperative evaluation and management of
igh-risk cardiac patients undergoing noncardiac surgery
equires careful teamwork and communication between
urgeon, anesthesiologist, the patient’s primary caregiver,
nd the consultant. In general, indications for further
ardiac testing and treatments are the same as in the
onoperative setting, but their timing is dependent on
everal factors, including the urgency of noncardiac surgery,
atient-specific risk factors, and surgery-specific consider-
tions. The use of both noninvasive and invasive preopera-
ive testing should be limited to those circumstances in
hich the results of such tests will clearly affect patient
anagement. Finally, for many patients, noncardiac surgery
epresents their first opportunity to receive an appropriate
ssessment of both short- and long-term cardiac risk. Thus,
he consultant best serves the patient by making recommen-
ations aimed at lowering the immediate perioperative
ardiac risk, as well as assessing the need for subsequent
ostoperative risk stratification and interventions directed at
odifying coronary risk factors. Future research should be
irected at determining the value of routine prophylactic
edical therapy versus more extensive diagnostic testingnd interventions.
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reas in Need of Further Research
uch progress has been made over the last few years
egarding perioperative evaluation of noncardiac surgery.
agle et al. found that patients undergoing low-risk proce-
ures are unlikely to derive benefit from CABG before
ow-risk surgery; however, patients with multivessel disease
nd severe angina undergoing high-risk surgery might well
enefit from revascularization before noncardiac surgery
142). Trials that identify specific subsets of patients in
hom preoperative coronary revascularization reduces peri-
perative and long-term MI and death are needed. The
ost effective method of preoperative coronary revascular-
zation and the value of complete revascularization are
nknown at this time.
The benefit of cardiac testing and preoperative cardiac
valuation, especially in those patients with established
AD, has been established (see Sections 5.2.3. and 5.3.);
hat is unknown is the cost-effectiveness and value of the
arious methods of cardiac testing for reducing cardiac
omplications. Further studies in this area are welcomed.
he implementation of various strategies of beta blockade in
atients undergoing major vascular surgery is cost-effective
nd even cost-saving from a short-term provider perspective
286), yet the efficacy and cost-effectiveness of various
edical therapies for specific subsets of patients (e.g., the
ole of beta blockers in those patients without a positive
tress test) are unknown.
Intraoperative and postoperative use of ST-segment
onitoring can be useful to monitor patients with known
AD or those who are undergoing vascular surgery, with
omputerized ST-segment analysis, when available, used
o detect myocardial ischemia during the perioperative
eriod, and this type of monitoring may be considered in
atients with single or multiple risk factors for CAD who
re undergoing noncardiac surgery. Although postopera-
ive troponin measurement is recommended in patients
ith ECG changes or chest pain typical of acute coronary
yndrome, its use is not well established in patients who
re clinically stable and have undergone vascular and
ntermediate-risk surgery. The efficacy of monitoring
atients for myocardial ischemia and infarction, particu-
arly the role of monitoring in affecting treatment deci-
ions and outcomes, is unknown.
Although randomized trials have examined the effect of
erioperative beta blockers on cardiac events surrounding
urgery, and observational studies have shown the benefit of
tatins during the perioperative period, further evidence is
eeded with regard to the length of time medical therapy
eeds to be initiated before noncardiac surgery to be
ffective. This includes management of antiplatelet agents in
he perioperative period.taff
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CC  American College of Cardiology
CE  angiotensin-converting enzyme
CS  American College of Surgeons
DA  American Diabetes Association
HA  American Heart Association
pm  beats per minute
ABG  coronary artery bypass graft
AD  coronary artery disease
ARP  Coronary Artery Revascularization Prophylaxis
ASS  Coronary Artery Surgery Study
HD  coronary heart disease
I  confidence interval
K-MB creatine kinase-myocardial band
TnI  cardiac troponin I
ECREASE  Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography
ES  drug-eluting stent(s)
SE  dobutamine stress echocardiography
CG  electrocardiogram
F  heart failure
R  hazard ratio
CD  implantable cardioverter-defibrillator
CU  intensive care unit
V  left ventricle/left ventricular
VEF  left ventricular ejection fraction
ACE  major adverse cardiac event(s)
ET  metabolic equivalent
I  myocardial infarction
R  odds ratio
AC  pulmonary artery catheter
CI  percutaneous coronary intervention
OBBLE  Perioperative Beta Blockade Study
TCA  percutaneous transluminal coronary angioplasty
R  relative risk
CAI  Society for Cardiovascular Angiography and Interventions
EE  transesophageal echocardiography
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Study
Year of
Publication Trial Type
No. of
Patients Patient Population Primary End Point
Analysis: HR,
RR, OR, NNT
95% CI
and/or p Results
angano et al.
(87)
1996 RCT 200 Patients with or at risk for
CAD undergoing
noncardiac surgery
“Overall mortality after
discharge from the
hospital was significantly
lower among the
atenolol-treated patients
than among those who
were given placebo over
the 6 months following
hospital discharge.”
0% versus 8% p0.001 The authors concluded, “The
principal effect was a
reduction in deaths from
cardiac causes during the
first 6 to 8 months.
Combined cardiovascular
outcomes were similarly
reduced among the
atenolol-treated patients;
event-free survival
throughout the 2-year
study period was 68% in
the placebo group and
83% in the atenolol
group; p0.008.”
Over the first year 3% versus 14% p0.005
Over 2 years 10% versus 21% p0.019
allace et al.
(381)
1998 RCT 200 Patients with, or at risk
for, CAD
“The incidence of
myocardial ischemia on
days 0–2 was
significantly reduced in
the atenolol group
(atenolol, 17 of 99
patients; placebo, 34 of
101 patients).”
p0.008 The authors concluded,
“Perioperative
administration of atenolol
for 1 week to patients at
high risk for CAD
significantly reduces the
incidence of
postoperative myocardial
ischemia. Reductions in
perioperative myocardial
ischemia are associated
with reductions in the risk
for death at 2 years.”
“The incidence of
myocardial ischemia on
Days 0–7 was
significantly reduced in
the atenolol group
(atenolol, 24 of 99
patients; placebo, 39 of
101 patients).”
p0.029
“Patients with episodes of
myocardial ischemia
were more likely to die in
the next 2 years.”
p0.025
oldermans et
al. (88)
1999 Randomized
multicenter
trial
112 Major vascular surgery “The primary study end
point of death due to
cardiac causes or
nonfatal MI occurred in 2
patients in the bisoprolol
group (3.4%) and 18 in
the standard-care group
(34%).”
p0.001 The authors concluded,
“Bisoprolol reduces the
perioperative incidence of
death from cardiac
causes and nonfatal MI in
high-risk patients who are
undergoing major
vascular surgery.”
“Two patients in the
bisoprolol group died of
cardiac causes (3.4%)
compared with 9 in
the standard-care
group (17%).”
p0.02
“Nonfatal MI occurred in 9
patients given standard
care only (17%) and in
none of those given
standard care plus
bisoprolol.”
p0.001
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Year of
Publication Trial Type
No. of
Patients Patient Population Primary End Point
Analysis: HR,
RR, OR, NNT
95% CI
and/or p Results
augg et al.
(377)
1999 RCT 63 Elderly, noncardiac
surgery patients. Group
I, no atenolol; Group II,
preoperative and
postoperative atenolol;
Group III, intraoperative
atenolol.
“Hormonal markers of the
stress response
(neuropeptide Y,
epinephrine,
norepinephrine, cortisol,
and adrenocorticotropic
hormone) were evaluated
preoperatively and for 72
hours after surgery.”
Perioperative
beta blockade
did not
significantly
alter the
hormonal
stress
response.
The authors concluded,
“Beta-blockade does not
reduce the
neuroendocrine stress
response, suggesting that
this mechanism is not
responsible for the
previously reported
improved cardiovascular
outcome. However, it
confers several
advantages, including
decreased analgesic
requirements, faster
recovery from anesthesia,
and improved
hemodynamic stability.
The release of cardiac
troponin I suggests the
occurrence of
perioperative myocardial
damage in this elderly
population, which
appears to be
independent of the
neuroendocrine stress
response.”
The beta-blocked patients
“received less fentanyl
intraoperatively (27.7%,
p0.0001), experienced
faster early recovery, had
lower pain scores, and
required less analgesia in
the postanesthesia care
unit. Cardiac troponin I
release was detected in 8
of 19, 4 of 20, and 5 of
20 patients in Groups I, II,
and III, respectively
(pnot significant).”
p0.0001
“Three patients in Group I
had cardiac troponin I
levels consistent with MI.”
aby et al.
(376)
1999 RCT 26 High-risk vascular surgery
patients
“Ischemia persisted in the
postoperative period in 8
(73%) of 11 placebo
patients but only 5 (33%)
of 15 esmolol patients.”
p0.05 The authors’ data suggest
that “patient-specific,
strict heart rate control
aiming for a predefined
target based on individual
preoperative ischemic
threshold was associated
with a significant
reduction and frequent
elimination of
postoperative myocardial
ischemia among high-risk
patients and provides a
rationale for a larger trial
to examine this strategy’s
effect on cardiac risk.”
rady et al.
(379)
2005 Double-blind
RCT
103 Patients without previous
MI who had infrarenal
vascular surgery
“Cardiovascular events
occurred in 15 (34%) and
17 (32%) patients in the
placebo and metoprolol
groups, respectively.”
Unadjusted
RR 0.94
0.53 to 1.66 The authors concluded,
“Myocardial ischemia was
evident in a high
proportion (one-third) of
the patients after surgery.
A pragmatic regimen of
perioperative beta-
blockade with metoprolol
did not seem to reduce
30-day cardiovascular
events, but it did
decrease the time from
surgery to discharge.”
Adjusted
RR 0.87
0.48 to 1.55
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Year of
Publication Trial Type
No. of
Patients Patient Population Primary End Point
Analysis: HR,
RR, OR, NNT
95% CI
and/or p Results
“Time from operation to
discharge was reduced
from a median of 12
days (95% CI 9–19 days)
in the placebo group to
10 days (95% CI 8–12
days) in the metoprolol
group.”
Adjusted
HR 1.71
1.09 to 2.66;
p0.02
uul et al. (372) 2006 RCT 921 Patients who have
diabetes 39 years of
age scheduled for
major noncardiac
surgery
“The composite primary
outcome measure was
time to all-cause
mortality, acute MI,
unstable angina, or CHF.”
The authors concluded,
“Perioperative metoprolol
did not significantly affect
mortality and cardiac
morbidity in these
patients with diabetes. CI,
however, were wide, and
the issue needs
reassessment.”
“The primary outcome
occurred in 99 (21%) of
462 patients in the
metoprolol group and 93
(20%) of 459 patients in
the placebo group during
a median follow-up of 18
months (range 6–30
months).”
HR 1.06 0.80 to 1.41
“All-cause mortality was
16% (74 of 462 patients)
in the metoprolol group
and 16% (72 of 459
patients) in the placebo
group.”
HR 1.03 0.74 to 1.42
oldermans et
al. (59)
2006 RCT 1476 Patients undergoing
elective open
abdominal aortic or
infrainguinal arterial
reconstruction
“Patients assigned to no
testing had a similar
incidence of the primary
end point as those
assigned to testing (1.8%
versus 2.3%).”
OR 0.78 0.28 to 2.1;
p0.62
The authors concluded,
“Cardiac testing can
safely be omitted in
intermediate-risk patients,
provided that beta
blockers aiming at tight
[heart rate] control are
prescribed.”
“Regardless of allocated
strategy, patients with a
heart rate65 bpm had
lower risk than the
remaining patients (1.3%
versus 5.2%).”
OR 0.24 0.09 to 0.66;
p0.003
ang et al.
(373)
2006 RCT 496 Abdominal aortic surgery
and infrainguinal or
axillofemoral
revascularizations
Primary outcome was
postoperative 30-day
composite incidence of
nonfatal MI, unstable
angina, new CHF, new
atrial or ventricular
dysrhythmia requiring
treatment, or cardiac
death.
The authors concluded,
“Metoprolol was not
effective in reducing the
30-day and 6-month
postoperative cardiac
event rates. Prophylactic
use of perioperative beta
blockers in all vascular
patients is not indicated.”
“Primary outcome events at
30 days occurred in 25
patients (10.2%) versus
30 (12.0%) in the
metoprolol and placebo
groups, respectively.”
RR reduction
15.3%
38.3% to
48.2%;
p0.57
Observed effects at 6
months were not
significantly different.
RR reduction
6.2%
58.4% to
43.8%;
p0.81
Intraoperative bradycardia
requiring treatment was
more frequent in the
metoprolol group (53 of
246 patients versus 19 of
250 patients).
p0.00001
Intraoperative hypotension
requiring treatment was
more frequent in the
metoprolol group (114 of
246 patients versus 84 of
250 patients).
p0.0045
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augg et al.
(378)
2007 Double-blind,
placebo-
controlled,
multicenter
trial
219 Patients undergoing
surgery with spinal
block
“One-year composite
outcome included
cardiovascular mortality,
nonfatal MI, unstable
angina, CHF, and
cerebrovascular insult.”
The authors concluded,
“Perioperative bisoprolol
therapy did not affect
cardiovascular outcome
in these elderly at-risk
patients undergoing
surgery with spinal block.”
“The primary outcome
occurred in 25 patients
(22.7%) in the bisoprolol
group and 24 (22.0%) in
the placebo group during
the 1-year follow-up.”
HR 0.97 0.55 to 1.69;
p0.90
“Carriers of at least 1 Gly
allele of the beta-1-
adrenergic receptor
polymorphism Arg389Gly
showed a higher number
of adverse events than
Arg-homozygous subjects
(32.4% versus 18.7%).”
HR 1.87 1.04 to 3.35;
p0.04
evereaux et al.
(371)
2008 RCT 8331 Patients undergoing
noncardiac surgery
“The primary end point was
a composite of
cardiovascular death,
nonfatal MI, and nonfatal
cardiac arrest. Fewer
patients in the metoprolol
group than in the placebo
group reached the
primary end point (244
[5.8%] patients in the
metoprolol group versus
290 [6.9%] in the
placebo group).”
HR 0.84 0.70 to 0.99;
p0.0399
The authors concluded their
“results highlight the risk
in assuming a
perioperative beta blocker
regimen has benefit
without substantial harm,
and the importance and
need for large
randomized trials in the
perioperative setting.
Patients are unlikely to
accept the risks
associated with
perioperative extended-
release metoprolol.”
“Fewer patients in the
metoprolol group than in
the placebo group had an
MI (176 [4.2%] versus
239 [5.7%] patients).”
HR 0.73 0.60 to 0.89;
p0.0017
“More deaths occurred in
the metoprolol group
than in the placebo group
(129 [3.1%] versus 97
[2.3%] patients).”
HR 1.33 1.03 to 1.74;
p0.0317
“More patients in the
metoprolol group than in
the placebo group had a
stroke (41 [1.0%] versus
19 [0.5%] patients).”
HR 2.17 1.26 to 3.74;
p0.0053
unkelgrun et
al. (369)
2009 RCT 1066 Intermediate-risk patients
undergoing
noncardiovascular
surgery
The primary end point was
the composite of
perioperative cardiac
death and nonfatal MI.
The authors concluded, “In
intermediate-risk surgical
patients, bisoprolol was
associated with a
significant reduction of
30-day cardiac
complications, while
fluvastatin showed a
trend for improved
outcome.”
“Patients randomized to
bisoprolol (n533) had a
lower incidence of the
primary end point than
those randomized to
bisoprolol-control therapy
(2.1% versus 6.0%
events).”
HR 0.34 0.17 to 0.67;
p0.002
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“The beneficial effects of
bisoprolol were not
modified by fluvastatin.
Patients randomized to
fluvastatin experienced a
lower incidence of the
primary efficacy end
point than those
randomized to
fluvastatin-control
therapy (3.2% versus
4.9% events).”
HR 0.65 0.35 to 1.10;
p0.17
Nonrandomized Studies
asternack et
al. (374)
1987 83 Patients scheduled for
abdominal aortic
aneurysm surgery
Group 1 was treated with
oral metoprolol
immediately before
surgery and with
intravenous metoprolol
during the postoperative
period. Group 2, who did
not receive metoprolol,
served as a control.
The authors concluded that
their “data demonstrate
that beta blockade with
metoprolol is effective in
controlling systolic blood
pressure and heart rate
both intraoperatively and
postoperatively in
patients undergoing
repair of AAA and can
significantly reduce the
incidence of perioperative
MI and arrhythmias.”
“In Group 1, only 1 patient
(3%) had an acute MI. In
contrast, 9 Group 2
patients (18%) had
perioperative MI.
p0.05
Only 4 Group 1 patients
(12.5%) developed
significant cardiac
arrhythmias as opposed
to 29 Group 2 patients
(56.9%).”
p0.001
asternack et
al. (78)
1989 Clinical trial 48 Peripheral vascular
surgery patients
“Patients treated with oral
metoprolol had
significantly less
intraoperative silent
ischemia with respect to
relative duration and
frequency of episodes, a
significantly lower
intraoperative heart rate,
and less intraoperative
silent myocardial
ischemia in terms of total
absolute duration.”
The authors concluded,
“These results suggest
that beta-adrenergic
activation may play a
major role in the
pathogenesis of silent
myocardial ischemia
during peripheral vascular
surgery.”
eager et al.
(375)
1995 Case-control
study
159 Vascular surgery “Beta blockers were used
less frequently in patients
with perioperative MI
than in control patients
without perioperative MI
(30% versus 50%).”
p0.01 The authors concluded,
“Beta blockade is
associated with a
decreased incidence of
perioperative MI in
patients undergoing
vascular surgery.
Prophylactic perioperative
use of beta-blockers may
decrease perioperative MI
in patients requiring
major vascular surgery.”
“Overall, beta blockade
was associated with a
50% reduction in
perioperative MI.”
p0.03
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oersma et al.
(246)
2001 Cohort study 1351 Of patients undergoing
major vascular surgery,
611 patients (45%)
had a Lee risk index of
1; 509 (38%) had an
index of 2; and 231
(17%) had an index of
3 points (all patients
underwent high-risk
surgery and thus had a
risk index1 point).
Cardiac death or nonfatal
MI within 30 days after
surgery was the main
outcome measure,
compared by clinical
characteristics, DSE
results, and beta-blocker
use.
The authors concluded the
“additional predictive
value of DSE is limited in
clinically low-risk patients
receiving beta blockers. In
clinical practice, DSE may
be avoided in a large
number of patients who
can proceed safely for
surgery without delay. In
clinically intermediate-
and high-risk patients
receiving beta blockers,
DSE may help identify
those in whom surgery
can still be performed
and those in whom
cardiac revascularization
should be considered.”
Among the 83% of patients
with 3 clinical risk
factors, patients receiving
beta blockers had a lower
risk of cardiac
complications (0.8% [2 of
263]) than those not
receiving beta blockers
(2.3% [20 of 855]), and
DSE had minimal
additional prognostic
value. In patients with
3 risk factors (17%),
DSE provided additional
prognostic information;
patients without stress-
induced ischemia had a
much lower risk of events
than those with stress-
induced ischemia
(among those receiving
beta blockers, 2.0% [1 of
50] versus 10.6% [5 of
47]). Patients with
limited stress-induced
ischemia (1–4 segments)
experienced fewer
cardiac events (2.8% [1
of 36]) than those with
more extensive ischemia
(5 segments, 36%
[4 of 11]).”
“Patients who did not
undergo DSE (i.e.,
patients without clinical
cardiac risk factors) and
those without NWMAs
during DSE had a
significantly lower cardiac
death or MI rate than
patients with NWMAs
during DSE (0.4% and
1.6% versus 13.5%,
respectively).”
p0.001
“In the 222 patients with
NWMAs, 67% received
beta blockers, with 4.7%
having a perioperative
cardiac event versus
31.5% of those not
receiving beta blockers.”
Mantel-Haenszel
test 0.1
0.1 to 0.3
222 Univariable relation
between DSE results and
perioperative cardiac
death or MI: NWMA (DSE
summary).
OR 39.5 5.3 to 292;
p0.001
SL
e116 Fleisher et al. JACC Vol. 54, No. 22, 2009
2009 ACCF/AHA Perioperative Guidelines November 24, 2009:e13–118Study
Year of
Publication Trial Type
No. of
Patients Patient Population Primary End Point
Analysis: HR,
RR, OR, NNT
95% CI
and/or p Results
“Multivariable model: After
correction for differences
in clinical characteristics,
patients receiving beta
blockers were still at
significantly lower risk for
the composite end point
than those who were not.”
Adjusted OR 0.3 0.1 to 0.7
“DSE results (especially the
presence or absence of
NWMAs) were the most
important determinants
of perioperative cardiac
outcome. In connection
with both clinical data
and DSE results, beta-
blocker therapy was
again associated with a
significantly reduced risk
of the composite end
point. The protective
effect of beta-blocker
therapy was observed in
long-term users and in
patients who received
bisoprolol as part of the
DECREASE study (OR 0.1,
95% CI 0.0 to 0.4).”
OR 0.1 0.0 to 0.3
“The incidence of the
composite end point in
patients with a Lee index
of 1, 2, or 3 points was
1.3%, 3.1%, and 9.1%,
respectively.”
p0.001
hammash et
al. (403)
2001 140 Major vascular surgical
procedures
“Mortality in the 8 patients
who had beta blockers
discontinued
postoperatively (50%)
was significantly greater
than mortality (1.5%) in
132 patients who
continued taking beta
blockers.”
OR 65.0 p0.001 The authors concluded,
“Discontinuing beta
blockers immediately
after vascular surgery
may increase the risk of
postoperative
cardiovascular morbidity
and mortality.”
“Beta-blocker
discontinuation also was
associated with increased
cardiovascular mortality
(0% versus 29%).”
p0.005
“Beta-blocker
discontinuation also was
associated with increased
postoperative MI.”
OR 17.7 p0.003
indenauer et
al. (370)
2005 Retrospective
cohort study
663 635 Patients18 years of
age who underwent
major noncardiac
surgery
“Among the 580 665
patients with an RCRI
score of 0 or 1, treatment
was associated with no
benefit and possible
harm.”
Adjusted
OR 1.09
1.01 to 1.19 The authors concluded,
“Perioperative beta-
blocker therapy is
associated with a reduced
risk of in-hospital death
among high-risk, but not
low-risk, patients
undergoing major
noncardiac surgery.
Patient safety may be
enhanced by increasing
the use of beta-blockers
in high-risk patients.”
RCRI score 2 Adjusted
OR 0.88
0.80 to 0.98
RCRI score 3 Adjusted
OR 0.71
0.63 to 0.80
RCRI score4 Adjusted
OR 0.58
0.50 to 0.67
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edelmeier et
al. (389)
2005 Retrospective
cohort study
37 151 Patients 65 years of
age who were admitted
for elective surgery,
without symptomatic
coronary disease
1038 patients experienced
an MI or died, at a rate
that was significantly
lower for patients
receiving atenolol than
for those receiving
metoprolol (2.5% versus
3.2%).
p0.001 The authors concluded,
“Patients receiving
metoprolol do not have as
low a perioperative
cardiac risk as patients
receiving atenolol, in
accord with possible
acute withdrawal after
missed doses.”
eringa et al.
(396)
2006 Observational
cohort study
272 Vascular surgery “In multivariate analysis,
higher beta-blocker doses
(per 10% increase) were
significantly associated
with a lower incidence of
myocardial ischemia.”
HR 0.62 0.51 to 0.75 The authors concluded,
“This study showed that
higher doses of beta
blockers and tight heart
rate control are
associated with reduced
perioperative myocardial
ischemia and troponin T
release and improved
long-term outcome in
vascular surgery
patients.”
Troponin T release HR 0.63 0.49 to 0.80
Long-term mortality HR 0.86 0.76 to 0.97
“Higher heart rates during
electrocardiographic
monitoring (per 10-bpm
increase) were
significantly associated
with an increased
incidence of myocardial
ischemia.”
HR 2.49 1.79 to 3.48
Troponin T release HR 1.53 1.16 to 2.03
Long-term mortality HR 1.42 1.14 to 1.76
oeks et al.
(404)
2006 Prospective
survey
711 Peripheral vascular
surgery patients
“After adjustment for
potential confounders
and the propensity of its
use, continuous beta-
blocker use remained
significantly associated
with a lower 1-year
mortality compared with
nonusers.”
HR 0.4 0.2 to 0.7 The authors concluded that
this “study demonstrated
an under-use of beta
blockers in vascular
surgery patients, even in
high-risk patients.
Perioperative beta
blocker use was
independently associated
with a lower risk of 1-year
mortality compared to
non-use, while
perioperative withdrawal
of beta-blocker therapy
was associated with a
higher 1-year mortality.”
“In contrast, beta-blocker
withdrawal was
associated with an
increased risk of 1-year
mortality compared with
nonusers.”
HR 2.7 1.2 to 5.9
aafarani et al.
(391)
2008 Retrospective
cohort study
646 All patients who
underwent various
noncardiac surgical
procedures
“Patients at all levels of
cardiac risk who received
beta blockers had lower
preoperative and
intraoperative heart
rates.”
The authors concluded,
“Among patients at all
levels of cardiac risk
undergoing noncardiac
surgery, administration of
beta blockers should
achieve adequate heart
rate control and should
be carefully monitored in
patients who are not at
high cardiac risk.”
The beta-blocker group had
higher rates of 30-day MI
(2.94% versus 0.74%)
than the control group.
p0.03
The beta-blocker group had
higher 30-day mortality
(2.52% versus 0.25%)
than the control group.
p0.007
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Patients in the beta-blocker
group who died
perioperatively had
significantly higher
preoperative heart rate
(86 versus 70 bpm).
p0.03
atyal et al.
(392)
2008 Retrospective 960 Vascular surgery
(primarily infrainguinal)
“Adverse outcome was
defined as MI, new-onset
CHF, significant
arrhythmias, renal failure,
or death. The incidence
of adverse outcomes was
lower when beta blockers
were administered in men
(12.6% versus 18.9%).”
p0.04 The authors concluded,
“Women did not benefit
from perioperative beta-
blockade. Women at high
risk appeared to have a
worse outcome because
of a higher incidence of
CHF.”
“The incidence of adverse
outcomes was not lower
in women (17.8% versus
13.7%).”
p0.37
“Among beta-blocker–naïve
subjects, men had
significant reductions in
MI and renal failure,
whereas women did not
have a reduction in the
incidence of any
outcome.”
“After risk stratification, the
high-risk women who
received beta blockade
had a statistically worse
outcome (36.8% versus
5.9%) because of an
increased incidence of
CHF.”
p0.02
AA indicates abdominal aortic aneurysm; bpm, beats per minute; CAD, coronary artery disease; CHF, congestive heart failure; CI, confidence interval; DSE, dobutamine stress echocardiography; HR,
azard ratio; MI, myocardial infarction; n, number; NNT, number needed to treat; NWMA, new wall-motion abnormality; OR, odds ratio; RCRI, Revised Cardiac Risk Index; RCT, randomized controlled
rial; and RR, relative risk.
